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Summary 
Corticotrophin releasing hormone (CRH) and CRH receptor (CRH-R) appears to play 
a number of important roles in human pregnancy. The purpose of the first part of my 
project was to clone and sequence CRH-R subtypes from human myometrial biopsies. 
In order to understand the molecular mechanisms that direct the expression of the 
CRH-R gene, the objective of the second part of my research project was to clone and 
characterise the promoter region of the human CRH-R2 gene. 
Our results demonstrated the presence of multiple CRH-R mRNAs in the human 
myometrium. Six subtypes of the CRH receptor, la, ID, I c, 2a, 20, and 2'y, were 
found in the pregnant human myometrium, whereas only three subtypes, 1 a, 1(3, and 
2ß were found in the nonpregnant myometrium. Multiple CRH-R mRNAs have been 
identified in human myometrium with differential expression pattern during 
pregnancy, which argues for multiple roles for CRH and/or related peptides in 
myometrial function and suggests distinct functional roles for each receptor during 
pregnancy. These findings suggest that CRH and its receptor play an important 
modulatory role in myometrial function. 
The genomic organisation of human CRH-R2 alternative exons has been determined 
in the project. The coding region of the gene spans over 18 kb. The genomic orders of 
the alternative exons are CRH-R20-2y-2a. The 5'-flanking region of the human CRH- 
R2 gene was cloned by the genomic walking method. Using 5'RACE, the 
transcription start sites were mapped. The results suggest that there may be a single 
promoter regulating the expression of all (2cc, 20, and 2i) subtypes. The CRH-R2 5'- 
flanking sequence has many characteristics of a housekeeping gene promoter. 
Therefore, we speculated that the strong and housekeeping gene-like activity of he 
CRH-R2 gene promoter may contribute to the ubiquitous expression of the CRH-R2 
gene. For functional analysis, 5'-flanking sequences up to-1393 bp were fused to the 
Chloramphenicol acetyltransferase (CAT) gene and tested using a HEK-293 cell line 
by transfection CAT assays. The results confirmed that the DNA region indicated 
demonstrated strong basal promoter activity. 
xvii 
Chapter 1. General description of corticotrophin-releasing 
hormone and its receptor 
1.1 Introduction 
In 1955, experimental support for the hypothesis that adrenocorticotropic hormone 
(ACTH) secretion is controlled by hypothalamic factors (Harris GW 1948) was 
obtained by Guillemin and Rosenberg. However, the chemical nature of this factor 
remained unknown until 1981 when a 41 amino acid C-terminal amidated peptide was 
purified from ovine hypothalami and shown to be capable of stimulating pituitary 
ACTH release in vitro (Vale et al., 1981). The biologically active form of this peptide, 
designated corticotrophin-releasing factor-41 (CRF-41), and also frequently referred 
to as corticotrophin-releasing hormone (CRH), was synthesised and found to have 
potent ACTH-releasing actions in vivo (Vale et al., 1983). 
Corticotrophin-releasing hormone, which is termed CRH in this thesis, is a 41 amino 
acid peptide which plays a major role in co-ordinating the behavioural, autonomic, 
endocrine and immune responses to stress. CRH mediates its effect via heterotrimeric 
guanine nucleotide-binding protein (G-protein) coupled receptors which belong to the 
large superfamily of seven-transmembrane domain receptors and transduce their 
signal through stimulation of adenylate cyclase and cAMP production (Perrin et al., 
1986, Battaglia et al., 1987). 
Molecular cloning studies indicate the existence of at least two major types of 
mammalian CRH receptors (CRH-R), termed CRH-R1 and CRH-R2. CRH-R1 has 
four subtypes, namely, CRH-R l a, CRH-R 1(3, CRH-R lc and CRH-R l d. CRH-R la is 
a 415-amino acid protein that is expressed mainly in the brain (Vita et al., 1993) and 
pituitary (Chen et al., 1993). Three spliced variants of CRH-Rla have been 
identified, which are CRH-R1(3 (Chen et al 1993), lc (Ross et al 1994) and Id 
(Grammatopoulos et al., 1999). CRH-R2 (Liaw et al., 1996), which shares 70% 
identity with CRH-R1, is expressed in the form of three functional splice variants, 
each of which has alternative 5'exon splicing: CRH-R2a (411 amino acids), 2ß (438 
amino acids) and 2y (397 amino acids) (Kishimoto et al., 1995, Lovenberg et al., 1995 
1 
a, Stenzel et al., 1995, Kostich et al., 1998). Human CRH-R2a and CRH-R2(3 are co- 
expressed in peripheral organs and the central nervous system (CNS), whereas CRH- 
R2y, which has been isolated only from humans, was found only in the brain (Kostish 
et al., 1998). 
These receptors show differences both at the level of their expression between tissue 
types and in their pharmacological properties; For example, CRH-R1 binds CRH and 
CRH-like peptides (Urocortin, Urotensin 1, oCRH, r/hCRH and Sauvagine) with 
equal affinity, whereas CRH-R2 preferentially binds Urocortin, suggesting that 
Urocortin is the native ligand. The difference in the pharmacological profile and 
distribution of CRH-R1 and CRH-R2, and their splice variants suggest that they may 
have different functions. 
It has been shown that CRH-R1 and CRH-R2 are encoded by separate genes. The gene 
coding for CRH-R1 consists of at least 13 exons and spans over 20 kilobases (Sakai et 
al., 1998). The CRH-R1 gene has been assigned to 17g12-q22 (Vamvakopoulos and 
Sioutopoulou, 1994). The gene coding for CRH-R2 consists of at least 12 exons and 
spans approximately 30 kilobares (Liaw et al., 1996). The gene has been mapped to 
the chromosome 7p21-p15 (Meyer et al., 1997). 
Human CRH receptors (hCRH-Rs) have been identified in many tissues such as the 
central nervous system (CNS), spleen, ovary, adrenal, and myometrium. The wide 
distribution of the CRH-Rs suggests that, in addition to its role in regulation of the 
hypothalamic-pituitary-adrenal (HPA) axis, CRH may play an important role in the 
physiology of many other organs. Recent studies have implicated CRH and its 
receptors in the aetiology and pathophysiology of disorders such as depression, 
anxiety disorders, anorexia nervosa, neurodegenerative diseases and inflammatory 
illnesses such as rheumatoid arthritis (De Souza EB 1995). 
The initiation of parturition in humans remains an enigma, but it seems to be 
multifactorial. Recently, interest has been directed toward placentally derived 
corticotrophin-releasing hormone (CRH). Although CRH concentrations in the human 
peripheral circulation are normally low, they increase throughout pregnancy and fall 
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rapidly after parturition. The physiological role of the these high concentrations of 
CRH during gestation is unknown, but it has been suggested that there is a "CRH 
placental clock" which determines the length of gestation and the timing of parturition 
and delivery (McLean et al., 1995). Placentally derived CRH influences myometrial 
function via specific CRH receptor. 
Evidence for a direct action of CRH on human myometrium was provided by the 
identification of a single, high affinity population of CRH receptors in the human 
myometrium which increase their affinity during the latter stages of pregnancy 
(Hillhouse et al., 1993) and become functionally linked to the adenylate cyclase 
system, leading to the increased production of cAMP, a well known myometrial 
relaxing factor (Grammatopoulos et al., 1994). At term, there is a reduction in the 
functional ability of CRH to stimulate cAMP due to (1) a reduction of the number of 
Gsa subunits and (2) an inhibitory action of oxytocin, which activates protein kinase 
C, leading to phosphorylation and desensitisation of the CRH-R (Grammatopoulos 
and Hillhouse, 1999). 
In particular, it has been demonstrated (Grammatopoulos et al., 1995) that the human 
myometrium expresses at least five isoforms of the CRH receptor: p14.65,4.8,4.95, 
5.1, and 5.2. These results suggest that the presence of different isoforms may 
subserve different properties and functions (Grammatopoulos et al., 1995). CRH may 
play a role by promoting myometrial relaxation during pregnancy and by facilitating 
myometrial contractions during labour. These effects are likely to be mediated via 
different receptor subtypes. It is possible that alterations in mRNA processing produce 
different spliced variant observances. 
1.2 Corticotrophin-releasing hormone (CRH) 
CRH is a 41 amino acid, single-chain polypeptide, which has now been described in 
many species (including rat, human, pig, sheep, horse, goat, cow, Xenopus, and white 
suckerfish). CRH has sequence homology and shares many biological properties with 
two other vertebrate peptides: sauvagine, a 40 amino acid peptide isolated from the 
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frog skin (Montecucchi et al, 1981), and urotensin I, a 41 amino acid peptide isolated 
from the caudal neurosecretory system of teleost fish (Lederis et al., 1982). CRH also 
has sequence homology to two diuretic hormones, Mas-DPI and MAS-DPII, from the 
tosacco hornworm, Manduca Sexta (Katoaka et al., 1989, Blackburn et al., 1991). The 
vertebrate homologies have been tested and found to possess potent mammalian and 
fish pituitary ACTH-releasing activity. In addition, they decrease peripheral vascular 
resistance and cause hypotension when injected into mammals (Rivier et al., 1983, 
Lenz et al., 1985). CRH is produced and secreted primarily from parvocellular 
neurones of the paraventricular nucleus (PVN) of the hypothalamus. It is abundant in 
PVN nerve terminals within the median eminence, where it is released into the 
hypophyseal portal circulation. 
CRH plays a major role in co-ordinating the behavioural, autonomic, endocrine and 
hormonal responses to stress. The major endocrine response to stress is via activation 
of the hypothalamic-pituitary-adrenal (HPA) axis, leading to rapid secretion of 
adrenocorticotropin (ACTH) by the pituitary corticotrophin and increases in 
circulating glucocorticoids, which are critical for adaptation (Figure 1.1). When the 
same stressor (homotypical) is repeated, the pattern of activation differs according to 
the type of stress, with desensitisation of ACTH responses to repeated homotypical 
stimuli for some stressors (such as cold exposure and repeated immobilization), or 
preservation of the responses after each homotypical stimulus for others (such as 
repeated foot shock, insulin hypoglycemia and intraperitoneal hypertonic saline 
injection) (Aguilera, G. 1998). In addition to its endocrine effects, 
immunohistochemical localisation of CRH has demonstrated that the hormone has a 
broad extrahypothalamic distribution in the central nervous system (CNS) 
(Olschowka et al., 1982, Cummings et al., 1983). These effects of CRH are mediated 
by adenylate cyclase/cAMP/protein kinase A-dependent mechanisms triggered by 
binding of CRH to CRH receptors (CRH-R) in the corticotrophin cell (Abou-Samera 
et al., 1987). 
CRH produces a wide spectrum of autonomic, electrophysiological, and behavioural 
effects which are consistent with a neurotransmitter or neuromodulator role in the 
brain. Intracerebroventricular administration of CRH provokes stress-like responses, 
including activation of the sympathetic nervous system and inhibition of the 
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parasympathetic nervous system (Brown et al., 1982). The behavioural profile 
following central administration of CRH is also characteristic of a compound which 
increases arousal and emotional reactivity to the environment. These effects of CRH 
include general arousal, as exhibited by increased locomotion, sniffing, grooming, and 
rearing in familiar surroundings and increased agitation in unfamiliar surroundings 
(Dunn AJ and Berridge CW 1990). Recent evidence suggests that CRH may also play 
a significant role in a variety peripheral functions, including cardiovascular function, 
inflammation, reproduction, and integration of the immune system's response to 
stressors (Blalock et al., 1989). 
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Figurel. l. Diagram illustrating the integrated responses to stress emphasising 
the activation of the hypothalamic-pituitary-adrenal (HPA) axis and the 
feedback and regulatory effects of glucocorticoids. Activation of the supraoptic 
nucleus (SON) and magnocellular paraventricular nucleus (PVN) with release 
of vasopressin (VP) from the neurohypophysis occurs only during osmotic 
stress. ACTH, adrenocorticotropin; BS, brain stem; CRH, corticotrophin- 
releasing hormone (Aguilera, G. 1998). 
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1.3 Corticotrophin releasing hormone receptor (CRH-R) 
1.3.1 CRH-R subtypes 
The function of CRH is mediated via its specific interactions with cell surface 
receptors. Molecular cloning studies indicate the existence of at least two major types 
of mammalian CRH-R, (CRH-R1 and CRH-R2). Recently, cDNAs corresponding to 
rat, mouse, and human CRH-Rs have been characterised. The CRH-Rs belong to the 
recently described family of "gut-brain" neuropeptide receptors and exhibit 
significant homology to the parathyroid and glucagon receptor family that has been 
designated as members of Class II in the G-protein coupled seven transmembrane 
helical domain receptors (GPCR) superfamily. The CRH-Rs are GPCRs and have 
been shown to be coupled to both adenylate cyclase and phospholipase C, stimulating 
cAMP production and phosphoinositide hydrolysis (Segre, G. V. and Goldring, S. R. 
1993). 
1.3.1.1. CRH-R1 
The CRH-Rla has been cloned from several species including human (Chen et al., 
1993), mouse (Vita et al., 1993), chicken (Yu et al., 1996) and rat (Perrin et al., 1993, 
Chang et al., 1993). Species homologues are 98% identical over their full length of 
415 amino acids. In general, the CRH-R1 shares approximately 30% identity with all 
other members of the neuropeptide receptor family. The structure of the cDNA 
encoding the human pituitary CRH-Rla has been characterised using expression 
cloning of cDNA from a human Cushing's corticotrophin adenoma (Chen et al., 
1993). The CRH-Rla is a 415 amino acid protein comprising seven putative 
membrane-spanning domains characteristic of most G protein-coupled receptors. The 
CRH-Rla has putative N-linked glycosylation sites in the N-terminal extracellular 
domain. There are five such sites predicted, substantiating the glycosylation profiles 
determined by chemical affinity cross-linking studies (Grigoriadis and De Souza, 
1989). In addition, there are potential protein kinase C phosphorylation sites in the 
first and second intracellular loop and in the C-terminal tail, as well as casein kinase II 
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and protein kinase A phosphorylation sites in the third intracellular loop (Chen et al., 
1993). 
Three variant human CRH-R1 cDNA clones have been identified from a 
corticotrophin adenoma (Chen et al., 1993), myometrium (Grammatopoulos et al., 
1999) and hippocampus (Ross et al., 1994). The former encodes 29 additional amino 
acids inserted in the first intracellular loop (named: CRH-R1(3), and the latter has a 40 
amino acid deletion in the N-terminal extracellular domain (CRH-Rlc). The amino 
acid sequence of CRH-Rld is identical to the CRH-Rla receptor except that it 
contains an exon deletion resulting in the absence of 14 amino acids in the predicted 
seventh transmembrane domain (Figurel. 2). Interestingly, studies in which COS-7 
cells have been transfected with CRH-R cDNAs have shown that the CRH-Rla is 
coupled efficiently to both adenylate cyclase and phosphoinositol hydrolysis whereas 
the spliced variant receptor (CRH-R1ß) is not well-coupled to adenylate cyclase and 
does not couple at all to phospholipase C (Xiong et al., 1995). The 29 amino acid 
insertion strongly reduces the coupling efficiency of the produced protein. Since the 
only difference between the CRH-R1 a and CRH-R1ß is the insert in the first putative 
cytoplasmic loop, these data indicate that the first cytoplasmic loop plays a crucial 
role in CRH-R1 coupling to the G protein. CRH-Rlc failed to bind to [125 I] CRH with 
high affinity in transfected COS-7 cell. This deletion results in a low affinity CRH -R 
protein which is only activated at high (>300 nM CRH) agonist concentrates. 
Recently, Hillhouse and his team have isolated and characterised a novel CRH-R 
(CRH-Rld) spliced variant from human myometrium by employing a RT-PCR 
technique. This variant of the CRH-Rla contains a 42 bp deletion in the last 
transmembrane domain. In HEK-293 cells stably transfected with this variant both 
CRH and urotensin, but not sauvagine or urocortin, can elevate intracellular cAMP 
levels at relatively high concentration. In contrast to CRH, urotensin and sauvagine 
can elevate high levels of intracellular cAMP in HEK-293 cells stably tranfected with 
CRH-1 a (Grammatopoulos, et al., 1999). 
In contrast to the human, these splice products have not been identified in rodents. In 
rats, a CRH-R1 frame shift mutant encoding a 224 amino acid protein has been 
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identified (Chang et al., 1993). This mutant lacks the entire third and parts of the 
fourth putative transmembrane domain. At present, nothing is known about the 
functional properties of this mutant receptor protein. 
CRH-R1 gene 
11234567 1819 1 10 1 11 121131 
33 21 41 327 34 555 709 770 843 929 1(651170 
el, extracellular loop 
11 ell 112 e12 i13 e13 
EC il, intracellular loop (1 46) 
123456 
TM 
exon 3 deletion 
120bp deletion: 
variant 1c 87bp (29aa) insert: 
type 1ß 
exon 12 deletion 
42bp deletion: 
variant 1d 
Figure 1.2. Genomic structure of human CRH-R1 
The diagram shows the position of CRH-R1 introns in relation to extracellular 
and transmembrane domains, where EC, extracellular; il, intracellular loop; 
transmembrane (TM) domains; el, extracellular loop cytoplasmic domain after 
TMVII (1-1246 bp): initiation to terminating codons. The numbers under the 
boxes refer to nucleotide sequence numbers (hCRH-Rl(x: GenBank Accession 
No. L23332: Chen et al., 1993). The gene coding for CRH-R1 consists of at least 
14 exons and spans over 20 kilobases (Sakai et al., 1998). 
1.3.1.2 CRH-R2 
A second molecularly distinct CRH-R has been identified in rat (Lovenberg et al., 
1995a), mouse (Perrin et al., 1995, Stenzel et al., 1995, Kishimoto et al., 1995), and 
human (Liaw et al., 1996). In the rat at least, there are two known forms of the second 
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CRH-R. CRH-R2a is a 411 amino acid protein, which is expressed almost 
exclusively in brain. The alternatively spliced form, CRH-R2(3, has the first 34 amino 
acids of R2a replaced with a 54 amino acid sequence, giving a full-length receptor of 
431 amino acids. CRH-R2f shows the highest level of expression in the heart and 
skeletal muscle and a lesser extent is expressed in brain, lung, and intestine 
(Lovenberg et al., 1995b). In the mouse, only the homologue of the rat CRH-R2(3 
form has been identified (Perrin et al., 1995, Stenzel et al., 1995, Kishimoto et al., 
1995). In the human, the high homology of the reported rat and mouse CRH-R2(3 
form has been described in Valdenaire et al., 1997 (Figure 1.3). 
CRH-R2ß 
h: MRGPSGPPGLLYVPHLLLCLLCLLPPPLQYAACQSQMPKDQPLWAL EQYCHTIMTLTNLSGPYSYCNTTL 
r: M- H- -S- PSAQ----- YS---++---LQV--QPGRPLQ------ T-------- RT+-TR--F------------ 
m: M-T-- S- PSAQ----- FS---++--VLQV--QPG-A-Q------ T-------- RT+-TG--F ---T------ 
Figure 1.3. Alignment of the amino acid sequences of the 5'end of the human 
(h), rat (r), and mouse (m) CRH-R2ß. A dash (-) represents a residue conserved 
in the CRH-R20 sequence, while a cross (+) indicates a deletion. 
The three splice variants diverge at the corresponding position of human CRH-R2 
where the first intron occurs. CRH-R 2 is expressed in the form of three functional 
splice variants, 2a (411 amino acids), 2(3 (438 amino acids), and 2y (397 amino acids) 
(Liaw et al., 1996, Valdenaire et al., 1997, Kostich et al., 1998). Structural 
comparison of these CRH-R2 subtypes showed that 377 amino acids at their C 
terminus are identical and they differ only their N terminus; the 34 amino acids N 
terminal to CRH-R2a are replaced by a 61 amino acid sequence to form the CRH- 
R2ß or a 20 amino acid sequence to form the CRH-R2y. CRH-R2a and 2ß are co- 
expressed in peripheral organs and the CNS (Valdenaire et al., 1997), whereas CRH- 
R2y, which has been isolated only from humans, was found only in brains (Kostich et 
al., 1998). Interestingly, only CRH-R2a was isolated from amphibian species 
(Dautzenberg et al., 1997), whereas in rodents an additional CRH-R2(3 form has been 
detected (Lovenberg et al., 1995a). 
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In adenylate cyclase activation assays, CRH-related peptides such as sauvagine and 
urocotin are 10-fold more potent at the CRH-R213 than CRH-R2ct or CRH-R2y, which 
suggests that the N-terminus of the receptor is involved in the ligand receptor 
interaction (Kostich et al., 1998). In these experiments, urocortin was found to be the 
most potent peptide for activation of the CRH-R2. 
CRH-R2 contains similar putative extracellular N-glycosylation and transmembrane 
phosphorylation sites to CRH-R1. CRH-R1 and CRH-R2 are 70% identical, with 
greater sequence homology toward the C-terminus and only 47% identity in the N- 
terminal extracellular domain (Liaw et al., 1996). It is interesting to note that there are 
very large regions of amino acid identity between CRH-R1 and CRH-R2, particularly 
between transmembrane domains five and six. This similarity underlies the 
conservation of second messenger function, since it is this region that is thought to be 
the primary site of G protein coupling. 
Very recently, Miyata et al (1999) have identified and characterised a cDNA 
encoding a novel isoform of the CRH-R, referred to as CRH-R2a-tr, from a rat 
amygdala cDNA library. The nucleotide sequence of the cloned cDNA has a structure 
of an alternatively spliced form of the CRH-R2cc, which contains unspliced introns 6 
and 7 in the message, and encodes a 236 amino acid truncated protein that comprises 
three unique transmembrane domains (Miyata et al., 1999). In contrast to rodents, 
this splice product has not been identified in humans. 
1.3.2 Seven transmembrane helical domain receptor 
Hormones can be generally divided into three major classes: (1) derivatives of amino 
acids (e. g., dopamine and catecholamines), (2) peptides and protein (e. g., CRH), and 
(3) derivatives of steroids (e. g., estrogen). For the most part, amino acid derivatives 
and peptide hormones interact with membrane receptors on the cell surface, whereas 
the steroid hormones act by crossing the plasma membrane to interact with 
intracellular receptors. 
Membrane receptors: receptors on the surfaces of cells provide an essential 
component of communication with extracellular ligands. These membrane receptors 
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fall into three general classes based on their structure and mechanisms of signal 
transduction: (1) the single transmembrane domain receptors; (2) the four 
transmembrane domain receptors; (3) the seven transmembrane domain (7TM) 
receptors. The letter receptors have a conserved structure that is characterised by 
seven hydrophobic domains that are inserted into the membrane (Figure 1.4). 
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Figure 1.4. Structure of a seven transmembrane domain receptor. 
The G protein coupled receptors share several structural features, including the 
characteristic seven transmembrane spinning domains. The amino-terminal 
(NH, ) domain is located extracellularly and is involved in hormone interaction 
for some receptors. The seven transmembrane domains are connected by intra- 
and extracellular loops of amino acids. In many receptors, the ligands bind 
within the transmembrane domains. The intracellular loops and carboxy- 
terminal tail (COOH) are involved in coupling to G proteins and in intracellular 
signalling. 
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Seven transmembrane domain receptors exhibit large diversity within the family and 
several 7TM receptors may recognise the same endogenous ligand. For example, 
eight unique 7TM receptors have been identified for glutamate. Many 7TM receptor 
genes contain multiple introns, which introduce the possibility of variants due to 
alternative splicing, exon skipping and intron retention. Variations in gene-product 
splicing occur at the level of processing of heteronuclear-RNAs (hn RNAs or pre- 
mRNAs) in the cell nucleus. In genes with multiple exons, the introns are removed. 
Alternative splicing pathways vary the particular introns to be deleted (Figure 1.5) 
and this is an important process for many gene families. A notable example, for a 
non-7TM receptor family, is the neurexin family, where three genes are thought to 
produce thousands of alternatively spliced gene products, many of which are 
functionally distinct (Missler and Sudhof, 1998). 
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Figure 1.5 The process by which splice variants can be produced. 
el-e4, exons 1-4 of a hypothetical gene, il-i3, introns 1-3 of a hypothetical 
gene. Gene transcription results in synthesis of a single stranded linear unit of 
RNA, called hnRNA, which contains all of the sequence encoding the exons 
and introns. Introna are removed and the remaining exons joined together at 
defined base sequences by a process called splicing. Many 7TM receptor genes 
12 
contain multiple introns, which introduce the possibility of variants due to 
alternative splicing, exon skipping and intron retention (Kilpatrick et al., 1999). 
It is possible that 7TM splice variants could allow further regulation of receptor 
function via different dimerization possibilities and additional regulation of 
distribution within cell via differential interaction with intracellular scaffolding 
proteins 
1.3.3 G proteins and G-protein-coupled receptors 
Molecular cloning approaches have led to the isolation and identification of several 
hundred individual G-protein-coupled receptors, which have been divided, into three 
subfamilies. The inclusion of a receptor in a subfamily requires the presence of an 
overall percentage amino acid identity and not any discrete motif. Most GPCRs, 
including the odorant receptors, are grouped in Family I. CRH-Rs belongs to the 
superfamily of neuropeptide receptors, which include receptors for vasoactive 
intestitial peptide (VIP) (Sreedharan et al., 1995), glucagon (Lok et al., 1994), 
parathyroid hormone (PTH) (Kong et al., 1994), calcitonin (Albrandt et al., 1995), 
growth hormone releasing factor (Mayo, 1992), pituitary adenylate cyclase-activating 
polypeptide (PACAP) (Arimura and shioda 1995) and secretin (Ishihara et al., 1991). 
The CRH-R1 and R2 complementary DNAs (cDNAs) have been cloned (as discussed 
in Section 1.3.1) and the encoded protein has been found to share several conserved 
features with other GPCR family II members. Family III comprises the metabotropic 
glutamate receptors, the Cat+-sensing receptor, pheromone receptors and the taste 
receptors. Within each family, GPCRs are grouped by sequence similarity and ligand 
specificity. 
The GPCRs are integral membrane proteins involved in the transmission of signals 
across membranes, When a ligand binds the GPCRs undergo one or more 
conformational changes that trigger interactions between the receptor and G proteins. 
These initiate the intracellular signalling response and modulate the activity of distinct 
effector systems such as adenylyl cyclase, phospholipases, cGMP, phosphodiesterases 
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and ion channels. GPCRs also undergo desensitization, becoming refractory to further 
stimulation after the initial response despite the continued presence of a stimulus of 
constant intensity. Phosphorylation is a critical event in regulating this process 
(Kaziro et al., 1991). 
G proteins are heterotrimers that consist of an a-subunit and a combined ß-y-subunit. 
There are at least twenty three different a-subunit genes as well as several different ß 
(6ß)- and y (12y)-subunits. Within any given cell type, multiple different receptors, G 
protein, and effectors are present. This diversity of G protein subunits requires 
specific interactions that appear to be mediated by the intracellular loops and C- 
terminus of the receptor. In the absence of ligand, the a-subunit is bound to guanosine 
diphosphate (GDP) and remains associated with the (3-y-subunits. Ligand binding to 
the receptor induces a conformational change in the receptor that promotes the 
binding of aG protein to the receptor. After coupling to the receptor, GDP is 
exchanged for GTP on the a-subunit and the ß-y-subunit dissociates. These steps 
activate the G protein and initiate interactions with downstream effector molecules 
(e. g., adenylate cyclase). The a-subunit contains an intrinsic GTPase activity that 
converts GTP to GDP, which restores the inactive state and allows reassociation with 
the (3-y-subunits. 
Recent studies have indicated that alternative splicing is responsible for the generation 
of a number of G protein coupled receptor isoforms. The Human Parathyroid 
Hormone (PTH)/PTH-related peptide (PTHrP) receptor, which is an example of 
GPCRs, can activate multiple second messenger systems through receptor activation 
of different G proteins. The multi-exonic structure of the PTH/PTHrP receptor gene 
raised the possibility that novel PTH/PTHrP receptor variants may arise by alternative 
splicing of this complex gene (Kong et al., 1994). Several alternatively spliced 
transcripts may occur in different regions of this gene. The PTH/PTHrP receptor is 
known to be capable of signalling in response to PTH or PTHrP via two G protein- 
coupled pathways: (1) Gq-mediated activation of phospholipase C (PLC), resulting in 
increased Ca2+ and activation of protein kinase C (PKC); and (2) Gs-mediated 
activation of adenylyl cyclase leading to cAMP production and protein kinase A 
(PKA) activation (Juppner et al., 1991). 
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Many structure-activity studies with 7TM G-protein-coupled receptors suggest that 
the concerted participation of several intracellular domains is involved in coupling to 
G proteins (Spiegel et al., 1992). Findlay et al has shown that the C-terminal 
cytoplasmic tail of the porcine calcitonin receptor is important for efficient coupling 
to cAMP- and calcium-mediated pathways. Mutations in the third intracellular loop 
can lead to constitutive activation of receptors (Samama et al., 1993). Differentially 
spliced PACAP receptors, containing different sequences in this region, show specific 
coupling to different G proteins (Spengler et A, 1993). In addition, a mutation in the 
putative second intracellular domain of the vasopressin type 2 receptor results in an 
inability of this receptor to stimulate adenylate cyclase (Rosenthal et al., 1993). 
1.3.4 Adenylate cyclase 
Adenylate cyclase, the enzyme that produces cyclic AMP (cAMP), is widely 
distributed in mammalian cells and most organisms, and is usually associated with the 
plasma membrane. Activities of adenylate cyclase are regulated by numerous 
hormones and transmitters which act through G-protein couple receptors to stimulate 
or inhibit enzyme activity. 
cAMP signalling cascades are typically initiated by the binding of peptide hormones 
to their membrane receptors. However, intracellular cAMP concentrations are also 
modulated by intrinsic processes such as the cell cycle. The pleiotropic array of 
cellular effects of cAMP is primarily mediated by protein kinase A, which acts on a 
number of cellular substrates, including enzymes, the cytoskeleton and transcription 
factors. As depicted in Figure 1.6, cAMP binds to a regulatory subunit of protein 
kinase A, leading to dissociation of an active catalytic subunit that phosphorylates 
specific substrates. 
In addition a group of transcription factors are important targets for protein kinase A 
pathway (see Section 1.7). These include the cAMP response element binding 
proteins (CREBs) and activating transcription factors (ATFs) that are members of the 
n-Zip class of transcription factors. Post-translational modification of CREB by 
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phosphorylation at serine residues induces conformational changes that alter the 
affinity of CREB for coactivator proteins, such as CREB-binding protein (CBP) or 
TATA box-binding protein coactivator TAF11110. CBP is thought to form a bridge 
between CREB and the basal transcription apparatus. CBP also interacts with other 13- 
Zip proteins, such as c-Jun and c-Fos, other transcription factors, including c-Myb, as 
well as specific kinases (Lowe et al., 1998). 
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Figure 1.6. cAMP stimulation of transcriptional responses. 
G protein coupled receptors provide a major pathway for the generation of 
cAMP by adenylate cyclase. Increased cAMP levels within the cell cause 
dissociation of the tetrameric protein kinase A (PKA) holoenzyme leading to the 
release of the active catalytic subunit of PKA. The active catalytic subunit is 
translocated to the nucleus, where it phosphorylation transcription factor CREB, 
which binds as a homodimer to specific cAMP response elements (CREs) on 
target genes. The phosphorylation of CREB induces the binding of the 
coactivator, CREB-binding protein (CBP), which is also a substrate for 
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phosphorylation. These transcription factors act by interacting with basal 
transcription factors such as TFIIB and TFIID (Lowe et al., 1998). 
1.3.5 Alternative CRH ligands 
A number of lines of evidence indicate the likely presence of one or more mammalian 
peptides that are ligands for CRH-Rs / or CRH-BP but are molecularly distinct from 
hypothalamic CRH(141). First, it has been demonstrated that amphibian sauvagine and 
fish urotensin I are not CRH orthologs which suggests the existence of sauvagine- and 
urotensin I-like peptides in mammalian species (Okawara et al., 1988). Second, while 
CRH-BP levels are relatively high in the blood of men and women, the circulating 
CRH concentrations are low except during pregnancy. Finally, the higher affinity of 
CRH-R2 sauvagine and urotensin I than CRH also suggests the possibility of 
equivalent mammalian peptides (Turnbull, A. V and River, C. 1997). 
Recently, Vaughan and his colleague have described a putative alternate CRH- 
R/CRH-BP ligand in rats (Vaughan et al., 1995). This peptide was called urocortin 
and was identified from mRNA that was extracted from the Edinger-Westphal 
nucleus in the rat brain; this peptide also exists in humans (Donaldson et al., 1996). 
Urocortin has sequence and functional similarity to urotensin I (63% sequence 
identity to carp urotensin I) and CRH (45% sequence identity to r/h CRH) 
(Figurel. 7). Urocortin also shares 35% sequence identity with sauvagine. CRH-R2 
binds urocortin with 10- to 40-fold greater affinity than CRH and urocortin has a 10- 
fold lower EC50 than CRH in activating adenylate cyclase in cells overexpressing the 
CRH-R2ß (Vaughan et al., 1995). Indeed, it has been proposed that urocortin is an 
endogenous ligand for the second CRH-R. Urocortin is also a potent agonist for the 
CRH-R1 and binds to CRH-BP. The binding coefficient of this interaction is about 2- 
fold lower than CRH, and urocortin displaces CRH bound to CRH-BP thus elevating 
"free" CRH levels in brain (Behan et al., 1996). 
The comparison of sequences for urocortin, carp urotensin I, CRH, and sauvagine is 
shown in Figure 1.7. 
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rUcn DDPPLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV 100% 
hUcn -N--S -------------------------------------- 95% 
cUro N ---- I ----------NMI-M--NEN---Q-GL---KYL-E- 63% 
r/hCRH SEE- - I- L- ----- --EV- - M- -AEQLAQQ-HS--- KLMEII 45% 
Svg EG- - I- -- -SLE- -- -KMI- IEKQEKEKQQ-AN--- LLL- TI 35% 
Figure 1.7 Aligment of the amino acid sequences of the CRH-like peptides rat 
(r) and human (h) urocortin (Ucn), carp urotensin I (cUro), rat/human CRH, and 
sauvagine (Svg). -, identical amino acid to rat urocortin; %, percentage 
sequence homology with rat urocortin. 
1.3.6 CRH-binding protein 
In the circulation CRH is bound with high affinity by a CRH-binding protein, CRH- 
BP, which inhibits the biological activity of CRH in a number of in vitro assay 
systems. CRH-BP was originally identified, isolated, and purified from human 
plasma, and is thought to regulate the biological activity of placental CRH in pregnant 
woman (Campbell et al., 1987). The human CRH-BP gene has been assigned to 
5g11.2-g13.3. Human and rat CRH-BP cDNA display a high degree of sequence 
homology (85%) and encode a precursor protein of 322 amino acids in length. Both 
proteins possess one putative N-linked glycosylation site and 11 conserved cysteine 
residues (Potter et al., 1991). Recently, highly homologous cDNAs encoding mouse 
and sheep CRH-BP have also been cloned. Although forms of the human and rat 
CRH-BP are homologous, the pattern of anatomical distribution is somewhat different 
in the two species. The human CRH-BP is found abundantly in tissues such as the 
liver, placenta and brain, while in the rat CRH-BP mRNA is found only in the brain 
and pituitary gland (Potter et al., 1991). The absence of CRH-BP in nonprimate blood 
presumably reflects the lack of its synthesis in liver. CRH-BP in brain appears to be 
membrane associated, as indicated by its solubilization profiles and its partitioning 
upon sucrose gradient purification (Behan et al., 1993). However, there is no evidence 
for a receptor function for CRH-BP since, unlike the identified CRH-Rs, it lacks 
obvious transmembrane domains or intracellular signalling motifs in its sequence. 
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The exact function of CRH-BP under normal or pathological conditions remains 
uncertain. The pharmacological profile of the CRH-BP is different from that of either 
the CRH-R1 or CRH-R2. Both human and rat CRH-BP exhibit high affinity for rat 
and human CRH and very low affinity for ovine CRH (Chalmers et al., 1996). CRH- 
BP binds urotensin I with extremely high affinity and sauvagine with much lower 
affinity. Recently, CRH-BP in brain was shown to modulate the availability of "free" 
CRH to interact with its receptors (Turnbull et al., 1997). 
1.3.7 Pharmacology of CRH receptors and CRH-binding protein 
The discrete distributions of CRH-R1 and CRH-R2 imply that they subserve distinct 
physiological functions and this suggestion is supported by the dissimilar 
pharmacologies of the CRH-R subtypes. Several studies have described the binding 
constants and potencies of various CRH-R ligands in cells transfected with the 
cDNAs of the different CRH-Rs. CRH-R1 indiscriminately binds CRH peptides such 
as urotensin I, rat/human CRH, urocortin and sauvagine with high affinity (Vaughan 
et al. 1995, Donaldson et al. 1996). The majority of studies have described sauvagine, 
urotensin I, and r/h CRH as having similar binding constants or potencies at CRH-R1. 
CRH-R2 exhibits a substrate specificity that is different from CRH-R1. CRH 
peptides, such as rat/human CRH or ovine CRH and to a lesser extent urotensin I, are 
bound with lower affinity than urocortin and sauvagine; the rank order being urocortin 
> sauvagine > urotensin I> r/hCRH (Kishimoto et al., 1995). CRH-R2a and R2ß 
display virtually identical pharmacological properlies with respect to these ligands. 
The EC50 values derived for CRH-R2a and CRH-R27 are very similar, whilst those 
for CRH-R2ß are approximately 10-fold lower for all peptides (Kostich et al., 1998). 
The CRH-R antagonist a-helical CRH(9-41) is a far more effective antagonist at CRH- 
R2 than at CRH-R1 (Kishimoto et al., 1995). Thus, the pharmacology and 
distributions of the molecular subtypes of CRH-Rs appear to bear out observations 
made in vivo regarding the pharmacology of CRH responses. In particular, the data 
discussed above strongly suggest that CRH-R1 is the major receptor isoform 
regulating pituitary ACTH secretion (Owens et al., 1995). On the other hand, 
anatomical distribution of the receptors imply that CRH's effects on the vasculature 
(e. g., vasodilatation, hypotension, and inhibition of injury-induced edema) may be 
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mediated by CRH-R2. Furthermore, the relative potencies of sauvagine, urotensin I, 
and CRH are suggestive of CRH-R2 mediated events in several other instances. For 
example, a rank order of sauvagine > urotensin > CRH is apparent in the induction of 
hypertension and elevation in plasma catecholamines after injection of peptides or 
peripheral peptide administration. (Brown et al., 1982). 
The pharmacological profile of the CRH-binding protein is different from that of the 
receptor. Using the ligand immunoradiometric assay (LIRMA), the purified 
recombinant hCRH-BP was found to exhibit the following rank order of potencies: 
r/hCRH > alpha-helical ovine CRH(941) > hCRH(6_33) > hCRH (9_33) > d-phe hCRH(12_ 
41) > oCRH (Sutton et al., 1995). The rat and human CRH fragments CRHI. 4I_014, 
CRH6_33 and CRH9_33 are inactive at CRH-Rs but have high affinity for the CRH- 
binding protein. Therefore, although there may be some similarities in the binding 
domain of the CRH-BP and the CRH-R, they are distinct proteins each with unique 
and discernible pharmacological characteristics. This ability of the CRH-BP to bind 
and functionally inactivate CRH is somewhat analogous to the role of high-affinity 
monoamine-transporter molecules, and represents an additional CRH "modulatory" 
molecule (Chalmers et al., 1996). 
1.3.8 Localisation of CRH receptor subtypes 
The availability of nucleotide sequences for CRH-R1 and CRH-R2 has allowed a 
detailed examination of the regional and cellular distribution of CRH-R subtype 
mRNA expression using in situ hybridisation histochemistry. The results of these 
studies indicate heterogeneous distribution patterns of CRH-R subtypes in the brain 
and peripheral tissues and suggest specific physiological roles for these sites in CRH- 
related functions. 
Although CRH-R1 mRNA expression is very high in neocortical, cerebellar and 
sensory relay structures, expression of CRH-R2 mRNA is generally confined to 
subcortical structures. Particularly high levels of mRNA for CRH-R2 are evident 
within the lateral septal nuclei, the choroid plexus, the olfactory bulb, specific 
amygdaloid nuclei and various hypothalamic nuclei (Chalmers et al., 1995). 
20 
This heterogeneous distribution of CRH-R1 and CRH-R2 mRNA suggests a distinct 
functional role for each receptor in CRH-related brain systems. For example, in the 
anterior pituitary, the hybridisation signal for CRH-R1 mRNA is clustered around a 
subset of cells identified as corticotropes (Potter et al., 1994, Chalmers et al., 1995). 
In contrast, the hybridisation signal for CRH-R2 mRNA in the anterior pituitary is 
either undetectable (Sawchenko et al., 1995) or detected only in scattered cells 
(Chalmers et al., 1995). The selective expression of CRH-R1 mRNA within the 
neocortex and cerebellar cortex suggests that CRH affects in these regions are likely 
to be mediated by CRH-R1. On the other hand, the specific expression of CRH-R2 
mRNA within the forebrain lateral septal nuclei suggests that hypothalamic CRH 
input to this region is likely to be mediated by CRH-R2. Such anatomical information 
provides a basis for functional hypotheses related to CRH-R subtypes. The CRH-R1 
may be regarded as the primary neuroendocrine pituitary CRH-R and important in 
cortical, cerebellar and sensory roles of CRH. The anatomical distribution of CRH-R2 
mRNA indicates a role for this novel receptor in neuroendocrine, autonomic and 
general behavioural actions of central CRH (Chalmers et al., 1995). 
The CRH-R2a appears to be the predominant CRH-R2 isoform which is expressed on 
neuronal tissue, as where CRH-R2(3 is localised to non-neuronal elements such as the 
choroid plexus and cerebral arterioles. The localisation of CRH-R2 to cerebral 
arterioles (Lovenberg et al., 1995b) provides a putative means by which CRH may act 
to directly modulate cerebral blood flow. In peripheral organs, CRH-R2a and CRH- 
R2ß mRNA are co-expressed in cardiac and skeletal muscle (Valdenaire et al., 1997). 
CRH-R2ß is also present in the lung and intestine (Perrin et al., 1995). CRH-R2y, 
which has been isolated only from humans, was found only in the brain (Kostich et 
al., 1998). In human brain, CRH-R2y mRNA expression in septum and hippocampus 
with weaker expression in amygdala, nuleus accumbens, midbrain and frontal cortex. 
CRH-Rla has been detected in the skin (Slominski et al., 1995) and ovary (Nappi and 
Rivest, 1995). CRH-Rlc has been characterised from the hippocampus and 
cerebellum of a normal 2-year old female. The CRH-Rlc differs from CRH-Rla only 
in the deletion of 40-amino acids from the N-terminal domain predicted to extend 
extracellularly (Ross et al., 1994). 
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1.4 Placental CRH 
At present, the initiation of parturition in humans remains an enigma. It is probable 
that the mechanism controlling uterine transition from relaxation to the contractile 
stage is multifactorial. Two important factors are oxytocin, which is important for the 
initiation of labour (Fuchs et al., 1982), and prostaglandins, which appear to be 
essential for the progression of labour (Karim et al., 1970). 
Recently, interest has been directed toward a third factor, placentally derived CRH. 
The placenta is an important source of circulating CRH (Perkins and Linton, 1995). 
CRH is secreted by placental trophoblast into the maternal circulation. In maternal 
plasma the levels of CRH increase exponentially as pregnancy progresses (Campbell 
et al., 1987) and reach concentrations 1000 fold greater than those found in the plasma 
of non-pregnant women. CRH has been implicated as a potential regulator of human 
parturition (McLean et al., 1994). 
The bioactivity of circulating CRH is also known to be influenced by the CRH 
binding protein (CRH-BP) (Potter et al., 1991), which binds to the hormone in an 
equimolar ratio and prevents its recognition at the CRH-R. It has been previously 
shown that CRH-BP is present in the maternal plasma during pregnancy (Linton et 
al., 1993), but the relative concentrations of CRH and CRH-BP have not been 
reported, and the bioactivity of circulating CRH was therefore uncertain. Furthermore, 
it has been recently reported (McLean et al., 1994) that the exponential rise in 
maternal plasma CRH concentrations with advancing pregnancy is associated with a 
concomitant fall in concentrations of the specific CRH binding protein in late 
pregnancy, leading to a rapid increase in circulating levels of bioavailable CRH at the 
time that coincides with the onset of parturition. In particular it has been suggested 
that there is a" CRH placental clock" which is active from the early stages of human 
pregnancy and determines the length of gestation and the timing of parturition and 
delivery (McLean et al., 1995). 
The biological role of this placental CRH is still uncertain; It may influence placental 
ACTH secretion (Petraglia et al., 1987) although maternal plasma ACTH level does 
not rise proportionally (Rees et al., 1975). CRH is a potent vasodilator of the human 
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foeto-placental circulation and may act as a regulator of placental vascular tone 
(Clifton et A. 1994). CRH is able to prime and potentate the effects of oxytocin 
(Quartero et al., 1992) and PGF2a (Benedetto et al., 1994) on the contraction force in 
human pregnant myometrium in vitro, suggesting that placental CRH may act as an 
important modulator of the human myometrium. Several reports indicate that CRH 
may stimulate prostaglandin production in placenta, decidua and fetal membranes in 
vitro (Jone and Challis, 1989); PGF2a and PGE2, in turn, are able to induce synthesis 
of CRH by human placenta (Petraglia et aL, 1987). 
1.5 Myometrial CRH-Rs 
The identification of specific CRH-Rs in human myometrium suggests that placental 
CRH might influence myometrial function, and hence parturition. Evidence for a 
direct action of CRH on human myometrium was provided by the identification of a 
single, high affinity population of CRH-Rs in the human myometrium which increase 
their affinity during the latter stages of pregnancy (Hillhouse et a!., 1993). In contrast, 
in non-pregnant myometrium, these CRH-Rs exist in a low affinity state which is not 
functionally coupled to adenylate cyclase. As pregnancy progresses, the CRH-R 
adopts a high affinity state and becomes functionally coupled to both adenylate 
cyclase and cyclooxygenase (Grammatopoulos et al., 1994). The functional 
significance of these events remain to be determined but it is likely that they promote 
myometrial relaxation since cAMP and PGE2 have been shown to be potent 
myometrial relaxants (Wikland et al., 1982). Hillhouse and Grammatopoulos 
suggested that during pregnancy CRH play a "protective" role for the myometrium, 
by preventing uterine contractions. In human pregnant myometrium at term, there is a 
modification in the coupling mechanisms between CRH-Rs and the catalytic 
component of adenylate cyclase, resulting in a reduction of CRH-stimulated cAMP 
production (Grammatopoulos et al., 1996). As term approaches, these changes appear 
to reduce myometrial relaxation and facilitate the action of contractile agents such as 
oxytocin and PGF2a. Oxytocin may play a role here because it can exert a direct 
inhibitory influence on myometrial adenylate cyclase activity. 
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In pregnant (at term but not pre-term) myometrium, oxytocin can switch the CRH-R 
to a low affinity state and uncouple it from adenylate cyclase; an affect mediated via 
activation of protein kinase C, leading to phosphorylation and subsequent 
desensitization of the CRH-R (Grammatopoulos and Hillhouse, 1999). This oxytocin 
effect appears to be specific to the human myometrium and is mediated by two basic 
isoforms of the CRH-R which are expressed in the human myometrium. 
1.6 CRH-R genomic structure and chromosomal localisation 
Proteins were originally thought to be encoded by continuous segments of DNA, but 
actually very few genes contain uninterrupted coding regions. The vast majority of 
genes are interrupted by one or, typically, several noncoding regions called 
intervening sequences or introns. Introns are transcribed into RNA but are removed 
when it is processed into its mature form (mRNA); therefore, the sequences contained 
in the intron are not represented in the translated product. The coding sequences, 
called exons, actually dictate the protein sequence. As illustrated in Figure 1.8, genes 
not only include the coding region but also include surrounding sequences that may 
help in regulation of gene expression. These sequences include: "start" and "stop" 
signals for both transcription and translation; the promoter region, which lies 5' to the 
coding region and helps regulate transcription; the 5'-untranslated region (5'-UTR), 
which may function in regulation; and the 3'-untranslated region (3'-UTR), which 
contains the polyadenylation signal that is important for maturation of mRNA and 
also may be involved in other aspects of RNA processing, transport, degradation, and 
translation. 
It is important to realise that for eukaryotes the active gene unit contains not only all 
the direct information defining the protein sequence as encoded in the mRNA and the 
sites to directly initiate and terminate mRNA transcription, but all of the information 
necessary to modulate gene transcription as well. Such information is represented in 
specific DNA sequences that act as sites to bind nuclear transcription factors that alter 
gene activity. 
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Figure 1.8. Gene structure and organisation. 
(A) DNA is replicated and transcribed into RNA. which is then processed to 
remove introns. Translation then produces a functional protein. (B) Diagram of 
the basic aspects of a gene for proper transcription and translation of the DNA 
(Elsea, S. H and Patel, P. 1998). 
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1.6.1 The genomic structure of the human CRH-Rl 
The gene coding for CRH-R1 consists of at least 14 exons and spans over 20 
kilobases (Sakai et al., 1998). The CRH-R1 gene has been mapped to the 
chromosome 17g12-q22 (Vamvakopoulos and Sioutopoulou, 1994). CRH-RI's four 
reported isoforms originate from the same gene by alternative splicing (Figure 1.1). 
CRH-Rla, which binds to CRH with the highest affinity and transduces the most 
sensitive cAMP accumulation in response to CRH, is encoded in a total of 13 exons. 
CRH-R1ß contains an additional 29 amino acid sequence which corresponds to exon 
6. Unlike the CRH-Rla, CRH-Rlc lacks a40 amino acid sequence, corresponding to 
exon 3. Exon-intron boundaries are the same as that of the consensus sequence. The 
CRH-R1 gene exhibits substantial similarity to the glucagon receptor gene family that 
is characterised by the presence of introns within its trasmembrane%ytoplasmic 
module, highly conserved cysteines in its extracellular domain and a highly conserved 
first intracellular loop. All members of this family induce cAMP generation and 
phosphoinositide hydrolysis. 
Several variant receptors have been found in the GPCR superfamily. Three human 
calcitonin receptor (CT-R) isoforms have been reported (Albrandt et al., 1995, 
Kuestner et al, 1994, Egerton et al., 1995; Nakamura et al., 1995, Gorn et al., 1995). 
Differences in the three isoforms result from distinct transcription starting sites and an 
alternative splicing manner. Only the largest CT-R cDNA has a 16 amino acid 
insertion in the first putative intracellular domain of the deduced protein. This 
insertion is located between exon 5 and exon 7 of the hCRH-RI gene. In growth 
hormone-producing pituitary adenomas, a variant growth hormone releasing factor 
receptor (GRF-R) mRNA has been reported (Hashimoto et al., 1995). This variant has 
a 561 base pair insertion which contains a premature stop codon in-frame. This 
cassette is inserted at the position that aligns with the junction of hCRH-R1 exons 11 
and 12. Rat and human type I adenylate cyclase-activating polypeptide receptor 
(PACAP-R) have been shown to express four major splice variants due to alternative 
splicing of two exons and to exhibit coupling to adenylate cyclase and phospholipase 
C (Spengler et aL, 1993, Pisegna and Wank, 1996). The insertion of the two exons in 
the third putative intracelluar domain is located at the junction of hCRH-R1 exons 11 
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and 12. The existence of these variants indicates that there may be other unknown 
splice variants of hCRH-R1. The 5'-flanking region of rat CRH-R1 gene was isolated 
and characterised (Tsai-Morris et aL, 1996). So far, the sequence of the promoter/5'- 
flank and transcription initiation site of the human CRH-RI gene has not been 
reported. 
1.6.2 The genomic structure of human CRH-R2 
The gene coding for human CRH-R2 consists of at least 12 exons and spans 
approximately 30 kilobases (Liaw et al., 1996). The gene has been mapped to the 
chromosome 7p21-p15 (Meyer et al., 1997). Analysis of the human CRH-R2 gene 
reveals a genomic structure similar to that of mouse CRH-R1, which has 12 introns, 
the last 10 of which interrupt the coding region at identical positions to human CRH- 
R2 gene introns. The mouse CRH-R1 gene has one extra intron (intron 1) in the most 
5'-coding region. Intron 2 of mouse CRH-RI and intron 1 of human CRH-R2 also 
occur at different positions of the coding region. A splice variant for human CRH- 
RI ß has 29 amino acids inserted in the first intracellular loop. The insertion occurs 
exactly at the corresponding position of the exon 4 and 5 junction of the human CRH- 
R2. There is no structural counterpart of this CRH-R1 splice variant in CRH-R2. 
Human CRH-2a and rat CRH-R1 genes contain 13 and 12 exons, respectively. The 
N-terminal extracellular domains of human and rat CRH-R1 are divided with four 
introns, whereas the N-terminal extracellular domain of human CRH-R2a was 
separated by three introns. However, in the domains toward the C-terminus, the 
locations of introns are quite similar among the three genes. 
Molecular cloning techniques have identified three alternatively spliced forms of the 
CRH-R2 differing in their N-terminal domains, which are CRH-R2a, CRH-R20 and 
CRH-R2y (Figure 1.10). The genomic structure of the human CRH-R2 gene was 
described (Liaw et al., 1996), but this did not extend 5' of the CRH-R2 alternative 
exon. Recently Walter et al date reported the genomic order of the alternative exons 
to be ß-y a. The CRH-R20 and CRH-R2y exons possess good consensus splice 
junctions flanking an apparent 2.9-kb intron. The distance between the CRH-R2y- 
27 
exon and the CRH-R2a-exon is not known, but it is at least 5.8 kb and may be 
significantly more (Kostich et al., 1998). 
CRH-R2 gene 
I1 23456789 10 11 12 
13 229 315 425 543 697 758 831 917 1053 1095 
2a il, intracell loop el, extracellular loop 
34 as il 1 ell H2 e12 il 3 el 3 
2ß EC TM (1233) 
61aa 1234567 
2y 
20 as 
Figure 1.9. Genomic structure of human CRH-R2 
The figure shows the position of CRH-R2 introns in relation to extracellular and 
transmembrane domains, where EC, extracellular; il, interacellular loop; el, 
extracellular loop; cytoplasmic domain after TMVII (1-1233 bp): initiation to 
terminating codons. The numbers under the boxes refer to nucleotide sequence 
numbers (hCRH-R2cz GenBank Accession No. U34587). The gene coding for 
human CRH-R2 consists of at least 12 exons and spans approximately 30 
kilobases (Liaw et al., 1996). extracellular (EC); intracellularloop (il); 
extracellular loop (el); transmembrane(TM) domains; 
1.7 Eukaryotic gene regulation and promoter structure 
Regulation of eukaryotic gene expression can potentially occur at many levels. These 
include (1) transcriptional control; (2) processing of the pre-mRNA; (3) transport to 
the cytoplasm; (4) stability of the mRNA; (5) selecting which mRNAs are translated; 
and (6) post-translational modification of the protein product. Most eukaryotic genes 
are regulated in part at the transcriptional level. Transcriptional control is the primary 
mechanism controlling gene expression. Transcription is modulated by the interaction 
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of regulatory molecules with short DNA sequences most of which are located 
upstream from affected genes. In the following section, emphasis is placed on 
transcriptional control mechanisms. The typical eukaryotic gene consists of up to four 
distinct transcriptional control elements. These are: firstly, the promoter itself; 
secondly, upstream promoter elements located close to it which are required for 
efficient transcription in any cell type; thirdly, other elements adjacent to the promoter 
which are interdigitated with the upstream promoter elements (UPEs) and which 
activate the gene in particular tissues or in response to particular stimuli; and finally, 
more distant enhancer elements which increase gene activity either in all tissues or in 
a regulated manner. Such sequences often act by binding positively acting 
transcription factors which then stimulate transcription. However, although most 
sequences act in such a positive way, some sequences do appear to act in a negative 
manner to inhibit transcription. 
The internal structure of eukaryotic genes has been discussed in Section 1.6. In 
addition, there are regulatory sequences adjacent to genes that control transcription. 
These sequences are of two types: promoters and enhancers. These regulatory 
elements can be on either side of a gene, or at some distance from the gene. They are 
called cis regulators because they are found adjacent to the structural genes they 
regulate, as opposed to trans regulators (e. g., binding proteins), which are not 
adjacent to the genes they regulate. 
1.7.1 Promoter structure 
The promoter region of most genes contains several elements. The first is a sequence 
called the TATA box, which is located at about 25 to 30 bases upstream from the 
initial site of transcription (designated as -25 to -30). Some promoters have a second 
short conserved sequence, instead of or together with a TATA box, which surrounds 
the start site and is called the Initiator (Inr) element (O'Shea-Greenfield and Smale, 
1992). Core promoter structures can contain both elements (composite: TATA+ Inr'), 
one element (distinct: containing either TATA+ Inr or TATA7 Inr+) or no elements 
(null: TATA7 Inr). Composite core promoters are found primarily in viral genes. The 
cellular TATA+ Inf promoter appears to be more common than its counterpart, the 
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TATA" Inr+ promoter, although the latter is prevalent among the hematopoetic 
lineage-specific genes and the homeotic genes in Drosophila and mammals (Carl et 
al., 1996). The TATA" Inf promoters might be involved in housekeeping functions, 
although their functional distribution is not well known. The TATA box is found in 
most eukaryotic genes, but it is absent in some genes, notably housekeeping genes 
expressed in all tissues and in some tissue specific genes (Weis and Reinberg, 1992), 
where it is replaced by a sequence known as the initiator element, which is located 
over the start site of transcription. This appears to play a critical role in determining 
the initiation point and acts as a minimal promoter capable of producing basal levels 
of transcription. 
In promoters which contain a TATA box and in those which lack it, the very low 
activity of the promoter itself is dramatically increased by other elements located 
upstream of the promoter. These elements are found in a very wide variety of genes 
with different patterns of expression indicating that they play a role in stimulating the 
constitutive activity of promoters. The basal transcription of a eukaryotic gene is 
controlled by a number of common elements (transcription factors). Two of the best 
characterised transcription factors responsible for basal transcription are the CCAAT 
box and a GC-rich sequence known as the SP-1 box. These sequences play an 
essential role in efficient transcription of the gene and have been termed upstream 
promoter elements (UPE). 
It has been reported that the 5'-end of vertebrate genes are often associated with an 
increase in (G+C) content, in particular with an increase in the frequency of the 
dinucleotide CpG (Bird, 1986). These CpG-rich islands have an average G+C content 
of -60%, compared with the 40% average in bulk DNA. They take the form of 
stretches of DNA several hundred base pairs long. In some cases, CpG-rich islands 
begin just upstream of a promoter and extend downstream into the transcribed region 
before petering out. It is possible that the presence of unmethylated CpG-rich islands 
is connected with constitutive gene expression. Some times, the presence of such 
islands is taken as an indication that an associated sequence comprises an active gene. 
According to Bird (1986), there is no relationship between the presence or absence of 
TATA boxes and CpG-rich 5'-DNA regions. 
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1.7.2 Enhancers 
One of the characteristic features of eukaryotic gene expression is the existence of 
sequence elements located at great distances from the start site of transcription which 
can influence the level of gene expression. These elements can be located upstream, 
downstream or within a transcription unit, and function in either orientation relative to 
the start site of transcription. They act by increasing the activity of a promoter, 
although they lack promoter activity themselves and are hence referred to as 
enhancers (Muller et al., 1988). Some enhancers are active in all tissues and increase 
the activity of a promoter in all cell types whilst others function as tissue-specific 
enhancers which activate a particular promoter only in a specific cell type. 
As with promoter elements, enhancers contain multiple binding sites for transcription 
factors which interact together (Carey, 1998). In many cases these elements are 
identical to those contained immediately upstream of gene promoters. Enhancers 
consist of sequence elements which are also present in similarly regulated promoters 
and may be found within the enhancer associated with other control elements or in 
multiple copies. 
Promoter sequences are essential for transcription, while enhancers are not. Enhancers 
are able to stimulate levels of transcription at a distance, whereas this is not true for 
promoters. In addition, enhancers are responsible for tissue-specific gene expression. 
As a group, promoters contain modules (the TATA box) that must be located at a 
fixed site upstream of the transcription start site, but enhancers do not contain these 
modules. Although enhancers and promoters share similar sequences, the sequences 
in enhancers are most often contiguous. In promoters, they are spaced apart. 
1.7.3 Transcription factors 
The presence of suitable DNA elements (e. g. TATA/CCAAT boxes) and RNA 
polymerases is not sufficient to initiate transcription of most eukaryotic genes. 
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Proteins, that are not part of the RNA polymerase molecule, are needed for the 
initiation of transcription and these are called transcription factors. 
The anatomy of a promoter is usually defined by a combination of gene transfer 
experiments to assess the effect of promoter mutants and studies of protein-DNA 
interactions. In the gene transfer experiments, various promoter regions are linked to a 
reporter gene, such as the gene encoding chloramphenicol acetyl transferase (CAT), 
ß-galactosidase or luciferase. Sequential deletions of the promoter provide a gross 
delineation of the locations of regulatory elements, but this strategy may miss 
functional elements that act in combination with sequences that have been deleted. 
Ideally, point mutations are introduced into candidate regulatory elements to assess 
their role in the context of the native promoter. It is advantageous to simultaneously 
search for transcription factor binding sites, either using DNase I footprinting or gel 
shift assays. 
A large number of transcription factors have now been identified in eukaryotic cells. 
Some of these bind to enhancer regions. Others bind to cis-acting elements in the 
promoter. Trans-acting factors (TAFs) help RNA polymerase II to initiate 
transcription and together with RNA polymerase they form a preinitiation complex. 
Many transcription factors have now been sufficiently purified to enable identification 
and assignment to families based on DNA-sequence binding similarities. Such 
transcription factors are extensively reviewed elsewhere (Latchman, 1997). 
1.7.3.1 Transcription factors and inducible gene expression 
All cells respond to various treatments by activating or repressing the expression of 
particular genes. There are a number of consensuses DNA segments which blind 
transcription factors (Table 1.1). 
Inspection of the regulatory regions of genes which showed similar patterns of 
transcription, revealed the presence of short homologous DNA sequences which were 
absent from other genes which did not show this pattern of regulation. Thus, for 
example, genes whose transcription is induced in response to exposure to elevated 
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temperature contain a common regulatory element known as the heat shock element 
(HSE), which is absent from genes that do not show heat inducible transcription 
(Davidson et al., 1983). Similarly, genes whose transcription is induced by exposure 
to glucocorticoid hormone contain a common glucocorticoid response element (GRE), 
which is absent in genes that do not show this pattern of induction (Latchman et al., 
1997). 
Table 1.1 Sequences that confer response to a particular stimulus 
Consensus sequence Response to Protein factor Examples of genes 
containing sequences 
CTNGAATNTT Heat Heat-shock hsp70, hsp83, 
CTAGA transcription factor hsp27 
T/G T/A CGTCA Cyclic AMP CREB/ATF Somatostatin fibronectin, a- 
gonadotrophin, c-fos, hsp7O 
TGAGTCAG Phorbol esters AP-1 Metallothionein IIA, 
a1-antitrsin, collagenase 
CC(A/T)6GG Growth factor in Serum response c-fos, Xenopus y-actin 
serum factor 
RGRACNNN Glucocorticoid Glucocorticoid Metallothionein II A, 
TGTYCY receptors tryptophan oxygenase 
RGGTCANNN Oestrogen Oestrogen receptor Ovalbumin, conalbumin, 
TGACCY vitellogenin 
RGGTCAT GACCY Thyroid Thyroid hormone Growth hormone, myosin 
hormone retinoic receptors heavy chain 
acid 
TGCGCCCGCC Heavy metals Mep-1 Metallothionein genes 
AGTTTCNN Interferon-a Stat- 1 Oligo A synthetase 
TITCNC/T Stat-2 Guanylate-binding protein 
TrNCNNNAA Interferon-y Stat-I Guanylate-bindig protein, Fc 
Remarks: CREB/ATF represents cAMP-responsive element binding protein, AP-1 
represents activator protein 1, Stat-1 represents signal transducers and activators of 
transcription (STAT) protein. N indicates that any base can be present at that 
position, R indicates a purine, i. e. A or G, Y indicates a pyrimidine, i. e. C or T. 
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1.7.3.2 Transcription factors and cell type-specific transcription 
In eukaryotes, transcription factors also play a critical role in processes which have no 
parallel in prokaryotes. The higher eukaryotes contain a vast range of different cell 
types, each of which expresses specific genes encoding particular products necessary 
for the specialised function of that cell type. The role of transcription factors in 
controlling the cell type-specific expression of particular genes is the subject of this 
section. 
Regulation of cell type-specific transcription is via the activity of specific 
transcription factors, which are synthesised or are present in an active form only in the 
particular cell type where the genes are active. These factors may bind directly to 
specific DNA sequences in their target genes as occurs for Oct-2 or NFKB or, like 
OCA-B, may act as co-activators which are recruited to the gene by DNA-bound 
factors which, like Oct-1, may be expressed in all cell types. By interacting both with 
each other and constitutively expressed factors, these cell type-specific factors control 
the specific transcription pattern of the genes which are dependent upon them. 
1.7.3.3 DNA binding by transcription factors 
Detailed analysis of a number of different transcription factors has indicated that they 
have a modular structure in which specific regions of the molecule are responsible for 
binding to the DNA, whilst other regions produce a stimulatory or inhibitory effect on 
transcription. Studies on the DNA binding regions of different transcription factors 
have revealed several distinct structural elements which can produce DNA binding 
(Harrison, 1993). 
Indeed, transcription factors are frequently classified on the basis of their DNA 
binding domains and a selection of these binding domains is listed in Table 1.2. Well 
characterised DNA binding domains include: the helix-turn-helix motif found in the 
homeobox transcription factors (Kornberg, 1993); the two cysteine-two histidine zinc 
finger which is found, for example, in the Sp transcription factor family (Lania et 
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a1., 1997); the multi-cysteine zinc finger which is found in the steroid-thyroid hormone 
receptor family (Parker, M. G 1993). 
This last example is of particular interest, since factors containing the basic DNA 
binding domain can only bind to DNA once they have formed transcription factor 
dimers. Hence, factors containing the basic binding domain are further sub-grouped 
according to the nature of the dimerization motif. Thus, some of these factors contain 
a helix-loop-helix motif which mediates dimerization (Littlewood and Evan, 1995). In 
contrast, other basic DNA binding domain-containing factors, such as the CREB 
factor, undergo dimerization via the so-called leucine zipper motif which contains a 
regular array of leucine residues (Hurst et al., 1996). Thus, a wide variety of DNA 
binding domains (which in some cases have associated dimerzation domains) allow 
transcription factors to bind to their appropriate DNA sequences within target genes. 
Table 1.2 Transcription factors families classified by their DNA binding domains 
Domain Factors containing domain Comments 
Homeobox Numerous Drosophila homeotic DNA binding mediated via 
genes, related genes in other organisms helix-turn-helix motif 
POU Oct-1, Oct-2, Pit-1, Unc-86 Consists of POU-specific 
domain and POU-homeobox 
Paired box Various Drosphila segmentation genes. Often found together with a 
PAX factors homeobox in PAX factors 
Cysteine-histidine TFIIIA, Kruppel, Sp I, etc. Multiple copies of finger 
motif zinc finger 
Cysteine-cysteine Steroid-thyriod hormone receptor family Single pairs of fingers. Related 
zinc finger motifs in Adenovirus EiA and 
yeast GAI. 4, etc. 
Basic domain C/EBP, c-fos, c jun, c-myc, MyoD, Often found in association 
GCN4 with leucine zipper or helix- 
loop-helix dimerization motifs 
Winged HTH Fork head, HNF 3A c-ets c-erg, Binds purine-rich sequences 
Drosophila E74, PU. 1 
Ets domain Ets-1, Elk-1, SAP Contain helix-turn-helix motif 
In addition to the DNA binding domain, many transcription factors contain specific 
regions which are necessary for the activation of transcription. As with DNA binding 
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domains, a number of distinct types of activation domains have been identified which 
are defined on the basis that they are rich in acidic amino acids, glutamine residues or 
proline residues, respectively. Following binding to their appropriate DNA binding 
site the activation domains of specific activating transcription factors can interact with 
the basal transcriptional complex so as to stimulate transcription. In this manner, the 
binding of specific transcription factors can stimulate gene transcription. 
1.7.4 Transcriptional regulation of eukaryotic cells by second messenger 
signalling pathways 
/ 
The ability of cAMP to stimulate expression of a variety of genes suggested that it 
might work through a discrete element that would be shared by a family of responsive 
genes. Activation of adenylate cyclase by various effector systems elevates 
intracelluar cAMP and stimulates protein phosphorylation by cAMP dependent 
protein kinases and transactivation of genes with the consensus palindromic sequence 
5'-TGACGTCA-3' in the 5'-flanking regions (Deutsch et a1., 1988). Several genes 
which are regulated by a variety of stimuli contain similar sequences in their promoter 
regions, although at different positions. A comparison of the CRE (CAMP response 
element) sequences identified to date, shows that the 5'-half of the palindrome, 
TGACG is the best conserved (Sassone-Corsi, 1995). 
The first CRE-binding factor to be characterised was CREB (CRE-binding protein; 
Hoeffler et al., 1988) but subsequently several additional CRE-binding factors have 
been identified and the corresponding genes have been cloned. Most of the CRE- 
binding proteins were identified by screening a variety of cDNA expression libraries 
with CRE and ATF sites (Foulkes et al., 1991). The ATF/CREB family includes 
several members, of which only the CREB, CREM and ATF-1 gene products have 
been shown to be directly phosphorylated by the cAMP-dependent protein kinase A 
(Sansone-Corsi, 1995). All ATF/CRE binding proteins belong to the bZip 
transcription factor class. Various different factors of the CREB/ATF family are able 
to heterodimerize with each other but only in certain combinations. A "dimerization 
code" exists, which seems to be a property of the leucine zipper structure of each 
factor. 
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CRE-binding proteins may act as both activators and repressors of transcription. The 
activators mediate transcriptional induction upon phosphorylation by PKA (Rehfuss 
et al., 1991). Their expression is constitutive and widely distributed in various tissues 
in a housekeeping fashion. Among the repressors, the Inducible cAMP Early 
Repressor (ICER) product deserves special mention. ICER is generated from an 
alternative CREM promoter and is the only inducible CRE-binding protein. ICER 
negatively autoregulates the alternative promoter, generating a feedback loop. ICER 
expression is tissue specific and developmentally regulated. The kinetics of ICER 
expression displays the characteristics of an early response gene. 
This canonical CRE is not present in the promoters of all genes that respond to cAMP. 
Despite the large size of the CRE binding protein family, it is apparent that other 
DNA regulatory elements and transcription factors are also capable of stimulating 
gene transcription in response to cAMP. This is not surprising once the possibility of 
using phosphorylation to regulate transcription is recognised. In fact, because so many 
transcription factors undergo phosphorylation before or during the transcription 
process, it may ultimately become difficult to classify regulatory elements based 
solely on their ability to be stimulated by cAMP. 
One of the first "non-consensus" cAMP regulatory elements was identified in the 
human metallothionein RA gene. The metallothionein IIA gene binds a transcription 
factor referred to as activator protein 2 (AP-2). An AP-2 acts as a basal level enhancer 
(Mitchell et al., 1987), but it also stimulates transcription in response to both phorbol 
esters and cAMP (Imagawa et al., 1987). AP-2 site has been identified in a number of 
genes, allowing derivation of the relatively variable GC-rich consensus 5'- 
GCCN3GGC-3' (Williams and Tjian, 1991) (Table 1.3). 
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Table 1.3 Selected cAMP responsive DNA sequences 
Gene promoter Nucleotide sequence References 
Sequences related to canonical CREs 
Somatostatin CRE 5'TGACGTCA3' Montminy et a!., 1986 
GPHa 5'TGACGTCA3' Silver eta!., 1987 
VIP 5'TGACGTCT3' Tsukada et al., 1987 
PEPCK 5'TGACGTAA3' Short et al., 1986 
c- os 5'TGACGTTT3' Fisch et al., 1989 
Adenovirus ATF 5'TGACGTAG3' Lin et al., 1988 
Proenkephalin 5'TGACGCAG3' Comb et al., 1986 
AP-1 5'TGA-GTCA3' Angel et al., 1987 
Consensus 5'TGACGTCA3' 
Other sequences involved in cAMP-regulated expression 
AP-2 5'GCCN3GGC3' Imagawa et a!., 1987 
Jun B 5'AGTGCACT3' de Groot eta!., 1991 
Ovalbumin ERE 5'TGGGTCA3' Doucas et al., 1991 
CYP11A1 5'TCACTGATGACCTTGAG000TGG3' Inoue et al., 1991 
CYP 17A 5'TTGATGGACA GTGAGCAAG3' Lund et al., 1990 
CYP21B GC-rich S 1-like element Kagawa et al., 1990 
hCG GC-rich region Albanese et al., 1991 
RH GC-rich region Kurten et al., 1992 
pST-cathCP2 GC-rich region Hjorth et al., 1990 
Activator protein (AP-1) was initially described as a nuclear factor required for 
transcription by phorbol ester tumour promoters such as TPA, an activator of the 
protein kinase C pathway (Lee et al., 1987). The TPA response element (TRE or AP- 
1 site) was identified initially in the promoter region of the human metallothionein 
RA and collagenase genes (Angel et al., 1987). The THE sequence has been 
identified in a large number of genes, that allows derivation of the consensus 
sequence of TGA (C or G) TCA, which differs from the palindromic CRE 
(TGACGTCA) by a single nucleotide. THE or AP-1 binding proteins are the Jun and 
Fos families of the bZIP superfamily of transcription factors. These proteins interact 
through their carboxy-terminal leucine zippers, and c-jun can form both homodimers 
with itself and heterodimers with c-fos, while c-fos can heterodimerize with c-jun but 
cannot form homodimers. TPA and the activation of PKC induce c-jun. This is due to 
positive autoregulation mediated by binding of c-jun homodimers or c jun: c fos 
heterodimers to an AP-1 site within the c-jun promoter (Radler-Pohl et a1., 1993, 
Karin M, 1990). 
38 
Although the THE (AP-1) site was first identified based on its response to phorbol 
esters, it also imparts sensitivity to cAMP in JEG-3 and HeoG2 cells (Deusch et 
al., 1988). A THE-like element in the human proenkephalin gene conveys 
responsiveness to both cAMP and phorbol esters (Comb et al., 1988), although the 
response to phorbol esters alone is small and is greatly potentiated by 
phosphodiesterase inhibitors. The THE mediated transcriptional responses through 
both the protein kinase A and protein kinase C pathways. This dual activity may 
reflect heterodimeric interactions between transcription factors or, alternatively, 
phosphorylation of TRE-binding factors by both pathways. The CRE and THE sites 
have been described as "general response elements" at the distal end of a complex 
signal transduction pathway (Figure 1.1 1). 
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Figure 1.11. Signal transduction pathways that modulate gene transcription. 
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Several examples of signal transduction "cross-talk" suggest that second 
messenger response elements can be activated by either the Protein kinase A or 
Protein kinase C pathway (Hunter T and Karin M 1992). 
1.8 Objective of the research project 
The objective of the first part of my research project was to detect the presence of 
CRH-R subtypes in human myometrial biopsies ( pregnant and non-pregnant) and 
myometrial cell cultures. 
As discussed in Section 1.3, the sequence of the promoter/ 5'-flanking and 
transcription initiation site of the human CRH-R1 and CRH-R2 gene is not yet 
understood and the relative importance of transcription effects is unclear. Therefore, 
the objective of the second part of my research project was to clone and characterise 
the promoter region of the human CRH-R genes in order to understand the molecular 
mechanisms that direct the expression of these genes. 
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Chapter 2 Materials and Methods 
The majority of materials used in the experiments related to the project are described 
in this chapter, which may include the names of the materials, suppliers, and general 
applications. The experimental methods or techniques adopted in the project are also 
briefly described in this chapter. The chapter is organised in two sections, namely, 
Materials and Methods. 
2.1 Materials 
2.1.1 General reagents 
Restriction enzymes were obtained from Gibco BRL and New England Biolabs, all 
other enzymes were obtained as stated in the text. 
All radioisotopes were supplied by Amersham at the following specific activities: 
[(X-32P] CTP 800 Ci/mmol; 
[a-32P] dCTP 3,000 Ci/mmol; 
[y-32P] ATP3,000Ci/mmol; 
[a-35S]dATP 1,000Ci/mmol. 
X-ray films were from Fuji and Kodak. 
Oligonucleotides were synthesised by the University of Warwick Oligonucleotide 
Synthesis Core Facility (Applied Biosystems DNA synthesiser, model 380B) or were 
ordered from Gibco BRL. 
Material for bacterial growth media were supplied by Difco laboratories (Michigan, 
USA) and Oxoid Ltd. (England). Antibiotics were supplied by Sigma Chemical Co., 
St. Loius, USA. Petri dishes were supplied by Falcon. 
Agarose were supplied by Gibco BRL. Acrylamide was supplied by Fisons and 
bisacrylamide by Kodak. The other chemicals were from BDH, Sigma, or Fisons. 
Molecular marker: lkb DNA ladder was from Gibco BRL. 
2.1.2 Stock solutions 
TE: 1 0mM Tris-Cl, pH 7.4 EDTA, pH 8.0. 
10 x TBE: 0.9 M Tris-borate, 20 mM EDTA, pH8.0. 
41 
20 x SSC: 3M NaCl, 0.3M sodium citrate, pH7.0. 
10 x MOPS: 0.1M MOPS, pH7.0,40mM sodium acetate, 5mM EDTA, pH 8.0. 
Phosphate buffered saline (PBS): 0.8% (w/v) NaCl, 0.02% (w/v) KCI, 0.144% (w/v) 
Na2HPO4,0.024% (w/v) KH2PO4, pH 7.4. 
2.1.3 Bacteriological media 
LB broth: 0.5% (w/v) bacto-yeast extract, 1.0% (w/v) bacto-tryptone, 1.0% (w/v) 
NaCl, pH 7.0. 
2x YT broth: 1.6% (w/v) bacto-tryptone, 1.0% (w/v) bacto-yeast extract, 0.5% NaCl, 
pH7.0 
Agar was added to 1.5% (w/v) for pouring plates. 
Antibiotics were used in plates and broth at the following final concentrations: 
ampicillin, 50-100µg/ml; tetracyclin, 15pg/ml. 
2.1.4 Cell lines 
The HEK-293 cell line was obtained from the ECACC (European Collection of 
Animal Cell Cultures) in frozen ampoules. Myometrial cell line is derived from a 
primary culture of uterine myocytes. 
2.1.5 Tissue collection 
Pregnant myometrial biopsies were obtained from women undergoing elective 
caesarean section at term. The biopsy site was standardised to the upper margin of the 
lower segment of the uterus in the midline, which provides the closest approximation 
to the upper segment of the uterus. 
Non-pregnant myometrial tissues were obtained from premenopausal controls 
undergoing hysterectomy for non-malignant conditions. The biopsies were 
immediately snap-frozen in liquid nitrogen and subsequently stored at - 70°C until 
use. Ethical approval was obtained from the local ethical committee and informed 
consent to the study was obtained from all patients. 
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2.1.6. Plasmid vector 
pBluescript II SK (+/-)(Stratagene) and pGEM-T (Promega) were used as a general 
purpose cloning PCR products vectors . 
pGEM-5Zf(+/-) and pGEM-7Zf(+/-) were used as general purpose subcloning vector 
(Promega). 
The pCAT3-Basic reporter gene plasmid (Promega) was used as a expression system. 
2.1.7 Genotypes of E. coli strains 
For general cloning in this project, four strains of Escherichia coli have been 
employed which had genotypes as shown below: 
XL1-Blue: recAl, endAl, gyrA96, thi-1, hsdR17, supE44, relAl, lac, [FproAB, lac! ' 
ZAM 15, Tn10 (tet`)]. 
XL2-Blue MRF: recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lac, [F proAB 
laclgZAM15Tn10 (tetr) Amy Cam]'. 
DH5a: supE44, hsdR17, recA1, endA1, gryA96, thi-1, relA1. 
JM109: recA1, supE44, endA1, hsdR17, gyrA96, relA1, thid(lac-proAB). 
2.1.8 PCR primers 
pBluescript T3 primer: 5'-ATTAACCCTCACTAAAG-3', 
pBluescript T7 primer: 5'-AATACGACTCACTATAG-3', 
pBluescript Reverse primer: 5'-AACAGCTATGACCATG-3', 
pBluescript M13-20 primer: 5'-GTAAAACGACGGCCAGT-3', 
The PCR primers for cloning CRH-R 
CRH-Rla and CRH-Rlc: 
1st IS: 5'-ACCCAAGCTTAGCCGAGCGAGCCGAGGATG-3' 
1 A: 5'-GTCGACAAGC(T)18-3' 
2nd 2S: 5'-GGGAATTCGAGGATGGGAGGGCACCCGC-3' 
2A: 5'-GGGAAGCTTCAGACTGCTGTGGACTGCTT-3' 
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CRF6: 5' -AAACAATGGCTACCGGGAGTG-3' 
CRF3: 5'-TGACCAACTTCTTCTGGATGTT-3' 
CRF5: 5'-CACCTACATGCTGTTCTTCGTCA-3' 
CRH-R 1(3 
Ist 2S: 5'-GGGAATTCGAGGATGGGAGGGCACCCGC-3' 
1 A: 5'-GTCGACAAGC(T)18-3' 
2nd 5'S: 5'-CAGCTCCGTCTCGTCAAGGC-3' 
5'A: 5'-GCACCGGATGCTCCTTCGAAC-3' 
2nd 3'S: 5'-ATGGAGTGGTGCCCCATTTC-3' 
2A: 5'-GGGAAGCTTCAGACTGCTGTGGACTGCTT-3' 
CRH-R2a 
1st S 1: 5'-GGGAATTCCATGGACGCGGCACTGCTCC-3' 
A 1: 5' -GGGAATTCCCGGGCCAAGAGGCATGGTTTATTTC-3' 
2nd S2: 5' -GGGAATTCTCCACAGCCTGCTGGAGGCC-3' 
A2: 5'-GGGAATTCCCGGGCAGGTGGGCGACCGAGGG-3' 
CRH-R2ß 
1st S 1: 5'-TCCAGTCCCTAACCCCAGCC-3' 
A 1: 5' -GGGAATTCCCGGGCCAAGAGGCATGGTTTATTTC-3' 
2nd S2: 5'-CTGGCATGAGGGGTCCCTCAG-3' 
A2: 5'-GGGAATTCCCGGGCAGGTGGGCGACCGAGGG-3' 
CRH-R2y 
1st S 1: 5'-CTGTGCTCAAGCAATCTGCCTAC-3' 
Al: 5'-GGGAATTCCCGGGCCAAGAGGCATGGTTTATTTC-3' 
2nd S2: 5'-CTTGGCTTCCCCAAGTGCTGAG-3' 
A2: 5' -GGGAATTCCCGGGCAGGTGGGCGACCGAGGG-3' 
5'RACE primers used for cloning CRH-R2 
CRH-R20 (1) 1st: 1A 5'-GAGAGGTTGGTGAGGGTCATGATGGTG-3' 
2nd: 2A 5'-GAGGAGGTGTGGGACGTAGAGGAG-3' 
(2) 1st: 1A 5'- GAGGAGGTGTGGGACGTAGAGGAG-3' 
2nd: 2A 5'-GGTATTCTGGACCCACTTCTTCCAC-3' 
CRH-R2a 1st: 1A 5'-CAGCCGTCCAAGAGCAGCTCTTCAG-3 
44 
2nd: 2A 5'-CTTCAGCCAGCGCCAGGCTGCAGTTG-3' 
CRH-R2y 1st: 1A 5'-GCAGAAGAGCTGAGGAAAGCCCAGTC-3' 
2nd: 2A 5'-AAAGCCCAGGTCCCTGTCTTCAGGC-3' 
Adaptor primer AP 1: 5'-CCATCCTAATACGACTCACTATAGGC-3' 
Nested Adaptor primer AP2: 5'-ACTCACTATAGGGCTCGAGCGGC-3' 
5'RACE used to identify the 5'-end cDNA of CRH-RI 
CRFII: 5'-GGGAAGCTTCAGACTGCTGTGGACTGCTT-3' 
CRF4: 5' -GGAAGGAGTTGAAGTAGATG-3' 
CRF7: 5'-ATGAACATCCATTTGCGCAGC-3' 
CRF8: 5'-GTCCACGGATGCGTTGCACTGC-3' 
PEI: 5'-CAGAAGGAGAAGGGCCTTGACG-3' 
PE3: 5'-CTTGACGAGACGGAGCTGCGG-3' 
Abridged anchor primer: 
5'-GGCCACGCGTCGACTAGTACGGGI IGGGI IGGGI IG-3' 
Abridged universal amplification primer (AUAP): 
5'-GGCCACGCGTCGACTAGTAC-3' 
Construction of plasmid for promoter analysis 
P 1: 5'-CCGGTACCGACCTGTGAGATT7CACAGGAG-3' 
P2: 5'-CCGGTACCGAGGCTCTGGAAGAACAGACC-3' 
P3: 5' -CCGGTACCACCTACCCACAGTACAGTATC-3' 
P4: 5'-CGGCTCGAGAGGTGTGGGACGTAGAGGAGG-3' 
PCR primers used for rat CRH-R1 promoter region 
RCRF: 5'-CTAGGTGCTTCTCAACCAGGCC-3' 
RCRF 1: 5'-CACCTGGCCGTGCTGAACCTC-3' 
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Genomic walking 
1) Universal-17: 5'-GAGGACTCGAGCTCAAGC(T)17-3' 
CRH-R20 (2) 1st: GAGGAGGTGTGGGACGTAFAGGAG-3' 
2) Universal: 5'- GAGGACTCGAGCTCAAGC-3' 
CRH-R20 (2) 2nd: 2A 5'-GGTATTCTGGACCCACTTCTTCCAC-3' 
PCR primers for analysis the clone containing the exon I of CRH-Rlcc gene 
PE5: 5'-GGAAACGGCGGCCAGACTTCC-3' 
PE3: 5'-CTTGACGAGACGGAGCTGCGG-3' 
PCR primers for amplify the region between the CRH-R2(3 and 2y exon 
B4: 5'-CATGACCCTCACCAACCTCTC-3' 
G3: 5' -GGTAGGCAGATTGCTTGAGAC-3' 
2.1.9 Genomic DNA library 
An amplified human placental genomic cosmid DNA library was obtained from 
Clontech, USA. The library was constructed from 30-50 kilobase fragments of the 
partial BamH I digest of placental DNA inserted into the BamH I site of the pWE 15 
cloning vector. 
2.1.10 Human CRH-Rl and CRH-R2 riboprobe 
Human CRH-R1 and CRH-R2 riboprobe were obtained from Dr. Lovenberg, 
Neurocrine Biosciences Inc., San Diego. 
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2.2 Methods 
2.2.1 Routine manipulation of DNA 
2.2.1.1 Extraction procedures 
Samples containing nucleic acids were routinely subjected to phenol, 
phenol: chloroform: iso-amyl alcohol (25: 24: 1) and chloroform. In order to remove 
protein contaminants. In extraction procedures the sample were added to equal 
volumes of Tris pH 8.0 buffer phenol or phenol: chloroform: iso-amyl alcohol or 
chloroform only and vortexed briefly to mix thoroughly. The mixtures were subjected 
to centrifugation (20,000g) in a 1.5 ml microcentrifuge for 5 minutes to separate into 
two phases. The top aqueous layer containing the DNA was recovered (such that the 
interface that usually contains protein was not disturbed) and transferred into a clean 
microcentrifuge tube. After these procedures, the DNA was precipitated as described 
below. 
2.2.1.2 Precipitation procedures 
The salt concentration of an aqueous solution containing DNA was adjusted to 0.3 M 
with sodium acetate (pH 5.2) or ammonium acetate (pH 7.2), and mixed by vortexing 
briefly. Two and half volumes of 100% cold ethanol, or an equal volume of 
isopropanol, were added and then mixed thoroughly either by vortexing or by 
inverting the tube several times. The process of precipitation was allowed to occur 
either at -20°C for two hours or at -70°C for 30 minutes. The DNA was then pelleted 
by centrifugation (20,000 g) in a microcentrifuge for 15 minutes. The ethanol was 
removed, the pellets washed with 70% ethanol to remove salt, then dried briefly under 
vacuum or air dried. After all above procedures, the DNA pellets were resuspended in 
an appropriate volume of TE buffer (10mM Tris-HC1 pH8.0,1mM EDTA) or sterile 
distilled water. 
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2.2.2 Electrophoresis of nucleic acids 
2.2.2.1 Non-denaturing agarose gels 
Sample has 0.2 volumes of Type III loading buffer (50% v/v glycerol, 0.25% v/v 
bromophenol blue, 0.25%w/v xylene cyanol FF) added to them run on gels of 0.6% to 
2.0% w/v agarose in lx TBE with 0.59g /ml ethidium bromide (from a stock solution 
of 10mg /ml). Gels were run in 1xTBE buffer containing 0.5µg/ ml ethidium bromide 
and photographed on an ultraviolet light box. 
2.2.2.2 Non-denaturing polyacrylaimd gels 
5% non-denaturing polyacrylamide gels were poured in gel plates 160mm in length 
and consisted of 5% polyacrylamide (acrylamide: N, N'-methylenebisacrylamide 29: 1 
(w/v) ), lx TBE, 0.07% (w/v) ammonium persulphate, and 0.035% (v/v) TEMED 
(Sigma). The gel was allowed to polymerise for 30 minutes and then the wells were 
flushed with 1x TBE running buffer. DNA samples were mixed with an equal volume 
of 6x gel loading buffer (50% v/v glycerol, 0.25% w/v bromophenol blue, 0.25% w/v 
xylene cyanol FF) and electrophoresed at 150 volt in 1x TBE until the bromophenol 
blue had migrated to the bottom of the gel. Finally, the gel was dried under vacuum at 
80°C and exposed to X-ray film. 
2.2.2.3 Denaturing polyacrylamide gels 
6% polyacrylamide (acrylamide: N, N'-methylenebisacrylamide 19: 1 (w: v) ) gels 
containing 8M urea, 1x TBE, 0.05% ammonium persulphate, 0.05% TEMED 
(Sigma) were poured between gel plates and allowed to polymerise for 4 hours at 
room temperature. For electrophoresis of products from RNase protection assays, gels 
of 16 cm in length were used, and for separation of sequencing products gels of 40 cm 
in length were employed. Gels were fixed to the electrophoresis tank and pre-run with 
1x TBE running at 40 watts (Sequencing gels at 70 watts) for 30 minutes after which 
sample wells were flushed with running buffer. 
Nucleic acid samples in denaturing gel loading buffer: 90% (v/v) formamide, 10mM 
EDTA, pH8.0,0.01% bromophenol blue, 0.01% xylene cyanol, were heated at 85- 
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100°C for 3-5 minutes, loaded onto the gel and electrophoresed at 40 watts, for 
sequencing gels at 70 watts. 
Sequencing gels were fixed in 10% (v/v) acetic acid for 30 minutes, transferred onto 
filter paper (3MM Whatman) and dried at 80°C on a vacuum drier and then exposed 
to X-ray film at room temperature. Gels with 32P samples were transferred onto filter 
paper and dried at 80°C on a vacuum drier and exposed to X-ray film with an 
intensifying screen at - 70°C. 
2.2.3 Extraction of total RNA 
RNA was extracted from isolated human myometrial tissues using the RNeasy Total 
RNA Kit (Qiagen GMBH) according to the manufacturer's instructions. 
a) The tissue was weighed, 100mg and homogenised in 600 µl lysis buffer (RAT). 
The flow-through fraction from QLAshredder was transferred to a 1.5m1 
microcentrifuge tube, and 225µl ethanol added to the flow-through fraction, and 
mixed by pipetting. The sample was applied to RNeasy spin column. It was 
centrifuged for 15 seconds at 10,000 rpm. The column was wash with 700µ1 washed 
buffer RW1, centrifuged for 1 minute, and washed again with 500µ1 wash buffer RPE. 
After centrifuged for 2 minutes to dried the spin column membrane, the RNA was 
eluted with 50µl water or TB buffer. 
b) DNase digestion reaction. The total RNA was in combined with 5X T3/T7 RNA 
buffer (Gibco-BRL), 20u RNase inhibitor, O. 1M DTT and 2 united RQ1 RNase-free 
DNase (Promega) in a volume of 100 µl. The sample was incubated for 37°C at 20 
minutes. 
c) RNeasy Total RNA Kit was used to purify RNA from DNase digestion reaction. 
The total RNA purity and recovery of each sample was determined using an UV 
spectrophotometer (260 and 280 nM). The integrity of the purified RNA was assessed 
by gel electrophoresis on denaturing agarose gels. 
2.2.4 Isolation of genomic DNA 
Tissue samples were frozen in liquid N2 and ground to a fine powder with a pestle and 
mortar. The powdered tissue was transferred to a 50m1 polypropylene tube (Falcon) 
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and 10 volumes of Extraction buffer: 10mM Tris, pH8.0,0.1M EDTA, pH8.0, 
20µg/ml pancreatic RNase (Sigma), 0.5% SDS added. The transferred tissue was 
incubated at 37°C for 1 hour with gentle agitation after which proteinase K was added 
to a final concentration of 100pg/ml and incubated at 50°C for overnight. The solution 
was extracted twice with an equal volume of phenol (pH8.0) and twice with an equal 
volume of phenol: chloroform(1: 1 (v/v) pH 8.0), the aqueous phase was removed each 
time using a 0.5ml pipette tip with the end cut. The DNA pellet was then precipitated, 
washed and resuspended using the procedure as described in Section 2.2.1.2. 
2.2.5 Cell culture 
2.2.5.1 Growth and subculture of tissue culture cells 
Adherent cells were grown in complete DMEM in disposable 75 cm2 or 175 cm2 
tissue culture flasks (Nunclon) at 37°C in a humidified atmosphere of 5% C02. 
Confluent monolayers were wash once with PBS and incubated with prewarmed at 
37°C 1X trypsin-EDTA (5 mg/ml trypsin, 5 mM EDTA, 145 mM NaCl) in PBS at 
room temperature the cells started to round up and detach from the flask (1 to 3 
minutes). Detachment was monitored under an inverted microscope. Then the trypsin 
solution was aspirated, the cells were resuspended in fresh complete medium and 
plate at the required density in new flasks or cell culture dishes. 
2.2.5.2 Storage and recovery of cells 
One 175 cm2 flask of nearly confluent cells (approximately 107 cells) was trypsinized 
as described above. Cells were collected by centrifugation at 400 g for 5 minutes and 
the cell pellet resuspended in 3 ml of medium containing 50% FCS and 10% DMSO. 
Aliquots of 1 ml were transferred to BIO-Freeze vials (Costar). The vials were 
allowed to freeze slowly to - 70°C over a period of 24-48 hours and then transferred to 
liquid nitrogen for long-term storage. 
For recovery of cells from the liquid nitrogen, the cell vials were thawed quickly in at 
37°C-water bath and their contents were mixed with 10 ml of performed (37°C) 
complete medium. The cells were pelleted by centrifugation at 400 g for 5 minutes to 
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remove the toxic cryopreservative DMSO, then resuspended in 25 ml complete 
growth medium, transferred to a 75 cm2 tissue culture flask and incubated under the 
conditions described above. Viable cells usually started to attach to the bottom of the 
flasks several hours after recovery from the liquid nitrogen. 
2.2.6 Preparation of myometrial cell cultures 
Pieces of myometrium were transferred into DMEM containing collagenase (300 
U/ml), deoxyribonuclease (30 U/ml), penicillin (200 U/ml) and streptomycin (200 
mg/ml), and then incubated at 37°C for 30 minutes. After filtration and centrifugation, 
cells were suspended in DMEM containing 10% foetal calf serum (FCS), penicillin 
(100 U/ml), streptomycin (100 mg/ml) and fungizone (2.5 pg/ml). The cells were kept 
at 37°C in a humidified atmosphere of 95% air and 5% CO2 until confluence (2-4 
weeks). The purity of myometrial muscle cells was assessed by immunocytochemical 
staining. Mouse antihuman smooth muscle actin-specific monoclonal antibody and 
peroxidase-conjugated rabbit antimouse antibody were used. Human fibroblast cells 
and omission of the primary antibody were used as negative controls, whereas frozen 
myometrial tissue was used as a positive control. To minimise fibroblast 
contamination we re-purified the myocyte preparation 48 hour before the experiments 
using 0.5% EDTA-trypsin. 
2.2.7 Subcloning techniques 
2.2.7.1 Restriction enzyme digests 
Restriction enzyme digests were carried out according to the manufacturer's 
instructions. The products of a digest were analysed using agarose gel electrophoresis 
with the presence of DNA markers (1 kb ladder, Gibco BRL). Complete digests were 
checked by ensuring that uncut plasmid was not present. In the case of double digests 
while the optimal buffer conditions of the enzymes were different, the reaction was 
carried out in a buffer that gave at least 80% enzyme activity. If the reaction 
conditions of the two enzymes were incompatible, one digest was carried out first. 
Afterward, a phenol: chloroform extraction followed by an ethanol precipitation step 
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were carried out. The pellet was resuspended in the appropriate reaction conditions for 
the second enzyme and the second digest carried out as usual. When temperature 
requirements of the enzymes in a double digest were different, the reaction was first 
carried out at one temperature then transferred to the second temperature and 
incubated for a similar length of time. 
2.2.7.2 Preparation of plasmid DNA for ligations 
Vectors that had been digested with two enzymes generating incompatible ends were 
desalted using QlAquick spin columns (Qiagen, see Section 2.2.10.2). Vectors cut 
with a single restriction enzyme or blunt-ended were heat inactivated at 65°C for 10 
minutes and then cooled to room temperature. For 5'-protruding ends, 1 unit calf 
intestinal phosphatase (CIAP) per 100 pmole DNA was added, then the enzyme was 
left for 60 minutes at 37°C. For 5'-recessed or blunt ends, 1 unit CIAP per 10 pmole 
DNA was used incubated for 15 minutes at 37°C, then for 15 minutes at 56°C. Added 
another aliquot of CLAP and repeat incubations at both temperatures. Finally the 
enzyme was inactivated with 2. Oµl of 0.5M EDTA and desalted using QlAquick spin 
columns (Qiagen, see Section 2.2.10.2). 
2.2.7.3. Making T-vector for the cloning PCR products 
Certain thermostable polymerases, including Taq, Tfl l and Tth DNA polymerase, add a 
single nucleotide, generally adenine, to the 3'-ends of amplified DNA fragments. T- 
vectors are convenient for the cloning of PCR products generated by such 
thermostable polymerases. These linearized vectors contain single 3' terminal 
thymidines (T's) at each end, which are complement to the overhang added by the 
polymerase. Thus, PCR products can be directly subcloned into these vectors without 
further manipulation. T-vector was made using the method as described by Mezei et 
al. (1994). 
2.2.7.4 Preparation of insert DNA for ligation 
Insert DNA was generally a restriction fragment isolated from an agarose gel using 
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QlAquick spin columns. For some purposes it is necessary to produce target DNA by 
PCR. This produced DNA terminus is lack of the 5' phosphate. Therefore, either the 
primers or the amplified DNA was phosphorylated by the addition of 1mM ATP, 1x 
forward reaction buffer (70mM Tri-Cl, pH 7.6,10mM MgC12,100mMKC1,1mM 2- 
mercaptoethanol), 20U of T4 polynucleotide kinase (Gibco-BRL) and incubated at 
37°C for 30-60 minutes. The sample was heat inactivated at 90°C for 2 minutes and 
desalted using QIAquick spin columns (see Section 2.2.11.1). 
DNA pre-digested with enzyme(s) that leave 5' overhang(s) was blunt ended by filling 
in the 5' overhang(s) with DNA polymerase I (Klenow fragment) in the presence of 2 
mM dNTP mixture and the appropriate volume of 10 X concentrated 5' overhang 
buffer (0.5 M Tris-HC1 pH 7.2,0.1 M MgSO4,1 mM DTT, 500pg/ml bovine serum 
albumin). The reaction was allowed to proceed for 30 minutes at 37°C. The sample 
was heat inactivated at 70°C for 5 minutes and desalted using QIAquick spin columns 
(see Section 2.2.11.1). 
2.2.7.5 Ligations 
Bacteriophage T4 DNA ligase (Gibco-BRL) was adopted in ligations involving both 
blunt-ended and protruding-ended which were carried out using the method as 
described by Sambrook et al. (1989). The ligation mixtures included 100 ng vector 
DNA, equimolar amount of insert DNA (in some cases 1: 2 or 1: 3 ratio of 
vector: insert), appropriate amount of 5x DNA ligase buffer (supplied with the ligase) 
and 1 Weiss units T4 DNA ligase in a final volume of 10-20 µl. They were incubated 
at 16°C for 12-16 hours. Following ligation, the samples were stored at -20°C, if they 
not are used immediately. 
2.2.8 Preparation and transformation of E. coil using calcium chloride 
Competent bacteria were prepared by the method described in Sambrook et al., 1989 
with slight modifications. A 10ml culture of LB broth and appropriate antibiotic was 
inoculated with a single colony of the host bacteria and incubated at 37°C overnight 
with shaking. They were diluted 50 x (1 ml bacterial culture in 50 ml LB broth) and 
incubated until the OD600 was around 0.3. The culture was left on ice for 30 minutes 
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and then centrifuged at 4°C for 10 minutes at 3,000 Xg to pellet the cells. They were 
then resuspended in half the original volume (25m1) which was freshly prepared 
sterile 0.1 M MgC12 (ice cold), immediately centrifuged as before. The cell pellets 
were resuspended in 1/20th of the original volume (2.5m1) of ice-cold 0.1 M CaCl2 
(sterile, freshly prepared from solid), 15% (v/v) glycerol. The cells were then 
aliquoted, those to be used in transformation reactions were immediately stored for 60 
minutes on ice and the rest stored at -70°C. 
Freshly prepared competent cells (0.2 ml) were mixed gently with 0.1 ml DNA (1- 
lOng) in Tris-HCL pH 7.4 or with half of original volume of ligation mixture (5- 
lOp1). Tubes were incubated on ice for 30 minutes with occasional mixing, and 
transferred at 42°C water bath for exactly 2 minutes, then returned to ice for further 15 
minutes. The sample was then warmed to room temperature, 800µl LB broth was 
added and tube was incubated at 37°C for 45 minutes. Aliquots of the samples (200 
µl, l00µ1,50µl, 10µl) were plated out onto LB agar plates containing ampicillin. To 
identify bacterial colonies containing recombinant plasmid by a-complementation, 
plates containing X-gal and IPTG. 401il of X-gal 20mg/ml and 4µi of IPTG 200mg/ml 
were spread onto pre-made plates and the solution was allowed to dry before adding 
bacteria suspension. The plates were incubated in inverted position overnight at 37°C. 
2.2.9 Small scale preparation and purification of plasmid DNA 
Minipreparations of plasmid DNA were obtained by two methods depending on the 
quality of DNA needed. An alkaline lysis method was used to obtain crude 
preparations for checking plasmid size by electrophoresis and performing restriction 
digests. QlAprep spin columns (Qiagen) were used to obtain high quality plasmid 
DNA for procedures such as sequencing, in vitro transcription and subcloning. 
A single colony was picked up and transferred into a 25ml tube containing 5m1 LB 
broth and ampicillin (100µ1/m1). The tube was incubated overnight at 37°C with 
shaking. 
2.2.9.1 Plasmid preparation by alikali lysis 
An aliquot (1.5ml) of the overnight bacterial culture was then transferred into a 
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microcentrifuge tube and centrifuged at 20,000g for 2 minutes. The supernatant was 
removed and the cell pellet was resuspended in 100µl ice-cold solution I (50 mM 
glucose, 25 mM Tris-HCL pH 8.0, IOmMEDTA). After two hundred microliters of 
freshly prepared solution II (0.2 M NaOH, 1% SDS) were added and mixed gently, the 
tube was left on ice for 5 minutes. The incubation was followed by the addition of 150 
µl solution III (2.9M potassium acetate, 11.5% (v/v) glacial acetic acid), the tube 
vortexed for 10-20 second and the cell debris was pelleted by centrifugation at 
20,000g for 5 minutes. The supernatant was transferred to clean tube containing 400µl 
phenol: chloroform: isoamyle alcohol, vortexed briefly to mix and centrifuged for 5 
minutes as before. The aqueous layer was transferred to a clean tube, 800 µl ethanol 
was added and left at - 20°C for 20 minutes and then centrifuged for 5 minutes as 
before. The pellet was washed with 70% ethanol, air dried and suspended in 50 µl 
distilled water containing 50 pg/ml RNase A (Sigma). 
2.2.9.2 Plasmid preparation using QlAprep spin columns 
1-5 ml of the overnight cultured plasmid DNA was pelleted and the supernatant was 
discarded. The plamid DNA was then isolated using a QlAprep spin plasmid kit 
(Qiagen) according to the manufacture's instructions. The preparation yielded up to 
20µg of plasmid DNA in the 50-100 µl of water. 
2.2.10 Large scale preparation of plasmid DNA 
The Qiagen Maxiprep kit was used when large amount of high quality DNA was 
required. 250ml of culture cells centrifuged in a Beckman J2-21 M/E centrifuge with a 
JA 14 rotor at 4000 rpm for 10 minutes at 4°C. The DNA was then prepared using the 
reagents and instructions supplied by the manufacturer. This usually gave a yield of 
between 1-2mg. 
A variation of the alkaline lysis mouthed of Sambrook et al. (1989) was used to obtain 
large quantities of DNA. A single colony was picked and transferred into a 25 ml tube 
containing 10 ml LB broth and ampicillin (100µ1/m1). The tube was incubated 
overnight at 37°C with shaking. The next day lml of this overnight culture was 
incubated in 500m1 of LB with ampicillin (100µ1/m1) in a2 litre flask at 37°C 
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overnight with shaking. The following day the culture was split into 250m1 tube and 
the cells centrifuged at 4000 rpm for 15 minutes at 4°C. The pellets were 
reseuspended in a total of 10ml of ice cold Solution I: 50 mM glucose, 25 mM Tris- 
HCI, pH 8.0,10 mM EDTA, pH8.0 and transferred to a 50m1 Falco tube. When the 
cells had resuspended, 20m1 of freshly prepared Solution II: 0.2M NaOH, 1 %SDS, 
was added into it and the contents were mixed by gently inverting. The tubes were left 
on ice for 10 minutes after which 15m1 of ice cold Solution III: 3M potassium acetate, 
2M glacial acetic was added, shaken to mix and stored on ice for 10 minutes, then 
centrifuged as above. The supernatant was now removed and DNA then precipitated 
by adding 0.7 volumes of isopropanol. The DNA was recovered by centrifugation at 
4000 rpm for 20 minutes at 4°C, washed in 70% ethanol, air dried and resuspended in 
6m1 of TE, pH8.0. 
2.2.11 Purification of plasmid DNA by CsCI/ethidium bromide centrifugation 
The plasmid DNA was purified by caesium chloride density gradient method 
described in Sambrook et al. (1989). 25g of CsCI were dissolved in 20 ml of water 
with 7.5 ml of the resuspended DNA in TE. Using a syringe, this solution was 
transferred to a Beckman Quick-Seal tube and 1.25 ml of 10mg/ml of ethidium 
bromide added. The tubes were topped-up with liquid paraffin, balanced and heat- 
sealed. They were then centrifuged at 45,000 rpm in Beckman Vti 50 fixed rotor, for 
at least 16 hours at 23°C. 
The tubes were viewed under U. V light and the plasmid band was removed using a 
5m1 syringe with a 19-gauge needle. The solution was extracted 3 times with an equal 
volume of isopropanol to remove the ethidium bromide. It was then dialysed against 2 
litres of TE for overnight in a cold room. The DNA was transferred into a tube, with 
300µl LiCI (10mM) and ethanol. The DNA was precipitated at -70°C for 30 minutes 
and recovered by centrifugation at 8000 rpm for 30 minutes at 4°C. The DNA was 
washed with 70% enthanol, dried and resuspended in 0.5m1 of TE. 
2.2.12 Recovery and purification of DNA fractionated on agarose gels 
DNA samples were electrophoresed on an agarose gel of appropriate concentration, 
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which would allow separation, and resolution of the DNA fragment to be excised. 
Electrophoresis continued until the DNA fragment of interest had separated 
significantly enough to be cut from the gel. The fragment of interest was then 
visualised using an UV light box and cut from the gel. 
2.2.12.1 Qiagen 
The purification of the DNA within the agarose was performed by the electrocution 
method described by Sambrook et al., (1989). More recently this procedure was 
replaced by purification with QlAquick Gel Extraction Kit (Qiagen) according to the 
manufacturer's instructions. 
2.2.12.2 Geneclean 
The Geneclean II kit (Bio 101 Inc. ) was used according to the manufacturer's 
instructions to remove and purify DNA from agarose gels and to desalt solutions of 
DNA. 
2.2.13 DNA sequencing by dideoxy chain-termination 
DNA sequencing was performed by the dideoxy chain-termination proposed by 
Sanger et al. (1977) using Sequencing kit version 2.0 (Amersham). The DNA was 
prepared using QlAprep Spin Plasmid kit (Qiagen) or QIAprep Maxiprep kit 
(Qiagen). Approximately 2µg DNA was made up to 20µl with TE and denatured by 
adding 5µl of 1M NaOH, 1mM EDTA and incubating at room temperature for 5 
minutes. The DNA was precipitated with 5µl 3M NH4Ac and 75µl ethanol. The pellet 
was resuspended in 7R1 H2O, 1µl of primer (lOµg/ml) and 2p1 5X Sequenase buffer 
were added and the reaction was heated to 65°C for 3 minutes and incubated at 37°c 
for 30 minutes. The remaining components of the sequencing reaction were added and 
the sequencing was carried out according to the manufacturer's instructions. 
2.2.14 Cycle sequencing with thermo Sequenase DNA polymerase 
Murray (1989) described cycle sequencing as the "sequencing linear amplification 
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version" of the polymerase chain reaction (PCR). Double stranded DNA sequencing 
was carried out using the Thermo Sequenase DNA polymerase (Amersham) following 
the manufacturer's instructions. 
This technique combines the use of thermostable polymerases and thermocycling 
procedure with dideoxy sequencing. The first stage was a labelling step, in which the 
primer was extended using three of four deoxynucleotide triphosphates including one 
35S-labelled dNTP. In this step the reaction mixture was thermally cycled (15 seconds 
at 95°C, 30 seconds at 60°C continued for 50 cycles). In the second step, the 
concentration of all the deoxynucleoside triphosphates was increased, a 
dideoxynucleoside triphophate was added, and the reaction was again thermally 
cycled (30 seconds at 95°C 100 seconds at 72°C) for 45 cycles. The reaction products 
were finally denatured by the addition of manide and heated to 70°C for 10 minutes. 
Analysed samples were denaturing polyacrylamid gel electrophored. 
2.2.15 RNase protection assays 
RNase protection assays were carried out using the technique described by Zinn et al. 
(1983). In this process, RNase protection assays kit (RPA II, Ambion) was used 
according to the manufacturer's instructions. 
10-30 µg of total RNA was added to 2-4 X 104 cpm of probe, made up to 20µ1 with 
water and co-precipitated at -70°C for 30 minutes by adjusting the concentration of 
NH4OAc to 0.5 M and adding 2.5 volumes of ethanol. The precipitate was recovered 
by centrifugation at 12,000 Xg for 20 minutes at 4°C and the pellet dried. The pellet 
was resuspended in 20µl of hybridisation buffer: 80% deionized formamide, 100 mM 
sodium citrate pH 6.4,300 mM sodium acetate pH 6.4,1 mM EDTA, heated at 90°C 
for 5 minutes and hybridised overnight at 42°C. 
After hybridisation was complete, 200µ1 of RNase digestion buffer: IOmM Tris-Cl, 
pH 7.5,5 mM EDTA, 300 mM NaCl containing 5µg/ ml RNase A/20U/ml RNase Ti 
Mix was added and the reaction incubated at 37°C for 30 minutes. Following RNase 
digestion, 300µ1 of RNase inactivation/precipitation mix was added and precipitated 
at -20°C for 30 minutes. Samples were then centrifuged at 12,000 Xg for 15 minutes. 
The pellets were resuspended in 8µl of denaturing gel-loading buffer: 90% (v/v) 
formamide, I OmM EDTA, pH 8.0,0.01% (w/v) xylene cyanol, 0.01% bromophenol 
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blue. The samples were heated at 95°C for 5 minutes and electrophoresed on a 6% 
denaturing polyacrylamide gel (see Section 2.2.4) at 60 Watts until the bromophenol 
blue was about 1 cm from the bottom. 
2.2.16 Labelling of nucleic acid probes 
2.2.16.1 End-lablling of oligonuleotide with T4 polynucleotide kinase 
Oligonucleotides (10 pmol/µl) were combined with 5X Forward Reaction buffer 
(supplied with the T4 polynuleotide kinase), 40 tCi [y-32P] ATP and 10 units T4 
polynuleotide kinase (Gibco-BRL) in a volume of l0µ1 and incubated at 37°C for 30 
minutes. The reaction was incubated at 65°C for 10 minutes to inactivate the enzyme. 
The unincorporated [y-32P] ATP was removed by purification through CROMA SPIN- 
10 columns (Clonthch Laboratories, Inc. ) with respect to the manufacturer's 
instructions. 
2.2.16.2 Random prime labelling with Klenow I and [a-32P]dCTP 
Probe fragments were isolated through restriction endonulease digestion and subjected 
to gel was electrophoresis and extracted. Probe fragments were labelled by random 
prime labelling for the purpose of probe in Southern blotting, and library screening 
was conducted by the method of Feinberg and Vogelstein (1983). 
The Oliglabelling kit (Pharmacia) was used to synthesise probes based on the 
manufacturer's instructions. Probes were synthesised by heating 50ng of probe 
fragments in a total volume of 34µl to 95°C for 3 minutes, and then the sample was 
placed on ice for 2 minutes. 101il of reagent mix (provided), 5µl (50jCi) a-32PdCTP 
and 5 units of Klenow fragment of DNA polymerase I were added and incubated at 
37°C for 60 minutes. Unincorporated nucleotides were removed using MicroSpin S- 
300 columns (Pharmacia) according to the manufacturer's instructions. The purified 
probe was then heated at 100°C for 5 minutes, cooled on ice and added to the relevant 
hybridisation buffer. 
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2.2.16.3 In vitro transcription of [a-32P] labelled RNA 
High specific activity RNA probes were prepared by in vitro transcription in the 
presence of [a-32P]CTP for use in RNase protection assays. 
The pBluescript II vector used in this project contained promoters specific for T3 and 
T7 RNA polymerase flanking polylinker site. The plasmid DNA of interest was 
linearized by restriction endonuclease digestion of a chosen site within the polylinker. 
This linearized plasmid was then used for the synthesis of "run off' sense and 
antisense probes of the insert. An appropriate restriction endonuclease was used to 
linearize 2µl of plasmid DNA. The plasmid was electrophoresed on a 1.0% agarose 
gel and purified from the gel using Qiagen. The In vitro transcription kit (Ambion) 
was then used to synthesise sense and antisense probes. Plamids were transcribed in a 
20µ. l reaction containing 1X transcription buffer, 10µM CTP, 0.5 mM NTP (ATP, 
UTP, GTP), 50gCi [a-32P]CTP, 500ng of template (linearized DNA) and 20 unite of 
T7 or T3 RNA polymerase and the reaction was incubated at 37°C for 60 minutes. 2 
units of RNase-free DNase I were added and incubated at 37°C for 15 minutes. These 
were subjected to gel electrophoresis as described in Section 2.2.23 to determine the 
efficiency of the reaction. The gel plates were then removed from the tank and the gel 
was covered in Saran Wrap and exposed to X-ray for 1-2 minutes. The autoradiograph 
was then placed on top of the gel and the area representing the probe was cut from the 
gel using a razor blade. The gel slice was diced, placed in a microcentrifuge tube and 
then 350 µl of Probe Elution Buffer (Ambion) was added, after all, the RNA was left 
to elute 2-4 hours or overnight at 37°C. 
2.2.17 Southern blotting 
For plasmid southern blots, the plasmid or restriction digest and 0.5µg of 1Kb marker 
(Gibco BRL) were run on a 1.0 % nondenaturing agarose gel, at 25 volts overnight. 
The gel was stained in 0.5pg/ml ethium bromide in distilled water for 15 minutes for 
photograph. Southern blotting was then carried out using the method of Southern 
(1975). To increase the efficiency of transfer of high molecular weight DNA the gel 
was first treated with 0.25M HCl for 20 minutes at room temperature. Then the gel 
was the rinsed in distilled water and treated with denaturation buffer; 1.5M NaCl, 
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0.5M NaOH for 30 minutes. The gel was further rinsed in distilled water and placed in 
neutralisation buffer containing 0.5M Tris-HCI, 1.5M NaCl, pH 8.0, for 30 minutes. 
A piece of filter paper (3MM Whatman) moistended with 20 x SSC was placed on top 
of a platform in tray of 20 x SSC so that ends of the filter paper were submerged in the 
20 x SSC. The product obtained above was placed on top of the filter paper and the 
exposed filter paper covered with cling film. A piece of nylon membrane (Hybond-N, 
Amersham) was cut with a lmm border over the gel, the filter was moistened in 
distilled water then immersed in 20 x SSC for 10 minutes. The filter was then placed 
onto the surface of the gel, which must not have air bubbles formed. Two pieces of 
filter paper were cut to the same size as the gel were soaked in 2x SSC and placed 
onto the surface of the nylon membrane. Tissue paper was stacked on top of this and 
weighed down with a water-filled 250 ml bottle weight. The gel was left to blot for 
overnight. The nylon filter was rinsed in 2x SSC for 15 minutes and the DNA were 
fixed to the nylon filter by baking at 80°C under vacuum for 2.0 hours or UV- 
crosslinked (Stratagene) by laying them face down on a UV transilluminator for 1 
minutes. 
Hybridisation and washing procedures were carried out in Hybaid C4 glass tubes. 
The membrane was prehybridised in QuikHyb hybridisation solution (Stratagene) at 
68°C for 60 minutes. The double-stranded probe (see in Section 2.2.15.2) and salmon 
sperm DNA mixture were boiled for 3 minutes, and then added the mixture to the pre- 
hybridisation solution in the glass tubes, and hybridised at 68°C for 4 hours. 
Filters were washed twice for 15 minutes at room temperature with a2x SSC, 0.1% 
(w/v) SDS wash solution and then washed once for 30 minutes at 60°C with 0.1 x 
SSC, 0.1% (w/v) SDS wash solution for a high-stringency wash. The filters were 
blotted on filter paper and while still damp, were wrapped in Saran Wrap and exposed 
to X-ray film with an intensifying screen at -70°C. 
2.2.18 Polymerase chain reaction 
PCR was used for several different purposes: identification of the upstream region of 
the CRH-R2(3 gene, construction of plasmid for promoter analysis, RT-PCR was used 
to identify the CRH-R subtypes in human myometrial tissue and 5'RACE PCR 
determination of CRH-R2 transcription initiation site or 5'-cDNA of CRH-R1. PCR 
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was also used to generate probes fragments for hybridisation to Southern filters and to 
analyse cultures or bacterial colonies for the presence and size of inserts. 
2.2.18.1 RT-PCR 
2.2.18.1.1 Reverse transcription 
Total RNA (3--5µg) was heated at 75°C for 5 minutes and cooled on ice, reverse 
transcription in 20gl reaction was carried for 1 hour at 42°C. The reaction contains 
200-400ng Oligo(dT)18 or 5 pmoles of a gene specific primer, 0.5mM each of four 
dNTPs (Promega), 50mMTris- HC1 pH 8.3,3mM MgC12 10 mM DTT and 200 units 
Reverse Transcriptase (Gibco-BRL). The reaction was stopped by incubation at 70°C 
for 15 minutes. The RNA was then removed by digestion with RNase H (2 units), and 
the incubation continued for further 20 minutes at 37°C. 
2.2.18.1.2 PCR 
To amplify CRH-R subtype cDNA, only 10% of the reverse transcription reactions 
were used for PCR. cDNA was amplified by PCR in 501il reaction containing 20 mM 
Tris- HCl (PH 8.4), 50mM KCI, 1.5mM MgC12,200µM dNTPs and 2.5 units Taq 
DNA polymerase (Gibco-BRL). 10µM each, of forward and reverse primers (see in 
Section 2.1.8) were also included. 
For the first round PCR, the sense primer was used in combination with an antisense 
primer adapter-(dT) with nucleotide sequence 5'-GTCGACAAGC(T)18-3'. The 
products of this reaction were served as templates for the second round of 
amplification, which two internal primers were adopted. (1) First round PCR: after an 
initial denaturation at 95°C for 2 minutes, cooled to 72C° at which point 2.5 units Taq 
DNA polymerase (Gibco-BRL) was added. 40 cycles of PCR were carried out, 
denaturation at 95°C for 45 seconds, annealing at 55°C for 45 seconds, extension at 
72°C for 1.5 minutes. The final extension was at 72°C for 15 minutes. (2) Second 
round PCR: after an initial denaturation at 95°C for 2 minutes, cooled to 72°C, at 
which point 2.5 units Taq DNA polymerase (Gibco-BRL) was added. 40 cycles of 
PCR were carried out, denaturation at 95°C for 45 seconds, annealing at 58°C for 45 
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seconds, extension at 72°C for 1.5 minutes. Final extension was at 72°C for 15 
minutes. As a negative control for all the reactions, distilled water was used in place 
of the cDNA. 
The reactions were analysed by agarose gel electrophoresis on a 1.0% agarose gel as 
described in Section 2.2.2.1 and the amplified products were gel isolated as described 
in Section 2.2.11. 
2.2.18.2 Genomic walking 
Approximately 1-2 pg of human genomic DNA (from peripheral blood leucocytes) 
was digested to completion with 80 units of Ncol (GibcoBRL). The sample was 
extracted with an equal volume of phenol: chloroform: isoamyl alcohol and precipitated 
with the addition of 2.5 volumes 100% ethanol. The pellet was washed with 70% 
ethanol and resuspended in 10µl of sterile distilled H20. The DNA was boiled for 5 
minutes then quickly cooled on ice. The entire sample was incubated with 0.5mM 
dATP and 1.5mM CoC12 in 20µ1 of terminal transferase (TdT) buffer containing 50 
units of TdT (Amersham) at 37°C for 60 minutes. The reaction was stopped by 
heating the sample at 65°C for 15 minutes. The polymerase chain reaction was 
performed using 2µl (100ng) of the polyadenylated genomic DNA as a template, 
200ng of gene-specific primer 
5'-GAGGAGGTGTGGGACGTAGAGGAG-3' 
200ng of universal-T17 primer 
5'-GAGGACTCGAGCTCAAGC F-I -1111111 -1 -1 -111 -1 -3', 
200uM dNTPs and lul of Advantage PCR 2 polymerase Mix (Clontech) in 50u1 
volume. The PCR was carried out at 95°C for 1 minute, then 95°C for 30 seconds, 
72°C for 1 minute, 5 cycles, 95°C for 30 seconds, 70°C for 1 minute, 5 cycles, 95°C 
for 30 seconds, 68°C for 1 minute cycled 35 times. Following the reaction, ipi of the 
sample was then used as a template for the second round of PCR under the same 
condition, except that 200ng of gene- specific primer 
5'-GGTATTCTGGACCCACTTCTTCCAC-3' 
and 200ng of universal primer 
5'-GAGGACTCGAGCTCAAGC-3' 
were used. The final PCR product was subcloned into the pGEM-T vector (Promega). 
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The insert DNA was cycle-sequenced using an ABI 373A (Applied Biosystems) 
automated fluorescent sequencer. 
2.2.18.3 5'-Rapid amplification of cDNA end (5'RACE) 
2.2.18.3.1 5'RACE to identify the 5'-cDNA of CRH-R1 
In order to confirm the sequence of the 5'-cDNA of CRH-Rla, the 5'-RACE system 
Version 2.0 (Gibco-BRL) was employed to amplify the 5'-cDNA for sequencing. The 
5'-RACE system Version 2.0 kit was used according to the manufacture's protocol. 
Briefly, 2.5pmol of a gene-specific primer 
CRFII 5'-CCCTTCGAAGTCTGACGACACCTG-3' 
was hybridised to 5 µg of human myometrial total RNA, and cDNA synthesised using 
Superscript II Reverse Transcriptase (Gibco-BRL). The RNA was then removed by 
digestion with RNase H, and the cDNA was isolated. A poly(dC) tail was then added to 
the 3'-terminus of the purified cDNA using dCTP and the TdT enzyme. The cDNA 
region corresponding to the 5'-cDNA was then amplified by two successive rounds of 
PCR using additional gene-specific antisense primers 
CRF4 5'-CCTTCCTCAACTTCATCTAC-3' 
and CRF7 5'-TACTTGTAGGTAAACGCGTCG-3', 
together with the anchor primer supplied by a manufacturer. The amplified products 
yielded through the second round of PCR, were analysed by electrophoresis on 1.0% 
agarose gel. The first round PCR conditions were 40 cycles of 95°C for 45 seconds, 
55°C for 45 seconds and 72°C for 1 minute followed by 72°C for 15 minutes. Aliquots 
of the above reaction were re-amplified with a nested, gene-specific primer CRF7 and 
anchor primer. PCR conditions for 40 cycles were as follow: 95°C, 45 seconds; 58°C, 
45 seconds; 72°C, 60 seconds. 
2.2.18.3.2 Determinations of the transcription start site. 
The 5'end of the human CRH-R2ß receptor cDNA was obtained by the rapid 
amplification of cDNA 5'-ends(5'RACE) procedure using the commercially prepared 
Marathon Ready cDNA system (Clontech) with respect to the manufacturer's 
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recommendations. An uncloned library of the adaptor-ligated cDNA prepared from 
human hippocampus was used to amplify the 5'-end of the CRH-R2ß cDNA. The first 
round PCR was performed with a CRH-R2ß cDNA specific primer (see Section 2.1.8) 
and plus anchor primer API supplied by Clontech. A nested PCR was then performed 
with the Clontech plus primer AP2 and a second cDNA specific primer. The resultant 
products were cloned into the pGEM-T cloning vector and the clones sequenced. In 
order to confirm the 5'-end cDNA region, a new primer was designed based on the 
sequences of the above clones. The products of those fragments amplified with the 
new primer were characterised by cloning, sequencing, and comparison with the 
above sequence results. 
5'RACE was used with combinations of CRH-R2cc and 2y (exon-1 gene specific 
primer) to clone the 5'-end cDNA from human hippocampus (Marathon-Ready 
cDNA, Clontech). The CRH-R2a, 2y of 5'RACE derived from cDNA clones include 
the 5'-Untranslated region (UTR) upstream of the CRH-R2(3 open reading frame. 
2.2.18.4 Promoter construct preparation 
The PCR fragments spanning different regions of promoter were cloned upstream of 
the CAT reporter gene in the pCAT 3-Basic vector (Promega). The oligonucleotides 
used for this PCR have a restriction site 5' to facilitate cloning into the pCAT 3-Basic 
vector polylinker. For construction derived from promoter of CRH-R2, a common 3' 
reverse oligonucleotide 
5'-CGGCTCGAGAGGTGTGGGACGTAGAGGAGG-3' 
was used in combination with the different 5' oligonucleotides: 
5'-CCGGTACCGACCTGTGAGATTTCACAGGAG-3' for construct -1393, 
5'-CCGGTACCGAGGCTCTGGAAGAACAGACC-3' for construct -1035, 
5'-CCGGTACCACCTACCCACAGTACAGTATC-3' for construct -553. 
The PCR fragments were digested with Kpn I and Xho I and cloned into equivalent 
site of the pCAT3-basic vector. 
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2.2.18.5 PCR for analysing colonies for the presence and size and an insert 
To analyse the clones containing the exon-1 of CRH-Rla gene, 25ng of minipreped 
DNA was used in a PCR reaction but only 20 cycles not 30 cycles were carried out. 
The gene specific primers PE5 and PE3 correspond to +2 to +23 nt and +239 to 260 nt 
in exon-1. The reaction was then analysed by electrophoreses on a 1.0% agarose gel. 
Colonies were picked up using a sterile tip and suspended in l00µ1 distilled TE. The 
tip was then used to seed a 50µ1 starter culture of L Broth with ampicillin. The 
suspension containing the colony was then heated to 95°C for 10 minutes, centrifuged 
at 13,000 rpm for 5 minutes in a bench top centrifuge and 5p. 1 of the "boilate" was 
used in the PCR. Each PCR reaction contained 1X PCR buffer (Gibco-BRL), 1.5mM 
MgC12,0.05% W-1,0.25mM dATP, 0.25mM dCTP, 0.25mM dGTP, 0.25mM dTTP, 
2.5µM of each primer and 2.5units Taq polymerase (Gibco-BRL). The primer used in 
the reaction depended on the plasmid to be analysed. The primers 77 and SP6 were 
used for pGEM-T vector, and T3 and T7 primer were used for pBluescript. 
2.2.18.6 Genomic PCR for amplify the region between the CRH-R2(3 and 2y exon 
In order to obtain the genomic sequence between the CRH-R2ß and CRH-R2y exons, 
PCR was performed with Elongase system (Gibco BRL) and human genomic DNA 
from peripheral blood leucocytes. (1) PCR reaction, we used a primer to the CRH- 
R20 exon 5'-end (B2: 5'-CTGGCATGAGGGGTCCCTCAG-3') and a primer to the 
5'-end of the CRH-R2y specific exon (G3: 5'-GTAGGCAGATTGCTTGAGAC-3'). 
(2) PCR reaction, we used a primer to the CRH-R2ß exon 3'-end (B4: 5'- 
CATGACCCTCACCAACCTCTC-3') and a primer to the 5'-end of the CRH-R2yy 
specific exon (G3: 5'-GTAGGCAGATTGCTTGAGAC-3'). PCR was performed with 
500ng of DNA in the presence of each primer at 200 nM, each dNTP at 200µM, 60 
mM tris/sulphate, pH 9.1,18 mM(NH4)2SO4,1.6mM MgSO4 and lµl of Elongase 
enzyme mix. Amplification was performed for 35-40 cycles with denaturation at 94°C 
for 30 second followed by annealing/extension at 68°C for 3-10 minutes. The PCR 
products were analysed by 1% agarose-gel electrophoresis in the presence of TBE 
buffer and then subcloned into the pGEM-T vector and sequenced. 
66 
2.2.19 Library screening 
2.2.19.1 Filter preparation 
The protocol was based on the standard protocol of Sambrook et al. (1989). Colonies 
were grown on a "master" filter and one replica was made for screening. The "master" 
filter was stored at 4°C for recovery of positive plasmids. Approximately 3x 106 
cosmid containing the transformed library (human placental genomic cosmid DNA 
library, Clontech Laboratories, Inc) were plated on 4x (20 x 20cm) Hybond N 
(Amersham) membrane placed on 4x (22 x 22cm) LB-agar which contained 50µg/ml 
ampicillin and grown at 37°C until the colonies were approximately 1mm in diameter. 
This master filter was then placed on a sterile 3MM Whatmann paper on a flat glass 
surface. A fresh 20 x 20 cm Hybond N membrane was placed on a fresh LB-agar 
which contained 50µg/ml ampicillin plate to moisten it, and was then placed on the 
master filter. Another sterile 3MM Whatmann paper was then placed on top. The 
second glass plate was placed on the stack and pressure applied too firmly press the 
plates together. The upper plate and 3MM Whatmann paper were then removed and 
the orientation of the filter was labelled using a small needle. The master and replica 
filters were separated and placed face up on LB-agar/ampicillin plates. The master 
filters were incubated at 37°C for 4 hours and sealed with cling film and then stored at 
4°C. The replica filters were incubated at 37°C for 6-8 hours until the colonies were 
approximately 1 mm in diameter. 
2.2.19.2 Preparation of replica filter 
The filter was placed colony-side up on the surface of 3MM Whatmann filter paper 
previously prewetted with 0.5 M NaOH and left for 3 minutes. Then the filter was 
placed on another set of 3MM Whatmann filter paper previously pre-wetted with 1M 
Tri-HC1 (pH 7.5) and left for 3 minutes. Afterward, the filter was placed on the third 
set of 3MM Whatmann filter paper previously pre-wetted with 1M Tris-HC1 (pH7.5) 
and 1.5 M NaC1 and left for 3 minutes. After all above has been done, the filter was 
removed into a solution of 1M Tris-HC1 (pH7.5) and 1.5 M NaCl. With a gloved 
hand, the bacterial debris was removed by gently rubbing the filter paper. 3MM 
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Whatmann filter paper was used to blot off excess liquid, and the filter was air-dried. 
The filter was baked for 1 hour at 80°C in a vacuum oven or the DNA UV-crosslinked 
to the filter by laying it DNA-side down on an UV transilluminator for 1 minute. 
Hybridisation and washing procedures were carried out in Hybaid C4 glass tubes. 
The membrane was pre-hybridised in QuikHyb hybridisation solution (Stratagene) at 
68°C for 60 minutes. The double-stranded probe (see in Section 2.2.15.2) and salmon 
sperm DNA mixture were boiled for 3 minutes, and then added the mixture to the pre- 
hybridisation solution in glass tubes, and hybridised at 68°C for 4 hours. 
Filters were washed twice for 15 minutes at room temperature with a2x SSC, 0.1% 
(w/v) SDS wash solution and then washed once for 30 minutes at 60°C with 0.1 x 
SSC, 0.1% (w/v) SDS wash solution for a high-stringency wash. The filters blotted on 
filter papers while they still damp, were wrapped in Saran Wrap and exposed to X-ray 
film with an intensifying screen at -70°C for 3-5 days. 
2.2.19.3 Second round screening 
The position of positive colonies on the master filter was determined and marked 
using the mm square plastic sheets with labelled marker holes. A 0.5 x 0.5 cm region 
surrounding the desired clone was excised. The filter piece was placed in a 25 ml tube 
containing 5 ml LB broth and ampicillin (100pUml). The tube was incubated 
overnight at 37°C with shaking. 10µl of this suspension was diluted in lml LB broth. 
This dilution was then further diluted to 1: 10,1: 15,1: 20 and 1: 100 with LB broth 
which contained ampicillin (100µ1/m1), and 100µl of each dilution was plated on LB- 
agar which contained ampicillin (100µ1/m1) and incubated at 37°C overnight. 
Plates with 400-600 colonies were screened. Hybond N (Amersham) filters were cut 
to sizes and placed on the colonies and their orientation was marked by 3 holes 
formed using a small needle. The filters were treated as described in the first round 
screening. The plates were incubated for 2 hours and then stored at 4°C. The baked, 
crosslinked filters were hybridised and washed as described for the filters in the first 
round screening and exposed to X-ray film in a cassette with an intensifying screen for 
several days at -70°C. 
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2.2.19.4 Third round screening 
Positive colonies were picked and resupended in 5m1 LB broth. Dilutions and 
screening were carried out as for the second round screening. Filters were treated, 
hybridised and washed as described above. 
Positive colonies from the third round screening were picked, minipreped using 
QIAprep spin plasmid kit (Qiagen), digested with restriction endonucleases, 
electrophoresed on a 1.0% agarose gel. The gel was Southern blotted as described in 
Section 2.2.16 and the plasmid Southern probed to ensure that the clones contained 
positive inserts. 
2.2.20 Transfection of eukaryotic cells 
Cell lines employed in reporter gene studies were transiently transfected with plasmid 
expression vectors. 
Confluent cell flasks were trypsinized, the number of cells counted and in six-well 
plates (Nunclon) were seeded with 3x 105 cells per well. Cells were grown in 2 ml of 
Dulbecos modified Eagle medium, 10% fatal bovine serum, penicillin (200Units/ml), 
streptomycin (200mg/ml) and incubated in 5% CO2 at 37°C for 24h before 
transfection. All DNA plasmid used in transfection were purified using QIAGEN 
plasmid Maxi Kit (Qiagen) and were analysed by agarose gel electrophoresis to verify 
plasmid integrity. The pCAT3-basic-less plasmid was routinely in all transfection 
experiments as negative controls. 
The cells were transfected using Lipofectamine Reagent (Gibco-BRL) in lml of 
serum-free medium (Optimem) for 3 hours according to the manufacture's instruction. 
Medium was replaced with 2m1 of fresh DMEM containing 10% fetal bovine serum 
24h after transfection. After the start of transfection of 48 hours, the cells were 
harvested. 
2.2.21 Analysis of extract from transfected cells 
2.2.21.1 preparation of cell extracts 
The wells containing monolayers of transiently transfected cells were washed three 
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times with 3m1 of ice cold PBS. After last work step, the cells were removed PBS 
with a fine-tipped Pasteur pipette and then added 340p1 of lysis buffer (Boehringer 
mannheim) and allowed to stand for 30 minutes at room temperature. The cells were 
transferred into microcentrifuge tubes and centrifuged at 13,000 rpm for 10 minutes at 
4°C. The supernatants were transferred into microcentrifuge tubes. Cell lysis was 
ensured by three cycles of freeze-thawing (2 minutes in ethanol/dry ice then 1 minute 
in 37°C water bath). The cell debris was subsequently removed by centrifugation at 
13,000 rpm for 10 minutes. The cell extracts were finally transferred into clean tubes 
and stored at - 70°C until use. 
2.2.21.2 Chloramphenicol acetyltransferase (CAT) assay 
The CAT activity of cytoplasmic extracts from cells transiently transfected with CAT 
expression vectors was measured by an enzyme-linked immunosorbent assay (ELISA) 
method. 
The CAT activity was measured using a CAT ELISA kit (Boehringer, Mannheim) 
according to the manufacturer's instruction. The cells extracted were added with lOµ1 
into the well (10µ1/well) instead of the recommend 200µl/well. 
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Chapter 3 Amplifying and cloning CRH-Rla, 10, and lc from 
human myometrium 
3.1 Introduction 
The aim of the first part of the project was to identify CRH-R subtype expression in 
human myometrial biopsies (pregnant and non-pregnant) and myometrial cell 
cultures. PCR primers were designed specifically for the CRH-R subtypes and their 
presence was confirmed by using RT-PCR and nucleotide sequencing. RNase 
protection assays was also employed to study CRH-R mRNA expression in the human 
myometrium. 
3.2 General description of PCR and CRH-R1 
Since protein synthesis is nearly always directly proportional to the level of mRNA 
encoding the peptide, the initial experiments on gene regulation are usually directed to 
quantitating changes in specific mRNAs. For example, the techniques of in situ 
hybridisation and the reverse transcriptase polymerase chain reaction (RT-PCR) can 
be used to localise the expression of specific mRNAs to individual cells or tissues. 
Other methods such as RNase protection have allowed detection of and discrimination 
between variant forms of similar mRNAs. 
The polymerase chain reaction (PCR) is a method which entails the use of two 
primers. The two primers hybridise to opposite strands of a template and are 
orientated so that there are 3'ends pointing towards each other. These primers are then 
used in an amplification reaction in which the product is the region between the two 
primers. The DNA segment amplified in the first round is then used as a template in 
subsequent cycles with the products accumulating in an exponential fashion (Saiki et 
al., 1988). PCR is a powerful technique for amplification of DNA and is the most 
sensitive technique available to measure extremely low levels of mRNA. The first 
step in measuring mRNA is to use the isolated RNA as a template to synthesise 
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complementary DNA with the viral enzyme reverse transcriptase. It is now possible to 
obtain accurate and sensitive measures of gene expression in small samples of tissue, 
or in a few cells in vitro, using RT-PCR. This represents a considerable increase in 
sensitivity over other analytical methods such as northern blot analysis or RNase 
protection assays. 
The CRH-Rla receptor has been cloned from several species including human (Chen 
et al., 1993), mouse (Vita et al., 1993), chicken (Yu et al., 1996), and rat (Perrin et al., 
1993, Chang et al., 1993). Species homologues are 98% identical over their full 
length of 415 amino acids. In general, the CRH-R1 shares approximately 30% identity 
with all other members of the neuropeptide receptor family. The CRH-Rla is a 415- 
amino acid protein comprising seven putative membrane-spanning domains 
characteristic of most G protein-coupled receptors. The CRH-R1 has three splice 
variants: 10 (444 AA), lc (375 AA) and Id (401 AA). The CRH-Rla encodes 29 
additional amino acids inserted in the first intracellular loop, named: CRH-R 1 ß, and 
CRH-Rlc has a 40 amino acids deletion in the N-terminal extracellular domain. The 
structure CRH-R 1 a, 1 ß, 1c and 1d is shown in Figure 3.1. 
The CRH-R 1 
CHR-R1a CCCGGGCATTCAGGACGGTAGCCGAGCGAGCCCGAGGATGGGAGGGCACCCGCAGCTCC(59) 
lßGGGAGGGCACCCGCAGCTCC 
lc AGCCGAGCGAGCCCGAGGATGGGAGGGCACCCGCAGCTCC 
Id ýGGGAGGGCACCCGCAGCTCC 
I. 1 
GTCTCGTCAA GGCCCTTCTC CTTCTGGGGC TGAACCCCGT CTCTGCCTCC CTCCAGGACC AGCACTGCGA(129) 
GTCTCGTCAA GGCCCTTCTC CTTCTGGGGC TGAACCCCGT CTCTGCCTCC CTCCAGGACC AGCACTGCGA 
GTCTCGTCAA GGCCCTTCTC CTTCTGGGGC TGAACCCCGT CTCTGCCTCC CTCCAGGACC AGCACTGCGA 
GTCTCGTCAA GGCCCTTCTC CTTCTGGGGC TGAACCCCGT CTCTGCCTCC CTCCAGGACC AGCACTGCGA 
12 
GAGCCTGTCC CTGGCCAGCA ACATCTCAGG ACTGCAGTGC AACGCATCCG TGGACCTCAT TGGCACCTGC (199) 
GAGCCTGTCC CTGGCCAGCA ACATCTCAGG ACTGCAGTGC AACGCATCCG TGGACCTCAT TGGCACCTGC 
GAGCCTGTCC CTGGCCAGCA ACATCTCAG ........................................................................................................ GAGCCTGTCC CTGGCCAGCA ACATCTCAGG ACTGCAGTGC AACGCATCCG TGGACCTCAT TGGCACCTGC 
TGGCCCCGCA GCCCTGCGGG GCAGCTAGTG GTTCGGCCCT GCCCTGCCTT TTTCTATGGT GTCCGCTACA (269) 
TGGCCCCGCA GCCCTGCGGG GCAGCTAGTG GTTCGGCCCT GCCCTGCCTT TTTCTATGGT GTCCGCTACA 
....................................................................................................................................................................................... TGGCCCCGCA GCCCTGCGGG GCAGCTAGTG GTTCGGCCCT GCCCTGCCTT TTTCTATGGT GTCCGCTACA 
13 
ATACCACAAACAATGGCTAC CGGGAGTGCC TGGCCAATGG CAGCTGGGCC GCCCGCGTGA ATTACTCCGA (339) 
ATACCACAAACAATGGCTAC CGGGAGTGCC TGGCCAATGG CAGCTGGGCC GCCCGCGTGA ATTACTCCGA 
... ACAATGGCTAC CGGGAGTGCC TGGCCAATGG CAGCTGGGCC GCCCGCGTGA ATTACTCCGA ATACCACAAACAATGGCTAC CGGGAGTGCC TGGCCAATGG CAGCTGGGCC GCCCGCGTGA ATTACTCCGA 
14 
GTGCCAGGAGATCCTCAATG AGGAGAAAAA AAGCAAGGTG CACTACCATG TCGCAGTCATCATCAACTAC (409) 
GTGCCAGGAGATCCTCAATG AGGAGAAAAA AAGCAAGGTG CACTACCATG TCGCAGTCAT CATCAACTAC 
GTGCCAGGAGATCCTCAATG AGGAGAAAAA AAGCAAGGTG CACTACCATG TCGCAGTCAT CATCAACTAC 
GTGCCAGGAGATCCTCAATG AGGAGAAAAA AAGCAAGGTG CACTACCATG TCGCAGTCAT CATCAACTAC 
15 
CTGGGCCACT GTATCTCCCT GGTGGCCCTC CTGGTGGCCT TTGTCCTCTT TCTGCGGCTC AG ..................... (471) 
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CTGGGCCACT GTATCTCCCT GGTGGCCCTC CTGGTGGCCT TTGTCCTCTT TCTGCGGCTC AGGCCAGGCT 
CTGGGCCACT GTATCTCCCT GGTGGCCCTC CTGGTGGCCT TTGTCCTCTT TCTGCGGCTC AG ..................... CTGGGCCACT GTATCTCCCT GGTGGCCCTC CTGGTGGCCT TTGTCCTCTT TCTGCGGCTC AG ................. 
GCACCCATTG GGGTGACCAG GCAGATGGAG CCCTGGAGGT GGGGGCTCCA TGGAGTGGTG CCCATTTCA 
...................... G AGCATCCGGT GCCTGCGAAA CATCATCCAC TGGAACCTCA TCTCCGCCTT CATCCTGCGC (532) GGTTCGAAGG AGCATCCGGT GCCTGCGAAA CATCATCCAC TGGAACCTCA TCTCCGCCTT CATCCTGCGC 
....................... 
G AGCATCCGGT GCCTGCGAAA CATCATCCAC TGGAACCTCA TCTCCGCCTT CATCCTGCGC 
................... G AGCATCCGGT GCCTGCGAAA CATCATCCAC TGGAACCTCA TCTCCGCCTT CATCCTGCGC 16 
AACGCCACCT GGTTCGTGGT CCAGCTAACC ATGAGCCCCG AGGTCCACCA GAGCAACGTG GGCTGGTGCA(602) 
AACGCCACCT GGTTCGTGGT CCAGCTAACC ATGAGCCCCG AGGTCCACCA GAGCAACGTG GGCTGGTGCA 
AACGCCACCT GGTTCGTGGT CCAGCTAACC ATGAGCCCCG AGGTCCACCA GAGCAACGTG GGCTGGTGCA 
AACGCCACCT GGTTCGTGGT CCAGCTAACC ATGAGCCCCG AGGTCCACCA GAGCAACGTG GGCTGGTGCA 
GGTTGGTGAC AGCCGCCTAC AACTACTTCC ATGTGACCAA CTTCTTCTGG ATGTTCGGCG AGGGCTGCTA (672) 
GGTTGGTGAC AGCCGCCTAC AACTACTTCC ATGTGACCAA CTTCTTCTGG ATGTTCGGCG AGGGCTGCTA 
GGTTGGTGAC AGCCGCCTAC AACTACTTCC ATGTGACCAA CTTCTTCTGG ATGTTCGGCG AGGGCTGCTA 
GGTTGGTGAC AGCCGCCTAC AACTACTTCC ATGTGACCAA CTTCTTCTGG ATGTTCGGCG AGGGCTGCTA 
CCTGCACACA GCCATCGTGC TCACCTACTC CACTGACCGG CTGCGCAAAT GGATGTTCAT CTGCATTGGC (742) 
CCTGCACACA GCCATCGTGC TCACCTACTC CACTGACCGG CTGCGCAAAT GGATGTTCAT CTGCATTGGC 
CCTGCACACA GCCATCGTGC TCACCTACTC CACTGACCGG CTGCGCAAAT GGATGTTCAT CTGCATTGGC 
CCTGCACACA GCCATCGTGC TCACCTACTC CACTGACCGG CTGCGCAAAT GGATGTFCAT CTGCATTGGC 
17 18 
TGGGGTGTGC CCTTCCCCAT CATTGTGGCC TGGGCCATTG GGAAGCTGTA CTACGACAAT GAGAAGTGCT (812) 
TGGGGTGTGC CCTTCCCCAT CATTGTGGCC TGGGCCATTG GGAAGCTGTA CTACGACAAT GAGAAGTGCT 
TGGGGTGTGC CCTTCCCCAT CATTGTGGCC TGGGCCATTG GGAAGCTGTA CTACGACAAT GAGAAGTGCT 
TGGGGTGTGC CCTTCCCCAT CATTGTGGCC TGGGCCATTG GGAAGCTGTA CTACGACAAT GAGAAGTGCT 
19 
GGTTTGGCAA AAGGCCTGGG GTGTACACCG ACTACATCTA CCAGGGCCCC ATGATCCTGG TCCTGCTGAT (882) 
GGTTTGGCAA AAGGCCTGGG GTGTACACCG ACTACATCTA CCAGGGCCCC ATGATCCTGG TCCTGCTGAT 
GGTTTGGCAA AAGGCCTGGG GTGTACACCG ACTACATCTA CCAGGGCCCC ATGATCCTGG TCCTGCTGAT 
GGTTTGGCAA AAGGCCTGGG GTGTACACCG ACTACATCTA CCAGGGCCCC ATGATCCTGG TCCTGCTGAT 
CAATTTCATC TTCC=CA ACATCGTCCG CATCCTCATG ACCAAGCTCC GGGCATCCAC CACGTCTGAG (952) 
CAATTTCATC TTCCTTTTCA ACATCGTCCG CATCCTCATG ACCAAGCTCC GGGCATCCAC CACGTCTGAG 
CAATTTCATC TTCCTTTTCA ACATCGTCCG CATCCTCATG ACCAAGCTCC GGGCATCCAC CACGTCTGAG 
CAATTTCATC TTCCTTTTCA ACATCGTCCG CATCCTCATG ACCAAGCTCC GGGCATCCAC CACGTCTGAG 
110 
ACCATTCAGT ACAGGAAGGCTGTGAAAGCC ACTCTGGTGC TGCTGCCCCT CCTGGGCATC ACCTACATGC (1022) 
ACCATTCAGT ACAGGAAGGCTGTGAAAGCC ACTCTGGTGC TGCTGCCCCT CCTGGGCATC ACCTACATGC 
ACCATTCAGT ACAGGAAGGCTGTGAAAGCC ACTCTGGTGC TGCTGCCCCT CCTGGGCATC ACCTACATGC 
ACCATTCAGT ACAGGAAGGCTGTGAAAGCC ACTCTGGTGC TGCTGCCCCT CCTGGGCATC ACCTACATGC 
TGTTCTTCGT CAATCCCGGG GAGGATGAGG TCTCCCGGGT CGTCTTCATC TACTTCAACT CCTTCCTGGA (1092) 
TGTTCTTCGT CAATCCCGGG GAGGATGAGG TCTCCCGGGT CGTCTTCATC TACTTCAACT CCTTCCTGGA 
TGTTCTTCGT CAATCCCGGG GAGGATGAGG TCTCCCGGGT CGTCTTCATC TACTTCAACT CCTTCCTGGA 
TGTTCTTCGT CAATCCCGGG GAGGATGAGG TCTCCCGGGT CGTCTTCATC TACTTCAACT CCTTCCTGGA 
4.11 4.12 
ATCCTTCCAG GGCTTCTTTG TGTCTGTGTT CTACTGTTTC CTCAATAGTG AGGTCCGTTC TGCCATCCGG (1162) 
ATCCTTCCAG GGCTTCTTTG TGTCTGTGTT CTACTGTTTC CTCAATAGTG AGGTCCGTTC TGCCATCCGG 
ATCCTTCCAG GGCTTCTTTG TGTCTGTGTT CTACTGTTTC CTCAATAGTG AGGTCCGTTC TGCCATCCGG 
ATCCTTCCAG ............... ..................... .................. ........................ ..... GTCCGTTC TGCCATCCGG 
AAGAGGTGGCACCGGTGGCAGGACAAGCAC TCGATCCGTG CCCGAGTGGC CCGTGCCATG TCCATCCCCA(1232) 
AAGAGGTGGCACCGGTGGCAGGACAAGCAC TCGATCCGTG CCCGAGTGGC CCGTGCCATG TCCATCCCCA 
AAGAGGTGGCACCGGTGGCAGGACAAGCAC TCGATCCGTG CCCGAGTGGC CCGTGCCATG TCCATCCCCA 
AAGAGGTGGCACCGGTGGCAGGACAAGCAC TCGATCCGTG CCCGAGTGGC CCGTGCCATG TCCATCCCCA 
- (1285) 
CCTCCCCAAC CCGTGTCAGC TTTCACAGCA TCAAGCAGTC CACAGCAGTC TGA 
CCTCCCCAAC CCGTGTCAGC TTTCACAGCA TCAAGCAGTC CACAGCAGTC TGA 
CCTCCCCAAC CCGTGTCAGC TTTCACAGCA TCAAGCAGTC CACAGCAGTC TGA 
CCTCCCCAAC CCGTGTCAGC TTTCACAGCA TCAAGCAGTC CACAGCAGTC TGA 
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Figure 3.1 Comparison of the sequence of human CRH-R1 subtypes 
(1) indicates intron positions (numbers according to human CRH-Rlcc 
sequence). The initiation and termination cordons are underlined and overlined, 
respectively. W, human CRH-R la (accession number L23332); 1(3, human 
CRH-R1ß (accession number L23333); lc, human CRH-Rlc (accession number 
U16273) and Id, human CRH-R ld (accession number AF 180301). 
The procedures used to clone and sequence CRH-R subtypes from human 
myometrium are described in the following illustrate (Figure 3.2). 
.. _r_ý. 
Figure 3.2. Flow chart to illustrate the procedure used to clone CRH-R subtypes 
from human myometrium. 
3.2 Amplifying and cloning strategy 
A schematic representation of the cloning strategy is shown in Figure 3.3. 
Polyadenylated RNA was isolated from pregnant (n=10) and non-pregnant (n=8) 
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myometrium tissues and myometrial cell cultures and used as a template to reverse 
transcribe cDNA. This reverse transcription reaction generates a cDNA template for 
PCR amplification. Specific primers for the CRH-R1 cDNA cloning have been 
described in Section 2.18. Oligonucleotide primers were based on the known 
sequence of the human brain CRH-R1cc cDNA. 
CRH Receptor mRNA 
5' 
RT 
3' 
a) 5'RACE A' 
cDNA 
700bp crf7 
P 
C 
R 
B 
crf 67 456bp crf7 C 
crf3 453bp crf4 D 
crf274bp crfll 
E 
crf3 650bp crfll b) 
CRFII-1 
First round PCR Adapted dT)18 
CRFI Nested PCR crfll 
1.2kb 1.1 kb CRH-R1 a 1.2kb 
CRH-R1 c 1.1 kb 
12 b 
Figure 3.3. Schematic representation of the RT-PCR for amplifying strategy 
a) RT-PCR was amplified for different fragments of CRH-R1 using different 
primer pairs. b) A nested RT-PCR was used to amplify the full-length CRH-R1 
subtypes. 
Initially, products were amplified using different primer pairs (crf 6/crf 7, crf 3/crf 4, 
crf 3/crf II and crf 5/crf II). To confirm the sequence of the 5'region cDNA of CRH- 
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RI, 5'RACE was used to amplify the 5'-cDNA for the purpose of sequencing. Next, 
in order to amplify the full length CRH-Rla cDNA, a nested PCR method was 
employed. In the first step, a "primary fragment" was generated with the first set of 
primers (1S and 1A for CRH-Rl(x, lc; 2S and 1A for CRH-R1ß). In the second step, 
each cDNA fragment was cloned with a second set of primers (2S and 2A for CRH- 
Rla, lc; 5'S and 5'A for 5'-end of CRH-R1ß, 3'S and 2A for 3'-end of CRH-R1ß). 
The first reaction was then used as template for the second round of amplification. 
The products of the full-length PCR reaction were cloned in two different ways. The 
first involved the use of the EcoR I and Hind III restriction sites incorporated into 
CRH-Rlct 2A and 2S. The PCR products were isolated by gel electrophoresis, 
restriction digested with EcoR I and Hind III, then cloned into pBluescript II SK. The 
second method utilised the A base added on to the 5' and 3' ends of the products by 
Taq polymerase and involved the cloning of the uncut, gel extracted PCR products 
into pGEM-T, a T-tailed vector. 
The products of the second PCR reaction were purified from a 1.0% agarose gel using 
"QIAquick Gel Extraction kit (Qiagen)" ligated using T4 DNA ligase kit into plasmid 
pBluescript H SK or pGEM-T. The plasmid with the insert was transformed into 
E. coli strain XL-1 blue cells. Clones with the insert were identified using blue-white 
selection. However, this did not always function efficiently as read-through often 
occurred due to the short length of the product. The clones were therefore checked for 
the insert by restriction endonuclease digestion using Hindu and EcoRI. The 
positively selected clones were subcultured. Plasmid DNA was then extracted using 
"QIAprep spin miniprep kit (Qiagen)" and digested using Hindul and EcoRI 
enzymes. Two bands were visualised on an ethidium bromide stained agarose gel 
corresponding to the plasmid and the insert. After the above procedure, isolated 
clones were sequenced using Sequenase version 2.0 T7 DNA polymerase kit 
(Amersham) and with an ABI 373 DNA sequencer (Applied Biosystems). The 
sequence data was analysed using Blast Nucleic Acid Database Searches from the 
National Centre for Biotechnology Information (NCBI). 
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3.4 Identification of CRH-R1 subtypes in human myometrium 
In order to detect the CRH-R1 subtypes, different specific primers were employed. 
Initially, RT-PCR was used to amplify internal cDNA fragments B (crf6/crf 7 primer 
pairs), C (crf 3/crf 4 primer pairs), D (crf 5/crf II primer pairs) and E (crf 3/crf II 
primer pairs) comprising 274,453,456 and 650 bp respectively. The nucleic acid 
sequences were shown to overlap each other and corresponded to human CRH-Rla, 
which are illustrated in Figure 3.4. 
To rapidly identify a 5' region sequence for this receptor, two approaches were taken. 
The first approach was used to amplify the 5' region cDNA of CRH-Rla by RT-PCR, 
but it was unsuccessful. The second was to use an anchored PCR to amplify the 
sequence of the 5'region of the cDNA. 5'RACE was used to amplify the 5'-cDNA for 
the cloning. Amplification products were size-selected, subcloned, and sequenced. 
The nucleic acid sequence of the cDNA fragment revealed that the 700 bp fragment 
corresponded to the human 5' region cDNA of CRH-R1a (see Figure 3.4). 
Next, in order to amplify the full length CRH-Rla cDNA, a nested RT-PCR method 
was employed. When primers 2S (containing the initiation codon) and 2A (containing 
the stop codon) were used for the nested PCR, two DNA fragments with sizes of 1.07 
and 1.18 Kb were amplified from the pregnant myometrium whilst only one fragment 
of 1.18 Kb was amplified from the non-pregnant myometrim (Figure3.5). These DNA 
fragments were subcloned for DNA sequencing. The nucleic acid sequence of the 
fragments revealed that, in both tissues, the 1.18 Kb fragment corresponded to the 
human CRH-Rla whereas the 1.07 Kb fragment amplified from pregnant 
myometrium was from the CRH-Rlc. CRH-R1 cDNA was also amplified from 
human pregnant myometrial cells using the same primers and PCR conditions. The 
CRH-Rla subtype was identified and shown in Figure 3.6. 
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Figure 3.4.5'RACE and RT-PCR amplification of the different fragments 
human CRH-R1a subtype extracted from pregnant human myometrium. 
Lane 1 and 7 are DNA size makers. RT-PCR was used to amplify internal four 
fragments. Four cDNA fragments were generated, which have the following 
sizes: 650 (Lane 2), 274 (Lane 3), 453 (Lane 4) and 456 (Lane 5) bp. Lane 6 
shows 5'RACE's amplification of a 700 bp fragment, which corresponds to the 
5'-end CRH-Rla mRNA. The nucleic acid sequences were shown to overlap 
each other and corresponded to human CRH-Rla. 
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Figure 3.5 Nested PCR amplification of the human CRH-Rla and CRH-Rlc 
from mRNA extracted from non-pregnant (Lane 1) and pregnant (Lane 2) 
human myometrium. The DNA sizes standards were the lkb ladder (Gibco- 
BRL; Lane 3). 
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Figure 3.6 Nested PCR amplification of the human CRH-R 1a and CRH-R 1ß 
from mRNA extracted from human pregnant myometrial cells (Primary 
culture). 
For the 3'-end of the CRH-R1(3, Lane 1 shows amplification of an 850 bp 
fragment. For the 5'-end of the CRH-R1ß, Lane 2 shows amplification of a 520 
bp fragment. For the CRH-Rla, Lane 3 shows amplification of a 1.18 kb 
fragment. Lane 4 is a negative control, distilled water was used in place of the 
cDNA. The DNA sizes standards were the 1kb ladder (Gibco-BRL; Lane 5). 
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Figure 3.7 (A) Nested PCR amplification of the human CRH-R1(3 (5'-end) 
subtype. 
Specific primers for the 5'-end region the mRNA were used. Human 
myometrium from non-pregnant (Lane 4 and 5) and pregnant (Lane 1,2 and 3) 
uterus were used. For the 5'-end of the mRNA, Lane 1,2,3,4, and 5 show 
amplification of a 520 bp fragment when compared with the DNA size marker 
(Lane 7). Lane 6 is a negative control, distilled water was used in place of the 
cDNA. 
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Figure 3.7 (B) Nested PCR amplification of the human CRH-R1ß (3'end) 
subtype. 
Specific primers for the 3'-end region the mRNA were used. Human 
myometrium from non-pregnant (Lane 1 and 2) and pregnant (Lane 3,4 and 5) 
uterus were used. For the 3'-end of the mRNA, Lane 1,2,3,4, and 5 show 
amplification of an 850 bp fragment when compared with the DNA size marker 
(Lane 7). Lane 6 is a negative control, distilled water was used in place of the 
cDNA. 
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In contrast, when the CRH-R1(3 specific primers, designed from the region of the 
mRNA encoding the 29 amino acid insert of the first intracellular loop of CRH-R1(3, 
were used in a nested PCR (with primers 5'S and 5'A for the 5'-end, and 3'S and 2A 
primers for the 3'-end). DNA fragments of 520 and 850 bp length were amplified 
from both pregnant and nonpregnant tissues. Sequencing confirmed that these two 
bands corresponded to the CRH-R1(3 mRNA (Figure 3.7). The same method was used 
to identify CRH-R1ß mRNA in the human pregnant myometrial cells. Sequencing of 
520 bp and 850 bp fragments of CRH-R1ß showed 100% homology with the reported 
sequence of the CRH-R1ß gene (Figure 3.6). 
3.5 RNase protection assay 
To confirm the results obtained from RT-PCR, the method of RNase protection assay 
was used. The RNase protection assay is a sensitive method for detecting specific 
RNA transcripts using radiolabelled riboprobes (Zinn, et al., 1983). Probes were made 
by synthesising antisense RNA from a DNA template using SP6 (SP6 RNA 
polymerase transcription initiation site), or T7 (T7 RNA polymerase transcription 
initiation site) RNA polymerase in the presence of at least one 32P-labelled 
ribonucleoside triphosphate, as described in Section 2.2.15.3. Hybridi$ation of the 
probe to target RNA and RNase digestion are described in Section 2.2.14. Gel 
electrophoresis is described in Section 2.2.2.3. 
The CRH-R1 probe was synthesised from a 450 bp 5' fragment of CRH-R1 cDNA in 
pBluescript SK, linearized with BamH I. The CRH-R2 cRNA riboprobe was produced 
from a 410 bp cDNA fragment of the CRH-R2 subcloned into pBluescript SK and 
linearized with Xho L Both CRH-R1 and CRH-R2 riboprobes were that directed 
against the 5' region of their respective receptors, covering the sequence up to the 
third presumed transmembrane region (Figure 3.8). 
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TM1 TM2 TM3 TM4 TM5 TM6 TM7 3' 
CRH-R1 
b57a'- 
'CRH-R2 
Figure 3.8 Schematic illustration of nucleotide sequence homology between CRH- 
R1 and CRH-R2 across the coding region of the receptors. 
Lower bars indicate the region of the receptors against which CRH-R1 and 
CRH-R2 cDNA probes were designed. 
The approximate nucleotide homology between the two probes is 65% in this region. 
In preliminary experiments cRNA probes directed against the 3' region of the CRH- 
R2 apparently labelled both CRH-R1 and CRH-R2 mRNAs whereas the two mRNA 
species could be clearly separated by 5' specific probes under similar hybridisation 
conditions. 
The RNase protection assay was employed to study CRH-R mRNA expression in the 
human myometrium. Labelled probes were hybridised with 10-30µg of total RNA 
isolated from human pregnant myometrium. But it was unsuccessful. The CRH-R is 
present in human myometrium, but blew the level of detection by the RNase 
protection assay technique. 
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3.6. Discussion 
CRH-R1 subtypes were identified in human myometrium by using RT-PCR. Initially, 
RT-PCR was used to amplify for different fragments of CRH-R1. To rapidly identify 
a 5' region sequence for this receptor two approaches were taken. The first approach 
was used to amplify the 5' region cDNA of CRH-Rla by RT-PCR, but it was 
unsuccessful. The second was to use an anchored PCR to amplify the sequence of the 
5'region of the cDNA. 5'RACE is a technique that facilitates the isolation and 
characterisation of 5'region from low-copy messages. The second method has been 
reviewed by both Frohman (1988) and Loh (1989) and typically requires the design of 
at least three degenerate oligonucleotides. The first two oligonucleotides are used to 
create an enriched "template" for the second round of PCR, which then requires 
additional oligonucleotides corresponding to target DNA created in the first round. 
Each new oligonucleotide requires the presence of a corresponding sequence in the 
target gene and, therefore, increases the risk of missing related genes. To reduce this 
risk, 5'RACE PCR was combined with the nested degenerate oligonucleotides. This 
procedure reduces the number of necessary degenerate oligonucleotides to two, thus 
increasing the probability of identifying sequences related to the initial template 
design. Initially, a single degenerate gene-specific antisense oligonucleotide in 
combination with a poly(dG) oligonucleotides was used to selectively amplify the 
first-strand human myometrium dC-tailed cDNA. Next, nested gene-specific antisense 
oligonucleotides were used in combination with the original degenerate 
oligonucleotide to amplify DNA fragments from the first reaction. Next, a nested PCR 
method was employed. 
This study has demonstrated that human myometrium and cultured myometrial cells 
(Figure 3.6) express CRH-R mRNA and extended previous observations 
demonstrating specific CRH receptors in human myometrium (Hillhouse et al., 1993). 
The CRH-R 1a and 10 subtypes were found in both nonpregnant and pregnant human 
myometrium at term before the onset of labour as well as human pregnant myometrial 
cells. In contrast, the CRH-Rlc subtype was only found in pregnant myometrium and 
cells. It is possible that CRH-Rlc is present in non-pregnant tissue but is below the 
level of detection by the RT-PCR technique. CRH-Rlc was originally cloned and 
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characterised from the hippocampus and cerebellum of a normal 2-year-old female 
(Ross et al., 1994). This is the second time that the CRH-Rlc variant has been 
detected outside the central nervous system. Our laboratory has identified the full 
length of the CRH-Rlc subtype in placental and fetal membranes (Karteris et al., 
1998). The function of CRH-Rlc remains obscure. The exon deletion means that the 
receptor has a short N-terminal domain which does not bind CRH well. It is possible 
that this receptor may have a different ligand. 
The presence of multiple CRH-R subtypes in the human pregnant myometrium as 
identified in this study suggests distinct functional roles for each receptor during 
pregnancy and raises the possibility of multiple roles for CRH and/or related peptides. 
Although we do not know which subtypes are more important, our data on the 
expression of CRH-R mRNA in myometrium support the concept that CRH plays a 
role in uterine physiology. 
Alternative splicing is a widespread mechanism for producing variant forms of 
proteins from a single gene. Four subtypes of CRH-R 1: 1 a, 10,1 c, and 1d 
(Grammatopoulos et al., 1999), were found in the pregnant human myometrium at 
term before the onset of labour. Three human calcitonin receptor (CT-R) isoforms 
have been reported. The largest CT-R cDNA has a 16-amino-acid insertion in the first 
putative intracellular domain of the deduced protein (Albrandt et al., 1995). This 
receptor with 16 amino acids inserted has been shown to have lower affinity and 
decreased G protein coupling efficiency to adenylate cyclase. This insertion is located 
between exon 5 and exon 7 of the CRH-R1 gene. The location of the 16 amino acids 
inserted within the first intracellular loop of the CT-R corresponds exactly to the 
location of the 29 amino acids inserted in the CRH-R1ß. Another CT-R cDNA has a 
14-amino-acid deletion in the seventh transmembrane domain of the deduced protein 
(Shyu et al., 1996). The calcitonin receptor family is of particular interest since it 
appears to have a similar isoforms profile to the CRH-R1 family; both receptor have 
splice variants that contain inserts in the first intracellular loop and exon deletion in 
the seventh transmembrane domain. In addition, the existence of alternative splicing 
events indicates that there may be other unknown, splice variants of CRH-R1. 
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In rats, a CRH-R1 frame shift mutant encoding a 224 amino acid protein was 
identified (Chang et al., 1993). This mutant lacks the entire third and parts of the 
fourth putative transmembrane domain. At the present, nothing is known about the 
functional properties of the mutant receptor protein. In contrast to rodents, this splice 
product has not been identified in humans. 
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Chapter 4 Amplifying and cloning CRH-R2oc, 20, and 2yy from human 
myometrium 
4.1 Introduction 
A second molecularly distinct CRH-R has been identified in the rat (Lovenberg et al., 
1995a), mouse (Perrin et al., 1995, Stenzel et al., 1995, Kishimoto et al., 1995), and 
human (Liaw et al., 1996). In the rat at least, there are two known forms of the second 
CRH-R. CRH-R2a is a 411 amino acid protein, which is expressed almost exclusively in 
brain. The alternatively spliced form, CRH-R20, has the first 34 amino acids of CRH- 
R2a replaced with a 54 amino acid sequence, giving a full-length receptor of 431 amino 
acids. CRH-R20 shows the highest level of expression in the heart and skeletal muscle 
with lower level expressed in brain, lung, and intestine (Lovenberg et al., 1995b). In the 
mouse, only the homologue of the rat CRH-R20 form has been identified (Perrin et al., 
1995, Stenzel, et al., 1995, Kishimoto et al., 1995). 
The human CRH-R2 family has additional diversity in three isoforms, which utilise 
alternative amino termini. The three splice variants appear to diverge at the 
corresponding position of human CRH-R2 where the first intron occurs. CRH-R2 is 
expressed in the form of three functional splice variants, 2a (411 amino acids), 2(3 (438 
amino acids) and 2y (397 amino acids) (Liaw et al., 1996, Valdenaire et al., 1997, 
Kostich et al., 1998). CRH-R2a and 20 are co-expressed in peripheral organs and the 
central nervous system (Valdenaire et al., 1997), whereas CRH-R2y, which has been 
isolated only from humans, was found only in the brain (Kostich et al., 1998). 
In order to detect the CRH-R2 subtype expression in human myometrial biopsies 
(pregnant and non-pregnant) and myometrial cell cultures, PCR primers were designed 
which were specific for the CRH-R2 subtype and used in nested RT-PCR. 
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4.2 Methods for amplifying and cloning CRH-R2 
Sense primers were designed from the previously reported sequence. Antisense primers 
were designed from a C-terminal region shared by three splice variants common to 
human. Specific primers for the CRH-R2 cDNA cloning and sequencing are described in 
Section 2.18. All primer sets were shown not to amplify a product from genomic DNA. 
A schematic representation of the cloning strategy is shown in Figure 4.1. 
In order to amplify the full length CRH-R2 cDNA, a nested RT-PCR method was 
employed. Polyadenylated RNA was extracted from human pregnant (n=10), non- 
pregnant (n=8) myometrium and myometrial cell cultures and reverse transcribed in each 
of 20µl reaction containing 400 ng Oligo (dT)18,0.5 mM each of four dNTPs, 50mM 
Tris-HCI pH8.3,3mM MgC12,10mM DTT and 200 units RNase If using Reverse 
Transcriptase (Gibco-BRL) for 1 hour at 42°C. The reactions were stopped by incubation 
at 70°C for 15 minutes. To remove RNA complementary to the cDNA 2 units RNase H 
was added and the incubation continued for 20 minutes at 37°C. The cDNA was used as 
a template for a first round PCR. The products of the first PCR reaction served as a 
template for the second round of amplification reaction. The products of the second PCR 
reaction were purified, subcloned and sequenced. These differences in the receptor 
pattern between pregnant and non-pregnant myometrium were consistent in all subjects 
studied in each group. 
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Fig 4.1 RT-PCR analysis of the human CRH-R2 mRNA isoforms 2a, 2y, and 2ß. 
The figure illustrates diagrammatically the approximate locations of 
oligonucleotides used as primers for RT-PCR analysis of the CRH-R2 mRNA 
isoforms. The original CRH-R2 mRNA is encoded by twelve exons, labelled 1-12. 
Short arrows indicate approximate locations of oligonucleotides. Note that 
oligonucleotides Al and A2 in the 3'-UTR of exon 12 are common for all 
isoforms, whereas oligonucleotides 2a S 1/S2,2y S 1/S2, and 20 S 1/S2 are specific 
for the different 5'-extremities. Total RNA from human myometrium was reverse 
transcribed using oligo(dT)18. The cDNA was then used as a template in a PCR 
reaction with 3'-oligonucleotide Al and various 5'-exon-specific primers CRH- 
R2cc, 2y, and 20-S 1. PCR products were reamplified using a nested common 3'- 
oligonucleotide A2 together with nested 5'-exon -specific primers 2a, 2'y, and 20- 
S2. 
I- 
The products of the second PCR reaction were purified from a 1.0% agarose gel using 
"QIAquick Gel Extraction kit" (Qiagen) and lighted into the pGEM T-vector (Promega). 
E coli strain XL -blue 1 (200 p1) was then transformed by CaC12 with 7-10 tl of the 
ligation reaction. The cells were placed in 800µ1 LB medium and incubated at 37°C forl 
hour, and plated on agar plates with ampicillin (lOµg/ml), 5-bromo-4-chloro-3-indolyl 
(3-D-galactopyranoside (X-gal 20mg/ml stock), and isopropythio-ß-D-galactoside (IPTG 
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0.5M stock). The plates were incubated overnight at 37° C. After the overnight cultures, 
only the white colonies were picked. Plasmid DNA was then extracted from 1.5m1 of the 
overnight culture using "QiAprep Spin Miniprep Kit" (Qiagen). The resulting plasmid 
DNA was then analysed using restriction enzymes Nco I and Nde L Two bands were 
visualised on an ethidium bromide stained agarose gel corresponding to the plasmid and 
the insert. Isolated clones were sequenced using the Sequenase version 2.0 77 DNA 
polymerase kit (Amersham) and with an ABI 373 DNA sequencer (Applied 
Biosystems). For each cDNA fragment, four independent clones were sequenced at least. 
4.3 Results of RT-PCR on CRH-R2 
Using CRH-R2a exon I specific primers a single strong band of 1.2 kb was amplified 
from human pregnant myometrium but not from the non-pregnant myometrium (Figure 
4.2). Nucleotide sequencing confirmed that this single band contained the full-length 
CRH-R2a. Interestingly, CRH-R2a mRNA was not found in myometrial cell cultures. 
Because RNA was isolated from the cells on the day of confluence (on day 13± 2), we 
investigated the effect of the culture period on the CRH-R subtype profile. Identical 
CRH-R subtypes were found in the cells from the 5th day up to the 10th week of cultures 
(3-5th passage). 
RNase protection assay was employed to detect CRH-R 2a mRNA expression in the 
human myometrium (as described in Section 3.3), but it was unsuccessful. 
When the CRH-R213 specific primers, designed from the N-terminal region of the 
mRNA CRH-R2ß, were used in a nested PCR, a DNA fragment of 1.3 kb length was 
amplified from both pregnant and non-pregnant tissues (Figure 4.3). Sequencing of this 
fragment showed 100% homology with the reported sequence of the CRH-R2(3 mRNA. 
Amplification of the CRH-R2P mRNA from myometrial cell cultures was accomplished 
employing the same RT-PCR reaction conditions and primers as those described above. 
Sequence of the PCR products showed full homology with the reported sequence of the 
CRH-R2(3 mRNA (Figure 4.4). 
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Figure 4.2 Nested PCR amplification of the human CRH-R2a subtype from 
mRNA extracted from non-pregnant (Lane 1) and pregnant (Lane 2) human 
myometrium. Lane 3 is a negative control, distilled water was used in place of the 
cDNA. The DNA size standards were 1 kb ladder (Gibco-BRL; Lane 4). 
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Figure 4.3 Nested PCR amplification of the human CRH-R2ß subtype from 
mRNA extracted from non-pregnant (Lane 1) and pregnant (Lane 2) human 
myometrium. Lane 3 is a negative control, is a negative control, distilled water 
was used in place of the cDNA. The DNA size standards were l kb ladder 
(Gibco-BRL; Lane 4). 
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Figure 4.4 Nested PCR amplification of the human CRH-R2 3 (315 bp deletion) 
subtype from mRNA which was extracted from non-pregnant myometrium 
(Lane 1). 
Lane I shows amplification of 1350 and 1035 bp fragments which correspond to 
the CRH-R2(3 and CRH-R-R2ß (315 bp deletion) mRNAs. (-*) Represents the 
CRH-R2ß and CRH-R2ß (315 bp deletion, mutant). The identities of the 
fragments were confirmed by nucleotide sequencing. Lane 2 shows first PCR 
product. Lane 3 shows amplification of a 1350 bp fragment of the CRH-R2f 
mRNA from human pregnant myometrial cells (Lane 3). Lane 4 is a negative 
control. Lane 5 is a DNA size marker. 
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In addition, when the primers were adopted, which were designed to identify the full- 
length CRH-R20, we also observed a second band at 1.0 kb from non-pregnant tissue 
(Figure 4.4). The nucleic acid sequence of the isolated CRH-R2(3 is identical to the 
previously published CRH-R2(3 mRNA, except for an in-frame 315 bp deletion of exon 
3-5 (Figure 4.5). The mutant lacks the entire first and second putative transmembrane 
domain. 
A 
S2--ß 
S1--ß 
TCCAGTCCCTAACCCCAGCCACTACTGGC29 
ATGAGGGGTCCCTCAGGGCCCCCAGGCCTCCTCTACGTCCCACACCTCCTCCTCTGCCT60 
CTCTGCCTCCTCCCACCGCCGCTCCAATACGCAGCCGGGCAGAGCCAGATGCCCAAAG120 
CAGCCCCTGTGGGCACTTCTGGAGCAGTACTGCCAGACCATCATGACCCTCACCAACC180 
TCAGGTCCCTACTCCTACTGCAACACGACCTTGGACCAGATCGGAACGTGCTGGCCCC240 
AGCGCTGCCGGAGCCCTCGTGGAGAGGCCGTGCCCCGAGTACTTCAACGGCGTCAAGT300 
I 
AACACGACCCGTCTGGTGCCACTGCATCACCACCATCTTCAACTACTTCGTGGTGACC360 
CTTCTTCTGGATGTTTGTGGAAGGCTGCTACCTGCACACGGCCATTGTCATGACCTACT 420 
B Deleted fragment 
I 
CGGAATGCCTATCGAGAATGCTTGGAGAATGGGACGTGGGCCTCAAAGATCAACTACTCA 
CAGTGTGAGCCCATTITGGATGACAAGCAGAGGAAGTATGACCTGCACTACCGCATCGCC 
CTGTCGTCAACTACCTGGGCCACTGCGTATCTGTGGCAGCCCTGGTGGCCGCCTTCCTGC 
TTITCCTGGCCCTGCGGGAGCATTCGCTGTCTGCGGAATGTGATTCACTGGAACCTCATC 
ACCACCTITATCCTGCGAAATGTCATGTGGTTCCTGCTGCAGCTCGTTGACCATGAAGTG 
CACGAGAGCAATGAG 
Figure 4.5. A shortened CRH-R2(3 mRNA which is identical to the normal CR13- 
R20 except for 315 bp deletion, the position of which is shown in (L) as indicated. 
Si is the first PCR primer. S2 is the second primer (underlined). B. Deleted 
fragment. The 315 bp fragment of CRH-R2(3 was deleted in the shortened CRH- 
R20, the positions at which the fragment is deleted are indicated by (1). 
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2ß la 2ß lb 2y 1 
exon 
`---1018 bp 
-506 bp 
4----298 bp 
Fig 4.6 Alternative splicing of the human CRH-R2 gene and RT-PCR with CRH- 
R213 (exon-la gene) and CRH-R2a (exon-I gene) primers. The structure of the 
5'flanking of the gene is shown on the top with locations of PCR primers indicated 
by arrows. CRH-R213 la 90 bp + Ib 93 bp = 183 bp (61 aa), CRH-R2y I= 60 bp 
(20 aa) and CRH-R2a 112 bp (34 aa). A PCR was performed using a primer from 
CRH-R23 exon la and a primer from CRH-R2a exon I, resulting in the two bands 
A, B, after separation on an agarose gel (C). Lane 1 and 2 are different human 
myometrium sample. Lane 3 are DNA size markers. Bonds were sequenced 
completely, and their structures are shown in the drawing on the over boxes 
representing exons. 
10 kb 
A 
2aI 
f 
2.57 kb 4 kb first common 
exon exon exon exon 
RT-PCR products 
2ß 2ß 2y 2a 
la lb 11 
Ba 
2ß 2ß 2 
la lb I 
C 
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In order to detect the expression of CRH-R2y in the myometrium, primers were designed 
from the reported sequence and used for RT-PCR amplification from both human 
pregnant and non-pregnant tissues. CRH-2'y mRNA was not detectable in the 
myometrium. Interestingly, a RT-PCR amplification using primers CRH-R2ß (exon Ia 
gene) and CRH-R2ct (exon I gene) resulted in two DNA fragments (A and B) of 
apparently 529 bp and 301 bp in the human pregnant myometrium sample (Figure 4.6). 
The nucleic acid sequence of one fragment revealed that a 529 bp fragment (A) 
corresponded to the CRH-R2(3 (189 bp), CRH-R2y (227 bp) and CRH-R2a (113 bp) 
exon. The sequence of another fragment (B) contains CRH-R2ß (189 bp) and CRH-R2cc 
(113 bp) exon. The results suggest that CRH-R2y is expressed in the human pregnant 
myometrium. But, CRH-R2y mRNA was not detectable in the human non-pregnant 
myometrium. However, RT-PCR was employed to detect CRH-R2 subtypes. CRH-R2a, 
20, and 2y mRNA were detectable in the human pregnant myometrium. Interestingly, 
only one CRH-R20 was detectable in the human non-pregnant myomtrium and 
myometrial cell cultures. In addition, the mutant CRH-R2ß (with a 315 bp deletion) was 
identified in human myometrium. 
These differences in the receptor pattern between the pregnant and non-pregnant 
myometrium were consistent in all subjects studied in each group. 
4.4 Discussion 
We have demonstrated that CRH-R2cx, 2(3, and 2y are expressed in myometrium from 
pregnant woman, whilst only one subtype, CRH-R2(3 was found in the nonpregnant 
myometrium and myometrial cell cultures. 
Of particular interest is the finding that the CRH-R2a subtype is present in human 
pregnant myometrium. To date the CRH-R2a was thought to be confined solely to the 
CNS and there has been no report of the existence of the CRH-R2a receptor in any 
another human tissue. This is the first report where the CRH-R2a receptor has been 
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identified in a tissue other than the brain. Since there are indications that another, as yet 
unidentified, peptide (not CRH) is the native ligand for this CRH receptor subtype; this 
raises the possibility that other signals may mediate CRH-R2a effects on myometrial 
function. Similarly this is the first report of the expression of CRH-R2y mRNA outside 
the central nervous system in humans. 
The myometrial cell cultures do not express mRNA for CRH-R2cc or CRH-R2y, 
although the tissues of origin (pregnant myometrial tissue obtained from individuals at 
term undergoing elective caesarean section) were found to be positive for these CRH-R 
subtypes mRNA. This finding suggests that maternal factors that are components of the 
pregnant environment may play a major role in the regulation of CRH-R subtype 
expression. 
We have isolated a novel CRH-R2ß spliced variant mRNA from human myometrium by 
employing the RT-PCR technique. This variant of the CRH-R2(3 contains a 315 bp 
deletion in the exon 3-5. This mutant lacks the entire first and second putative 
transmembrane domain. This variant of the CRH-R2ß took place just at the splicing site, 
suggesting that it is due to an aberrant splicing event. To date nothing is known about the 
functional properties of the mutant receptor protein. It is possible that the CRH-R2(3 
variant may modulate the function of the CRH-R20. Recently, Miyata et al. has 
identified a novel isoform of the CRH receptor, referred to as CRH-R2a-tr, from a rat 
amygdala cDNA library. The nucleotide sequence of the cloned cDNA has a structure of 
an alternatively spliced form of the CRH-R2a, which contains unspliced introns 6 and 7 
in the message, and encodes a 236 amino acid truncated protein that comprises three 
unique transmembrane domains. These findings suggest that this truncated CRH-R is the 
major isoform of CRH-R2a mRNA transcripts in the amygdala and might mediate some 
functions of CRH pathways in the central nervous system (Miyata et al., 1999). No rat 
CRH-R2a-tr messenger RNA (mRNA) was identified in the human myometrium. At 
present, there is no evidence for the existence of a CRH-R2a-tr homolog in humans. 
In addition, Granunatopoulos et al (1995) have identified previously, by isoelectric 
focusing, at least five populations of CRH receptors in the human myometrium and we 
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do not rule out the existence of other subtypes of CRH receptors. These subtypes may 
arise due to alternate splicing or due to post-translational modifications 
(Grammatopoulos et al., 1995). 
Our results demonstrate the presence of multiple CRH-R mRNAs in the human 
myometrium (CRH-R1 mRNA, as discussed in Chapter 3). Six subtypes of the CRH 
receptor, la, 10, lc, 2a, 2ß, and 2y, were found in the pregnant human myometrium at 
term before the onset of labour, whereas only three subtypes, la, 10, and 20, were found 
in the non-pregnant myometrium. It is possible that the receptors are present in 
nonpregnant myometrial tissues but are below the level of detection by the RT-PCR 
technique. 
This would suggest that CRH, acting via different receptor subtypes, is able to exert 
different actions on the myometrium in the pregnant state compared to the non-pregnant 
state. This was confirmed by an independent laboratory, which also showed that there is 
CRH-R regional distribution in the human myometrium and that CRH-R1 mRNA in the 
lower uterine segment was decreased during pregnancy and increased significantly in 
both preterm and term labour, but remained unchanged in the fundus (Stevens et al., 
1998). 
This finding demonstrates, for the first time, that during pregnancy there is an alteration 
in the pattern of CRH-R subtype expression. This original observation coupled with 
previous studies (Hillhouse et al., 1993. Grammatopoulos et al., 1995,1996) argue for a 
functional role for CRH and/or related peptides in myometrial function. During 
pregnancy CRH is produced by the placenta and feto-maternal tissues and secreted into 
the maternal circulation. The biological role of placental CRH is still uncertain, but it 
may modulate myometrial contractility, as it is able to activate specific CRH-Rs in the 
human myometrium. The CRH-Rs are capable of adopting a high affinity state during 
the latter stages of pregnancy (Hillhouse et al., 1993) when they become functionally 
coupled to adenylate cyclase (Granunatopoulos et al., 1994). This data suggests that 
during pregnancy CRH may play a "protective" role for the myometrium, by preventing 
uterine contractions. As term approaches the ability of CRH to activate myometrial 
adenylate cyclase is reduced (Grammatopoulos et al., 1996). In particular, the ability of 
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CRH to activate Gsa at term is reduced. Grammatopoulos et al. suggested that in the 
term myometrium, CRH receptor function is modulated by oxytocin, leading to reduced 
biological activity, lower cAMP levels, and a subsequent shift in favour of contractility 
rather than relaxation (Grammatopoulos et al., 1999). 
Alternative splicing is a widespread mechanism for producing variant forms of 
proteins from a single gene. Generation of protein isoforms by alternative splicing is 
known to occur in numerous members of the G protein-coupled receptor family, 
correlating with differences in affinity potency, coupling efficiency, specificity, 
subcellular localisation or sensitivity to desensitisation of receptor. Ross et al reported a 
variant of the CRH-Rla with a deletion of 40 amino acids in the N-terminus (Ross et al, 
1994). This form of the receptor (CRH-Rlc) has previously only been identified in one 
individual. We now report that this variant is also expressed in the human myometrium 
and recent reports have also shown expression in placenta and fetal membranes (Karteris 
et al., 1998). However, it is of interest because it has a low affinity for CRH. 
Interestingly, variants have also been described for which differences in interacellular 
regions lead to modified ligand binding, presumably as a result of altering the receptor 
tertiary structure. The CRH-Rla with additional 29 amino acids inserted in the putative 
first intracellular loop (CRH-R1 ß) displays a lower affinity for CRH. A number of other 
G protein-coupled receptors possess variants that display different signalling 
characteristics. Both type I vasoactive intestinal peptide (VIP) and type I pituitary 
adenylate cyclase-activating polypeptide (PACAP) receptors can positively couple to 
concurrent increases in intracellular cAMP and free Cat+, presumably through 
association with different G proteins (Sreedharan et al., 1994, Spengler et al., 1993). 
Spengler et al. described five splice variants of the PACAP receptor differing in the 
region corresponding to the third intracellular loop of this receptor (Spengler et al., 
1993). Four of these five splice variants exhibited the multifunctional signalling 
capability of PACAP receptors described in several cell types, activating both adenylyl 
cyclase and phosphoinositide phospholipase C. Structurally, the PACAP receptor 
exhibits sequence homology to the corticotrophin-releasing hormone, parathyroid and 
glucagon receptor family that have been designated as member of Class II in the 
GPCR superfamily. Amplification of this region (the third intracellular loop) from 
cDNA made from the myometrium has not indicated the presence of other isoforms of 
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the CRH-R. 
The human CRH receptor is a member of a newly characterised family of G protein- 
coupled receptor that shares several characteristics structural features. It has been 
reported that different subtypes of CRH receptor have different efficiencies of coupling 
with G proteins (Chen et a1.1993, Perrin et al., 1995). Different mechanisms may be 
involved in order to increase myometrial sensitivity to different ligands dependent upon 
the presence of the subtypes of CRH receptor on the membrane of myometrial smooth 
muscle cells. Therefore, the high concentration of CRH in the maternal circulation, 
coupled with high expression of CRH receptor subtype and high cAMP production in 
the uterus, would favour myometrial quiescence during pregnancy. 
Although the physiological role of CRH in myometrial function is not fully understood, 
the pattern of expression of the CRH receptor mRNA suggests that this receptor has a 
physiological role in the regulation of uterine function. Further studies are currently 
under way in order to identify the distribution of CRH receptor subtypes in uterine feto- 
maternal regions as well as to investigate the signals that regulate the pattern of 
expression of the CRH-R subtypes. 
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Chapter 5: Screening of a human genomic cosmid library for the 
5' end of the CRH-R1 
5.1 Introduction 
Molecular biology has greatly aided our understanding of the expression and 
regulation of peptide hormone receptors. The isolation and characterisation of peptide 
hormone receptor genes have led to deductions about their primary structure as well 
as their biological activity. Study of the control regions of these genes has also given 
insight into factors that control both basal and hormonally regulated expressions. 
Mammalian genes, unlike prokaryotic genes, contain both exons and introns. Exons 
are DNA sequences that appear as RNA sequence in the mature messenger RNA 
(mRNA) encoding a particular gene. Introns are DNA sequences that do not appear as 
mRNA in the mature mRNA. The first exon contains 5'-untranslated sequence. The 
last exon contains 3'-untranslated region (Mout 1982). At the borders of all introns 
there are consensus sequences that allow for RNA splicing. The consensus sequence 
for a splice donor at the 5'end of an intron is GT. The consensus splice acceptor at the 
3'end of the intron is AG. These splice donor and splice acceptor sites in the primary 
DNA sequence of mammalian genes are important for accurate and efficient RNA 
splicing. 
Exons can contain either coding sequence or non-coding sequence; the latter is 
referred to as untranslated sequence. These DNA sequences are present in the mRNA 
sequence and are important for translation initiation as well as mRNA stability. 
Control regions for mammalian genes can be located at any position within the gene. 
However, most control regions to date have been found in the 5'-flanking region of 
the gene. This region contains DNA sequences necessary for accurate and efficient 
transcription, as well as enhancer, repressor, cell-specific, and hormonal regulatory 
elements. Mammalian genes have a consensus TATA box approximately 20-30 bp 
upstream from the start of transcription. The TATA box is important for binding the 
transcription initiation complex, which is composed of a variety of different protein 
subunits. Also located within the 5'-flanking region is DNA sequences that bind 
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specific trans-acting factors important for basal, cell-specific, and hormonally 
regulated expression. 
Corticotrophin-releasing hormone (CRH) is a principal neuro-regulator within the 
hypothalamo-pituitary-adrenal axis that co-ordinates endocrine, behavioural, and 
autonomic responses to stress. CRH exerts its effects by initially binding to a 
membrane-bound receptor. High affinity CRH binding sites has been characterised in 
the rat, mouse, and human. Cloning of cDNA from different species and tissues has 
revealed that all species investigated so far produce two receptor subtypes, CRH-R1 
and CRH-R2. These receptors show differences both at the level of their expression 
between tissue types and in their pharmacological properties, (as discussed in Chapter 
1.3. ) The CRH-R cDNA from human, rat, and mouse indicates that the expressed 
protein is a member of the G protein-coupled seven-transmembrane receptor (GPCR) 
family and has been shown to couple to both adenylate cyclase and phospholipase C, 
stimulating cAMP production and phosphoinositide hydrolysis. The CRH-R exhibits 
significant homology to the parathyroid and glucagon receptor family that has been 
designated as members of Class II in the GPCR superfamily. This class exhibits little 
primary sequence similarity to the Class I GPCR, and members contain specific 
conserved amino acid motifs in the extracellular and transmembrane domains. In 
addition, genomic structures of the parathyroid and glucagon receptors suggest that 
most members of the Class II family differ from the Class I families by the presence 
of introns in both the N-terminal extracellular and the transmembrane/cytoplasmic 
domains. 
The gene coding for human CRH-R1 consists of at least 13 exons and spans over 20 
kilobases (Sakai et al., 1998). The rat CRH-R1 gene has a similar origination (Tsai- 
Morris et al., 1996). The CRH-R1 gene has been mapped to chromosome 17g12-q22 
(Vamvakopoulos and Sioutopulou 1994). CRH-R1's three reported isoforms originate 
from the same gene by alternative splicing. So far, the sequence of the promoter or 5'- 
flanking and transcription initiation site of the human CRH-R1 and CRH-R2 gene is 
not yet understood. To understand the molecular mechanisms that direct the 
expression of the gene encoding the CRH-R and to analyse the structure and pattern 
of transcription of the CRH-R genes, it is important to clone and characterise the 
promoter region of the human CRH-R1 genes. 
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5.2 Screening and analysis of results 
5.2.1 Library screening 
A genomic library is a large number of DNA fragments derived from the genome, 
which are inserted into a vector which can be a plasmid, a bacteriophage, or a cosmid. 
Genomic DNA is first fractionated into sizes compatible with the chosen vector. In 
general, vectors are chosen based on the size of genomic DNA fragments that will be 
inserted. The plasmid-based vectors are useful for inserts that are less than 10 kb in 
size. Bacteriophage vectors are useful for inserts that are approximately 8-20 kb in 
size. Cosmid vectors will accept genomic DNA fragments of 50 kb and greater in 
length. Cosmid vectors are modified plasmids that contain % cohesive ends sites and 
are packaged like a bacteriophage, but are propagated like plasmids in E. coli. An 
amplified human placental genomic cosmid DNA library (Clontech) was used for this 
project. The advantages of screening cosmid DNA libraries are (a) isolation of larger 
genes than those that can be found in other vector cloning systems; (b) isolation of 
linked genes on one DNA segment; (c) recovery of flanking sequences of the gene of 
interest, and (d) reduction of the number of colonies that need to be screened. 
Although cosmid libraries offer the advantage of very large inserts, these libraries are 
more difficult to screen than bacteriophage libraries because the cosmid vector 
contains plasmid sequences that may contaminate any radiolabeled DNA probe. 
An amplified human placental genomic cosmid DNA library (Clontech) was used to 
isolate clones containing the 5'-flanking of the CRH-R1 gene. The library was 
constructed from 30-50 kilobase (kb) fragments of the partial BamH I digest of 
placental DNA inserted into the BamH I site of the pWE15 cloning vector. Plaque lift 
of 4x 105 recombinants was hybridised with a 450-base pair radiolablled CRH-Rla 
cDNA probe (Oligolabelling kit, Pharmacia Biotech) As discussed in Chapter 2, the 
fragment was derived from the 5'-end (1-450bp, ATG translation initiation codon in 
exon I, which is denoted as nt +1) of a human CRH-Rla cDNA clone (Figure 5.1). 
Filters were washed twice for 15 minutes at room temperature with a2x SSC, 0.1% 
SDS, once with 0.1 x SSC, 0.1% SDS at 60°C for 60 minutes. Positive plaques were 
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identified by autoradiography and purified through a secondary and tertiary round of 
screening. 
Human CRH1 receptor in situ probe 
450 bp insert Notl 
BamHI Sad 
Pstl 5' 3' T3 
EcoRl 
Hindill 
Clal 
Xhol 
T7 
pBluescript (SK+) 
Figure 5.1 Human CRH-R1 probe inserted into the pBluescript (SK+) cloning 
vector. Plasmids were digested with Xho I and Not I, and purified from a 1.0% 
agarose gel using "QlAquick Gel Extraction kit (Qiagen). 
5.2.2 Restriction digests, southern blot, and sequence analysis 
Detailed restriction maps and Southern blot hybridisation should be performed with 
restriction enzymes known to digest cosmid vector DNA in only a limited number of 
locations. After a detailed restriction map is performed, the individual DNA 
fragments can be further subcloned and sequenced to confirm their identity. The 
restriction map of any genomic clone should match a southern blot of genomic DNA. 
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The isolated exon-containing DNA fragments were digested, subcloned into pGEM- 
5Zf vector (Promega) and purified by the QlAprep spin columns (Qiagen) method. 
The nucleotide sequence was determined by the dideoxy chain termination method 
with modified T7 DNA polymerase (sequenase Version 2.0 DNA sequencing Kit 
Amersham) and with an automated DNA Sequencer (ABI 373A, Applied 
Biosystems). 
From a screen of = 500,000 independent clones, one positive clone was found. The 
clone was named J I, and was = 30kb in length. Restriction digestion of the genomic 
clone with BamH I released five fragments of approximately 4kb, 3.5kb, 3kb, 1.8kb 
and 900bp. The Genomic fragments were individually subcloned into a pGEM-5Zf 
vector. The DNA was digested with BamH I and separated on a 1% agarose gel. 
Denatured DNA was transferred to nylon membrane (Hybond-N, Amersham) and 
hybridised with random prime labelled cDNA (CRH-Rla). The blots were hybridised 
to the labelled cDNA corresponding to exons MI and exons I-V. Firstly, two BamH I 
fragments 1.8kb and 4.0kb were labelled when a Southern blot was hybridised to the 
radiolabelled CRH-Rla cDNA probe from exons I-V (Figure 5.2). A J1-BamH I 
1.8kb fragment was subcloned and sequenced. Based on the sequence analysis, the 
fragment included exons 5-6 of the human CRH-R1a gene. 
Next, A J1-BamH I 4.0kb fragment was identified when a Southern blot was 
hybridised to the radiolabelled cDNA corresponding to exons I-II (Figure 5.3). This 
probe was generated from 450 bp cDNA by restriction digestion with Pst I and 
corresponded to the first 157 nucleotides of CRH-Rla. 
The Jl-BamH I 4.0kb fragment was digested again with Sph I. After electrophoresis 
and blotting onto Hybond N, Southern blot was hybridised with a cDNA probe from 
exons I-II. The fragment contains a J1-Sph I 1.2kb signal (Figure 5.4). 
A J1-BamH I 1.8kb fragment was subcloned and sequenced. Based on the sequence 
analysis, the fragment included exons V-VI of the human CRH-Rlcc gene. The J1- 
Sphl 1.2 kb fragment was subcloned and sequenced. The nucleic acid sequence of the 
fragment revealed that the J1-Sph I 1.2 kb fragment corresponded to exon II of the 
human CRH-R 1a gene. 
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BamHI BamHI BamHI kb 
40 4.0 
3.0 
2.0 
1.6 
1.0 
Figure 5.2 Southern blot analysis of clone contain CRH-R2a gene 
The genomic clone was digested with BamH I and subcloned into a pGEM-5Zf 
vector. The plasmid DNA was digested with BamH I and separated on agarose 
gel. DNA was and transferred to Hybond-N. Filter was probed with the 
radiolabeled cDNA (CRH-Rl(x). This identified two BamH I fragment with 
sizes of 1.8 and 4.0 kb, respectively. 
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Figure 5.3 Southern blot analysis of the genomic clone fragment with the CRH- 
R1a cDNA probe (157 bp length) 
The genomic clone was digested with Bam HI (lane 2,3 and 4), separated on 
agarose gel, and transferred to Hybond-N. Filter was probed with the 
radiolabeled cDNA corresponding to the first 157 nucleotides of the human 
CRH-R 1 a. Lane 1, plasmid Bam H 14kb fragment is used as a positive control. 
This identified a Bam HI4.0 kb fragment. 
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Apai BamHl BamHl 
12 
kb 
2.0 
1.6 
1.0 
Figure 5.4 Southern blot analysis of the clone fragment containing the 5'end of 
the CRH-R 1 gene 
The J1-BamH I 4.0kb fragment was digested again with Sph I. After 
electrophoresis and blotting onto a membran, Southern blot was hybridised with 
a cDNA probe from exons I-II of the CRH-Rl gene. The fragment contains a 
J1-Sph I 1.2kb signal (Lane 2). The plamid BamH I 1.8 kb fragment was used as 
a positive control (Lane 1). 
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The nucleotide sequence of the coding region was determined on both DNA strands. 
Intron-exon junctions were determined by sequence comparison with CRH-R1 cDNA 
and Homo Sapiens Chromosome 17 (clone HCIT 104N19, GenBank No. A0003662). 
The DNA sequence (clone HCIT 104N19), including the CRH-R1 gene except for 
exon I, was made available recently. After identification with two different cDNA 
probes (fragments 1-450 and 1-157 bp) and sequencing part of the subclones, a 
restriction map of the genomic clone was constructed, as shown in Figure 5.5 A. The 
J 1-BamH 11.8 kb fragment has been shown to contain the exons V-N. The J 1-BamHI 
4.0 kb fragment has been shown to contain the exons II (Figure 5.5 B). The exon I is 
not included in the isolated genomic clone, as already suggested by Southern blotting. 
Partial nucleotide sequences of the introns revealed no deviations from the consensus 
sequences for splice site in the 5' -donor and 3' -acceptor splice site and all intron- 
exon splice junctions followed the GT/AG rule. 
BamHI 
A) 
B) 
exon I 
BamHI BamHI 
Snhl 
BamHI BamHI 
II III IV VVI 
BamHI 
Figure 5.5. The analysis of the genomic organisation of the CRH-R1 
Schematic representation of a BamH I/ Sph I restriction map of the isolated 
genomic clone (A), the deliniated exon-intron structure of the CRH-R1 gene. 
The partial nucleotide sequence confirmed that the clone contained exons II, V 
and VI. The black boxes represent the 3 exons identified. Introns are 
represented by double lines, the arrow represents genomic sequences that have 
not been analysed. 
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The exon I of CRH-Rlgene contains a very GC-rich region (Figure 5.6). In order to 
confirm the clones contain the exon I of CRH-R1 a gene, the J1-clone DNA was 
digested with restriction endonucleases, fractionated on agarose gel, and transferred to 
Hybond N filter membrane for Southern blot analysis. The filter was probed with [y- 
32P]dATP end-labelled oligonucleotide. The labelled oligonucleotide used a CRH-R1 
specific primer (PE3 primer) 5'-CTTGACGAGACGGAGCTGCGG-3' that 
correspond to exon I. No positive hybridisation was found. 
Further analysis was carried out using PCR 25ng of DNA was used in the PCR 
reaction, which was carried out for 20 cycles. The gene specific primers PE5 and PE3 
correspond to -224 to -203 nt and +13 to +33 nt in exon I. The reaction was then 
analysed by electrophoresis on a 1.0% agarose gel. Sequence analysis of the PCR 
products did not correspond to any known DNA sequence. CRH-Rla (exon I) was 
not detectable in this clone. 
Based on the sequence of the CRH-R1 exon I region shown in Figure 5.6, the Sam I 
enzyme can be used to cut this region at two sites and generate one product with 167 
bp between the two cutting points. The cloned genomic DNA was digested with Sam 
L fractionated on agarose gel, and visualised under UV light by ethidium bromide 
staining. The fragment obtained had a different size from that expected at the 
beginning of the experiment. Therefore, the result shows that the clone did not contain 
the exon I of CRH-R1a gene. 
In order to obtain the transcriptional start site for CRH-R1 mRNA, we used the 
5'Rapid amplification of cDNA ends (5'-RACE system Version 2.0 Gibco-BRL) 
technique using total RNA extracted from human myometrium. Briefly, cDNA was 
synthesised with CRF8 5'-GTCCACGGATGCGTTGCACTGC-3' primer and 
Superscript II Reverse Transcriptase. After RNase H treatment, the cDNA was 
purified with the Glass Max DNA isolation spin cartridge (Gibco-BRL). The purified 
cDNA was 5'tailed with polyC and then further amplified with an anchor primer 
provided by the kit and a gene-specific primer PE1. After primer extension and the 
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first round of PCR, the cDNAs obtained were amplified by the second round of PCR 
using a nested primer (PE3) and the kit's PCR anchor primer. The sequence of PE3 
was 5'-CTTGACGAGACGGAGCTGCGG-3' which correspond to a region of exon 
I. The PCR products were cloned in the pGEM-T vector. Using this technique we 
were unable to find any cDNA extending upstream of exon I. 
PE5 Sma 14 PE6 
-226 GGGGAAACGGCGGCCAGACTTCCCCGGGAAGGGGCGACCGAGAGC 
-181 CGGGCCGGGCCGGGCCGGGCCGCGGGGCCGGGAAGCGCCGAGCCG 
-136 GGCATCTCCTCACCAGGCAGCGACCGAGGAGCCCGGCCGCCCACC 
-91 CCGTGCCGCCCGAGCCCGCAGCCGCCCGCCGGTCCCTCTGGGATG 
Sam I4 
46 TCCGTAGGACCCGGGCATTCAGGACGGTAGCCGAGCGAGCCCGAG 
PE3 LExonl PE1 
-1 GATGGGAGGGCACCCGCAGCTCCGTCTCGTCAAGGCCCTTCTCCT 
TTCTGG 
Figure 5.6. DNA sequence of the exon I region of the human CRH-R1 gene 
(L) indicates intron position; (u) indicates Sam I restriction digest site. The 
underlined regions indicate PCR primers (PE5, PE6, PE3, and PE1). ATG 
translation initiation codon in exon I, is denoted as nt +1. Human CRH-R1 
(GenBank/EMBL accession number x72304). 
We also tried to detect the cDNA corresponding to the exon I, using either the primer 
PE5: 5'-GGAAACGGCGGCCAGACTTCC-3' or the primer PE3: 5'- 
CTTGACGAGACGGAGCTGCGG-3' (Figure 5.3), and total RNA extracted from 
human myometrium. We were unable to detect the cDNA corresponding to exon I, 
this may be due to the particular GC rich composition of this RNA segment. 
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Since the 5'-flanking region of the rat CRH-R1 gene was isolated and characterised 
(Tsai-Morris et al., 1996), the present study attempted to use this information to 
identify the human homologue of CRH-R1 promoter region. We used the PCR 
technique to generate probe fragment for hybridisation to human library screening. 
PCR amplification of the 5'-flanking region of the rat CRH-R1 gene was performed 
using genomic DNA from rat brain tissue. The primer pair was based on the 5'- 
flanking region of the rat CRH-R1 sequence (GenBank/EMBL accession number: 
U53486). The PCR reaction was carried out for 35 cycles with an anneal temperature 
of 58°C. Sequence analysis of the PCR product did not correspond to a known DNA 
sequence of the rat CRH-R1 gene. 
5.3 Discussion 
At the time when this study started, no sequence of the promoter region of the human 
CRH-R1 had been reported. The initial attempt to screen the human placental 
genomic cosmid DNA library with a cDNA probe from exons I-V resulted in the 
isolation of only one clone. The clone was named J1, and was 30kb in length. 
Mapping by Southern analysis and sequencing confirmed that the clone contains 
exons II-VII of the CRH-R1. More specifically, the J1 BamH I 1.8 fragment was 
subcloned and sequenced with various primers from both exon V and other up- and 
down-stream regions. Sequencing demonstrated that this fragment contained only 
exons V-VII. The J1-Sph 11.2 kb was also subcloned, sequenced. The results showed 
that it contained exon H. The most upstream region identified in the library screen 
was the J1-BamH I 4.0 fragment that was subcloned and sequenced with 
oligonucleotides to exon I (PE3 primer +13/33 bp and PE6 primer -183/202 bp). 
However, sequencing information obtained using either primer did not suggest that 
exon I resided more upstream of this fragment. Thus intron I of the human CRH-Rla 
is a large intron, and may span over 10 kb. 
In order to isolate the 5'-upstream region of the CRH-R1 gene, we attempted to make 
a new probe with a 5'-end cDNA of the CRH-R1. The first approach was to look for 
the 5'-end cDNA of the CRH-R1 gene, using the 5'Rapid amplification of cDNA 
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ends (5'-RACE system Version 2.0 Gibco-BRL) technique and total RNA extracted 
from human myometrium. We failed to find any cDNA extending upstream of exon I. 
The results suggested that there was either a blocking of the primer extension by the 
GC rich region located at the 5'end of exon I, or the GC rich sequences that possess 
strong secondary structure that resists denaturation and prevents primer annealing. 
We also tried to detect the cDNA corresponding to the exon I of the human CRH-R1. 
RT-PCR was amplified using a pair of gene specific primers for the exon I, but we 
were unable to detect the cDNA corresponding to the exon I, which may be because 
of the particularly GC rich composition of this RNA segment. This could also be due 
to the GC rich region, located at the exon 1, which could have blocked the primer 
extension step. 
It has been reported that the 5'-flanking region of the rat CRH-R1 gene was isolated 
and characterised (Tsai-Morris et al., 1996). This gave me some knowledge to do with 
in designing the PCR primer to generate a probe. PCR was performed using rat brain 
DNA as template and amplified to the promoter region of the rat CRH-R1 gene. But 
the promoter was not found in which may be due to the high GC content of this 
region. The PCR products were still failed to yield any 5'-flanking region of the rat 
CRH-R 1 DNA. 
Although the promoter of the human CRH-R1 was not found from the above work, 
some findings may be interesting. The intron-exon junctions conform entirely to the 
consensus spice site sequence of 5' donor (GT) and 3' acceptor (AG) (Mount, 1982). 
These are in consistence with the view that the sequence region (exons II-VII of 
CRH-R1) is the obligatorily conserved nucleotides, which include GT in the 5'-donor 
and AG in the 3'-acceptor region. Another finding is that the exons II-VII of CRH-R1 
sequences matched the previously published human CRH-R1 cDNA sequences 
(GenBank accession no. AF039510 to AF039516). 
/ 
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Chapter 6 Screening of a human genomic cosmid library (CRH-R2) 
6.1 Introduction 
The gene coding for human CRH-R2a consists of at least 12 exons and spans 
approximately 30 kilobases, with the protein-coding sequence interrupted by 11 
introns (Liaw et al., 1996). The gene has been mapped to the chromosome 7g14-15 
(Andrews et al., 1998). The genomic structure of a significant portion of the human 
CRH-R2 gene has been described, but this did not extend the 5'of the CRH-R2a 
alternative exon. Neither the 5'-flanking region nor the transcriptional initiation site 
has been defined. Without upstream sequence data, the precise mechanism of the 
receptor's regulation remains unknown. To understand the molecular mechanisms that 
direct the expression of the gene encoding the CRH-R2, a genomic clone of the CRH- 
R2 was isolated and analysed. 
6.2 Screening and its results analysis 
6.2.1 Isolation of genomic DNA clone containing 5'-flanking region CRH-R2a 
gene 
Screening of = 500,000 clones of a human genomic cosmid library with a 32P-labeled 
DNA containing nucleotides 1-197 bp of CRH-R2a cDNA probe (Figure 6.1) 
resulted in the isolation of one positive clone. Positive clones from the second or third 
round screens were picked, and minipreped using QlAprep spin plasmid kit (Qiagen). 
The clone was named Jp 1. 
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Human CRH2 receptor in situ probe 
410 bp insert 
Scal Notl 
Xhol 
Sad 
T3 
T7 
pBluescript (SK+) 
Figur 6.1 Human CRH-R2 probe inserted into the pBluescript (SK+) cloning 
vector. The plasmids was digested with Xho I and Sca L and purified from a 
1.0% agarose gel using "QIAquick Gel Extraction kit" (Qiagen). 
Phage DNA from this positive clone was prepared and digested with Not I restriction 
enzyme to release the insert. Restriction digestion of the genomic clone with Sst I 
released seven fragments of approximately 5kb, 4kb, 3kb, 1.8kb, 1.2kb, 1.0kb and 
650bp. The DNA from this positive clone was digested with Sph I which released 
nine fragments of approximately 5kb, 3.5kb, 3.2kb, 2.5kb, 1.8kb, 1.2kb, 700bp, 
600bp, and 450bp. 
The genomic clone DNA was digested, fractionated on agarose gel and transferred to 
Hybond-N filter membrane for Southern blot analysis. The filter was probed with 32P- 
labeled cDNA corresponding to the region of human CRH-R2a cDNA as indicated in 
exon I- II. This was hybridised to two restriction fragments, a JP1-Sst 1 4.0 kb 
116 
fragment and a JP1-Sph I 3.5 kb fragment (Figure 6.2 A). In addition, the JP1-Sst 14.0 
kb fragment was digested again with Nco I and Kpn I and probed with the 
radiolabelled cDNA. This identified 2 positive fragments a JP1-Kpn I 1.7 kb and a 
JPI-Nco I 2.5 kb. (Figure 6.2 B) These fragments were subcloned and sequenced. The 
nucleic acid sequence of the fragments revealed that, both Jp1-Kpn 11.7 kb and Nco I 
2.5 kb, contained exon I (103 bp), intron I (137 bp) and exon II (126 bp). Comparing 
the genomic DNA with the cDNA sequence, the location of intron I was identified. 
6.2.2 Isolation of genomic DNA clone containing 5'-flanking region CRH-R2y 
gene 
The CRH-R2 has three spliced variants, CRH-R2a, CRH-R20, CRH-R2'y. Each of the 
products has different 5'-exon splicing and distinct tissue distributions. The three 
splice variants appear to diverge at the corresponding position of human CRH-R2 
where the first intron occurs. The three first exons are alternatively spliced on to the 
first common exon (CRH-R2a exon II), followed by a second common exon. Based 
on the results of the genomic screen described above, the CRH-R2a exon lies 
downstream of the CRH-R2y and CRH-R2(3 exons. In order to confirm this the JP1- 
clone DNA was digested with restriction endonucleases, fractionated on agarose gel, 
and transferred to Hybond N filter membrane for Southern blot analysis. The filter 
was probed with [y-32P]dATP end-labelled oligonucleotide designed from the CRH- 
R2y exon I (5'-CTGTGCTCAAGCAATCTGCCTAC-3'). This probe hybridised to a 
unique JP-1 Sph I 3.2 kb fragment (Fig 6.3) which was subcloned and sequenced. 
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Figure 6.2 (A) Southern blot analysis of clone containing 5'-Flanking region 
CRH-R2a 
Each lane contains the clone DNA which was digested each with Sph I, Sst I, 
Xho I, BamH I and Xba I, respectively. After electrophoresis and blotting onto 
Hybond N, different strips of the same run were hybridised with an exons I-II 
probe of the CRH-R2a gene. This hybridised to two restrictions fragments a 
Sph I 3.5 kb fragment and a Sst I 4.0 kb fragment. 
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Figure 6.2 (B) Southern blot analysis of the clone containing 5'-Flanking region 
CRH-R2a 
The Sst I 4.0 kb fragment was digested again with Nco I and Kpn I., fractionated 
on agarose gel and transferred to Hybond-N. Filter was probed with the 
radiolabeled cDNA from corresponding to exon I- H of the human CRH-R2a. 
This identified 2 positive fragments a JP1-Kpn 1 1.7 kb and a JPI-Nco I 2.5 kb. 
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Figure 6.3 Southern blot analysis of the clone containing 5'-Flanking region of 
CRH-R2y 
The isolated clone DNA was digested with Sph I, Sst I, Xho I, BamH I and Xba 
I, respectively. After electrophoresis and blotting onto a nylon membrane 
(Hybond N), different strips of the same run were hybridised with an exon-I 
probe of the CRH-R2y gene. A unique Sph 13.2 kb fragment signal was found. 
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The nucleotide sequence of the genomic DNA fragment showed that it contained the 
CRH-R2y exon I (227 bp) and the CRH-R2ß intron Ib (205 bp). These results indicate 
that the CRH-R2f exon lies upstream of the CRH-R2y and CRH-R2a. The genomic 
order of the alternative exons is CRH-R 20-2y-2a. 
6.2.3 Restriction map and Southern blot analysis of the clone containing 5'- 
flanking region CRH-R20 
Our results indicate that the CRH-R2(3 exon lies upstream of the CRH-R2y and CRH- 
R2(x, and also, the CRH-R2y exon lies between CRH-R213 and CRH-R2a. In order to 
confirm that clone (JP1) contains 5'-flanking region CRH-R20, detailed restriction 
maps and Southern blot hybridisation were performed. 
The clone, entitled JP I, was = 40 kb in length. Phage DNA from this positive clone 
was prepared and digested with Not I restriction enzyme to release the insert. The 
genomic clone was, by single and double, digested and then released several 
fragments. These fragments were separated by gel electrophoresis (Figure 6.4). DNA 
digested with Not I released two fragments of 23kb and 8kb. The latter fragment is a 
pWE15 vector (8kb in length size). DNA was digested with Cla I and released one 
fragment. Cla I cut one site of the end of the pWE15 vector. The two fragments (as 
same size) obtained by digestion with Nde L. The enzyme did not cut the pWE15 
vector, but it cut one site of the cDNA of CRH-R2y. DNA double digested with Cla I 
and Nde I released three fragments of approximate 8kb, 19kb, and 21kb. The double 
digestion with Not I and Nde I obtained the three fragments. The double digested with 
Cla I, Nde I or Not I, Nde I had it of size fragments. When Cla I cut one end of the 
pWE15 vector, Nde I cut another end of the vector, it released one fragment of 
approximate 8-8.5kb (possible only vector). If this is the case, the position of the 
CRH-R2yy is likely at one end of the insert. This clone did not include the exon I of the 
CRH-R213. The nucleotide sequence of the genomic DNA fragment revealed that the 
clone did not include CRH-R2ß exon I. 
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Figure 6.4 Restriction map analysis of the clone containing 5'-flanking region 
CRH-R2ß 
Lane 7 is 1 Kb DNA ladders. Lane 6 Hind III fragments of bacteriophage a. were 
included as size markers. The clone was digested with single and double 
restriction enzymes give distributions of digestion products. Lane 5, the comid 
clone digested with Not I released two fragments of 23 kb (over) and 8 kb, 
respectively in sizes. Lane 4 the cosmid clone was digested with Cla I released 
one fragment. Lane 3 the two fragments (with same size) were obtained by 
digestion with Nde I. Lane 2 the cosmid clone double digested with Cla I and 
Nde I released three fragments of 8kb, 19kb, and 21 kb, respectively. Lane 1 the 
cosmid clone double digested with Not I and Nde I released three fragments of 
8kb, 19kb, and 21 kb, respectively. 
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We also examined whether the clone contained the exon I of the CRH-R20 gene, 
using the synthetic oligonucleotide Si (5'-TCCAGTCCCTAACCCCAGCC-3'), 
corresponding to a sequence located in exon I. The [y-32P]dATP end-labelled 
oligonucleotide failed to hybridise to the Southern blot confirming that the clone did 
not contain exon I of the CRH-R20. PCR was used to analyse the clone for the 
presence and size of insert, but the result shows that the clone did not contain the exon 
I of the CRH-R20. 
6.3 Isolation of genomic DNA clone containing 5'-flanking region CRH-R2ß gene 
6.3.1 Library screening with a CRH-R2(3 probe 
In order to isolate the 5'-flanking region of the CRH-R2ß gene, we used 5'RACE. 
The 5'RACE kit from (Clontech) was used, following the supplier's 
recommendations. The gene specific primer 1A (corresponding to +182 to +156 nt in 
the CRH-R2 f exon-I) and nested primer 2A (corresponding to +51 to +28 in the 
CRH-R2(3 exon-I) were used for the first and second amplifications, respectively, 
with plus anchor primer API supplied by Clontech. The resultant products were 
cloned into the pGEM-T cloning vector and the clones were sequenced. The sequence 
resulted in one DNA fragment of apparently 255 bp in the human hippocampus 
sample. The 5'RACE derived from cDNA clones included the previously reported 30 
nt 5'-UTR sequence upstream of the CRH-R2ß open reading frame as well as an 
additional 171 nt of 5'-UTR sequence. 
This clone was selected for use as a probe in the screening of a genomic cosmid DNA 
library. An amplified human placental genomic cosmid DNA library (Clontch) was 
employed to isolate clones containing the 5'-flanking of the CRH-R20 gene. Plaque 
lift of 1X106 recombinants were hybridised with a 255-base pair 32P-labelled 
(Oligolabelling kit, Pharmacia Biotech) fragment derived from the 5'-end (+54 to - 
201 bp, ATG translation initiation codon in exon I, which is denoted as nt +1) of a 
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human CRH-R2ß clone. 1,000,000-phage clones were screened but no positive clones 
were isolated. 
6.3.2 Genomic walking 
Since the introduction of the polymerase chain reaction, several PCR-based cloning 
methods to isolate genomic DNA have been devised. Several PCR-based methods 
have been used for genomic walking. These include inverse PCR (Ochman et al., 
1988), ligation-mediated PCR (Mueller and Wold, 1991), Biotin-RAGE (Bloomquist 
et al., 1992), one-armed PCR (Macrae and Brenner, 1994) and rapid amplification of 
genomic ends (RAGE) PCR (Buckler et al., 1991). The last method has been used for 
the genomic walking in the project. 
A CRH-R2ß specific primer was designed, based on the published CRH-R2(3 cDNA 
(Valdenaire et al., 1997) and 5'RACE-derived cDNA sequence. Human genomic 
DNA (from peripheral blood leukocytes) was first incubated with a restriction enzyme 
(Nco I) that recognises a site within the 5' end of a gene, followed by denaturation 
and polyadenylation of its free 3'ends with terminal transferase. The modified DNA 
was then used as a template for PCR using a gene-specific primer complementary to a 
sequence in the 3' end of its cDNA (located 51-28 bp downstream of the ATG 
translation initiation site) and anchored deoxyoligothymidine primer. A second round 
of PCR was then performed with a second, nested gene-specific primer (located 121- 
146 bp upstream of the ATG translation initiation site) and the anchor sequence 
primer (see Chapter 2.2 18.2). 
The final PCR products were size-selected by gel electrophoresis, (Figure 6.5) and 
subcloned into the pGEM-T vector (Promega). Several clones were selected and 
sequenced in both directions. The insert DNA was cycle-sequenced using an ABI 
373A (Applied Biosystems) automated fluorescent sequencer. 
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Figure 6.5 The 5'-flanking region of the CRH-R2 gene by the PCR based 
genomic walking method. 
A nested PCR was used to amplify the 5'-flanking region of the CRH-R2 gene. 
The DNA was digested with BamH I (Lane 2) or Nco I (Lane 3 and 4 are 
samples with different concentrations). Lane 4 shows the PCR amplification of a 
734 bp fragment, containing the 5'-flanking region of the CRH-R2 gene. Lane 1 
and 5 are DNA size markers. 
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Figure 6.6 PCR amplification further upstream of the 5'-flanking region of the 
CRH-R2 gene. 
Lane 1 shows the PCR amplification of a 1440 bp fragment, which contained 
1393 bp upstream of the ATG translation initiation site and an 51 bp downstream 
sequence. Lane 2 are DNA size markers. 
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6.3.3 Database sequence analysis 
The sequence data was analysed using Blast Nucleic Acid Database Searches from the 
National Centre Biotechnology Information (NCBI). Blast server search of existing 
sequences in GenBank revealed the existence of a sequence CRH-R20 cDNA which 
has been published (GenBank accession No. Y10151). The result (DNA digested with 
Nco I restriction enzyme) revealed that the fragment contained 835 bases upstream of 
the ATG translation initiation site. Comparison of this fragment sequence with Gene 
Bank data base revealed that the sequence showed 100% homology with reported 
sequence of the Homo Sapiens PAC clone DJ1143H19 from 7p14-p15 (GenBank 
accession No. A0004976). 
In order to obtain the region further upstream, we designed a new primer based on the 
sequences of the above results. The PCR product was purified from a 1.0% agarose 
gel (Figure 6.7), then subcloned and sequenced. The nucleotide sequence of the 
fragment revealed that a 1393 bp upstream sequence of the ATG translation initiation 
site and 51 bp downstream sequence. Alignment of the DNA fragment sequence with 
the 5'RACE derived cDNA sequence of the CRH-R2(3 (see Chapter 8) revealed that 
the DNA fragment included the 226 nt 5'-UTR sequence upstream of the CRH-R20 
open reading frame (Figure 6.8). 
-1393 AGACCTGTGAGATTTCACAGGAGAGGGAGGTGGGACCTGGAAC 
Bgl I 
-1350AGCCAGGAAGGCTGCCTGGAGGAAGGGGCTGAGGGTGGGGAGGAAGCACT 
-13000AAGGACAGAAAAGTGTCCCATGTCTTAGATAGGGAGACCGGAAGGAGCA 
-1250 CAGAGTGTCTGAGTTACTTAAATCGGGACTGAGTTTTCCAAGGTCTCTCT 
-1200 CCACCATGCCTGCATCTCCAGGAGAAAGTTTGGTGCCCCACTAATCACAT 
-1150 TCCTCACATGCTTTCCCCTCAGATCCTAACAACAAGCAAGGTGCAACTGT 
Hind III Dra I 
-1100 GGCTTAAGCTI'ITAAACCCCCTGCACCAGGCCCACCTGTCAGGAACAGCT 
-105000TAAGGAGGCTTCTGAGGCTCTGGAAGAACAGACCTCACCTCATGAGCC 
-1000CTGACCCAGCCCCAGGTTGAACCTGTCCCCGCCAAGAACAGCACTGCTCA 
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EcoR V BamH I 
-950 GCCACCTGATATCAGGATCCCTAACCATTTCCTGAAATGGAACCTGGGCC 
-900 CCATACAGACAGACACCTGGGCCCCATCCCAAGCTACTTCATTGGAATCT 
Nco I 
-850 CTGGGTGAGCCCTGCCATGGCTGTATTTGCTGTCGGTTGGG'ITTT'TTTTT 
-800 1111111 ITGAAAGCATTTTA=GATAGAATTTCAAACGTACAGAAAA 
-750 GTTGGAAGAATGATCCAAAGCATATCCATATACCCCTTTTCCAGATTTAC 
-700 CAACAATTTACATTTTGCCCCATCTGCTCTCTTGTTCTATCTATGTATCT 
-650 ATCTGAGTTTATTTCTGAACCATTTGAAAGTATGTTGGAAACATGGTGCC 
-600 CCTTTAATCCTAAATGTGTATTTTCCAAGAATGAGAACATTCTCTTACCT 
Sca I 
-550 ACCCACAGTACAGTATCAGAATCAGCAGATGTAGCATTGATACAGTACTA 
-500 TCTAACCCAGCATCCACACTCCCATCTCAGTCATCCCAGTAGGCATTAGC 
-450ACCTGTTAAAAGCTCCTCAGATAGGTGTTAGGCAGTGCTGGTTCAGCTGA 
-400GACCCAGGGCAGCCCAACCCTGTGCTGAAGCAGGGACCACAGCCTAGGCC 
XmaI 
-350 CCTCCTGCCTGTCTCAATTCCTCTCTCCCACCTGGGGAGCTACAGCCCCG 
Pst I 
-300 GGCAATGCTGGCAGCCGATAGAAGGCATTAACCCCTTCTCTGCAGGCTGG 
-250 ATGGAGAGCATAGCCCCTTGGCTGGCTGGGTAGCAGCAGCTGTCTGGGAC 
11 2ß 
-200 CAGCTATAAATAACCTGGAGGCTGTGGGCTGTGGGGCGGGGTCACCACTG 
-150 CCCTGTGGAAGAAGTGGGTGGAGAATACCTCCTCATGCCCAAGGCCTTAC 
2nd: 2A Bal I 
-100 CTTGGCCTCCCCTCCAGGGCCGGGTGGGGTGGGGCTGGCCAGGGTGTGAC 
-50 CACCGTGCTGGGCAGCAGGCTCCAGTCCCTAACCCCCAGCCACTACTGGC 
VT 
+1 ATGAGGGGTCCCTCAGGGCCCCCAGGCCTCCTCTACGTCCCACACCTCCTC 
1st: 1A 
Figure 6.7 Nucleotide sequence of the 1.3 kb 5'-flanking region of the CRH-R2 
gene. 
The translation start site is indicated by the mark defined as + 1. Nucleotide 
numbers are marked on the left side. The primers used for PCR (1 A and 2A) are 
underlined. (T) marks the location of the known cDNA previously reported by 
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Valdenaire et al. (11) represents the transcription start site identified by 5'RACE 
with CRH-R2(3 primers., 
6.4 Discussion 
From the description of above sections, we can see that screening of a human 
genomic cosmid library has been carried out and resulted in the isolation of one 
positive clone Jp 1. Mapping by Southern hybridisation and sequencing analysis 
confirmed that the clone contains 5'-flanking CRH-R2y and CRH-2a. More 
specifically, the Jpl-Sst I 4.0 kb fragment was subclond and sequenced with various 
primers from both exon V and other up- and downstream regions. Sequencing 
analysis demonstrated that this fragment contained CRH-R2a exon I (103 bp), CRH- 
R2a intron I (137 bp) and exon II (126 bp). Comparing the genomic DNA with 
cDNA sequence of the CRH-R2, the location of intron Ia was identified. The JP-1 
Sph I 3.2 kb fragment was subcloned and sequenced. The nucleotide sequence of the 
genomic DNA fragment revealed that the clone included CRH-R2y exon I (227 bp), 
CRH-R2y intron I (2831 bp) and CRH-R20 intron ]b (205 bp). Unfortunately, 
screening of a human genomic library with a probe specific for the 5'-region of the 
CRH-R2ß was unsuccessful. 
We have cloned the 5'-flanking region of the CRH-R2(3 gene by the PCR based 
genomic walking method. A CRH-R2ß specific primer was designed based on the 
published CRH-R2ß cDNA (Valdenaire et al., 1997) and the 5'RACE-derived cDNA 
sequence which were then amplified, cloned and sequenced. The nucleic acid 
sequence of the fragment revealed that 1393 nt sequence upstream of the CRH-R2(3 
open reading frame and an 51 nt downstream sequence. The 1393 nt fragment 
included the previously reported 30 nt 5'-UTR sequence upstream of the CRH-R2(3 
open reading frame. Alignment of the DNA fragment sequence with the 5'RACE 
derived cDNA sequence of the CRH-R2ß (see Chapter 8) revealed that the DNA 
fragment included the 226 nt 5'-UTR sequence upstream of the CRH-R2(3 open 
reading frame. Comparison of this fragment sequence with GenBank data base 
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revealed that the fragment corresponded to the Homo Sapiens PAC clone DJ1143H19 
from 7p14-p15 (GenBank No: A0004976). This PAC clone includes the 5' exon of 
the CRH-R2 type. 
The 5'-untranslated region extends 226 bp (5'RACE) upstream of the initiator codon 
and is GC-rich (61%). Some members of the secretin and glucagon receptor family 
have multiple untranslated (non-coding region) exons in the 5'-untranslated region. 
The parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor gene has 
three untranslated exons in the 5'-untranslated region (Manen et al., 1998). The 
pituitary adenylate cyclase-activating polypeptide (PACAP) receptor gene has four 
untranslated exons in the 5'-untranslated region (Chatterjee et al., 1997). Alternative 
splicing of 5'-untranslated regions of genes for other G protein receptors, human Al 
adenosine, PTH/PTHrP, and PACAP receptors, seems to be related to the tissue- 
specific expression of their transcripts. However, this does not appear to be the case 
for the CRH-R2.5'RACE (with CRH-R2 primers) analysis which identified four 
transcriptional start sites located at 226,201,97, and 12 bp upstream of the translation 
start site of the CRH-R2ß. This is a hypothesis or prediction only and further 
experiments may be required to provide more solid evidence. On the other hand, it is 
probable that there is a single start site at 226 bp. It is also more likely that the 12,97, 
and 201 bp are incomplete transcripts (see Charter 8). The results suggest that there 
may be a single promoter regulating the expression of all (CRH-R2(x, 20, and 2y) 
subtypes. The promoter of CRH-R2 lies upstream of the 5'-end of the CRH-R2(3. 
Multiple promoter regions have been described for PTH/PTHrP and glucagon 
receptor genes. The PTHIPTHrP receptor gene has been shown to be controlled by 
two promoters, one of which is not GC-rich and is only active in kidney (McCuaig et 
al., 1995). We cannot rule out the existence of multiple promoters in the CRH-R2 
gene. 
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Chapter 7 Analysis of the human 5'end CRH-R2 genomic DNA 
structure 
7.1 Introduction 
The CRH-R2 gene has been mapped on to the chromosome 7g14-15 (Andrews et al., 
1998). The gene coding for CRH-R2a consists of at least 12 exons and spans 
approximately 30 kilobares, with the protein-coding sequence interrupted by 11 
introns. The exons vary in length from 42-154 bp and are separated by introns that 
vary in size from 130 bp to 14.5 kb. The N-terminal extracellular domain of the 
receptor is encoded by the first three exons and a part of the fourth exon. 
Transmembrane domains I, II, III, and VI are entirely within exons 4,5,6, and 10, 
respectively, while transmembrane domains IV, V, and VII are each interrupted by a 
single intron. When appropriately spliced, it should yield a message with 1233 bp of 
open reading frame, with no difference from the available corresponding cDNA 
sequence. All exon/intron junctions are confirmed with the consensus sequences, with 
exons flanked by AG and GT at the 5' and 3'end, respectively (Liaw et al., 1996). 
Molecular cloning techniques have identified three alternatively spliced forms of the 
CRH-R2 differing in their N-terminal domains, identified as CRH-R2ct, CRH-R2(3 
and CRH-R2y. The genomic structure of the human CRH-R2a gene was described, 
but this did not extend 5'end of the CRH-R2 alternative exon. Our results described in 
Chapter 8 suggest that the CRH-R2 genomic order of the alternative exons is 2ß-2y- 
2a. The mature receptor subtype mRNA appears to be generated via 5' exon 
differential splicing. The detailed analysis of the 5' end of the CRH-R2 genomic DNA 
structure is given in this Chapter. 
7.2 Sequence analysis of the genomic region between the CRH-R2y and 
CRH"R2a exons 
Screening of a human genomic cosmid library with a 32P-labeled cDNA containing 
nucleotides 1-197 of CRH-R2a cDNA probe resulted in the isolation of one positive 
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clone, Jp 1. Mapping by Southern analysis and sequencing confirmed that the clones 
contained 5'flanking CRH-R2y and CRH-2a. (As discussed as Chapter 6). 
In order to analyse the 5'end CRH-R2 of genomic region with sequences, two of the 
four following sequencing strategies were chosen: 
(1) Primer walking. 
If the segment of DNA to be sequenced is small, a primer that binds to a known 
sequence in the flanking DNA can be used to initiate a sequence run across the region 
of interest. A second sequencing run over the same region from the opposite direction 
is highly recommended, since factors that affect the sequence quality on one strand 
are often not present in the opposite strand. If the length of the DNA to be sequenced 
exceeds the length of a single sequencing run, sequence data from the far end of the 
first run can be used to prepare the primer of the far end of a second run into the 
region of interest. This process, called primer walking, can be repeated many times to 
sequence extensive tracts of DNA. The major advantages of primer walking are that 
no subcloning is required, and the location and direction of each sequencing run are 
known. In order to sequence the genomic region between the CRH-R2a and CRH- 
R2y exons, this method was employed. 
(2) Nested deletion. 
Nested deletion strategies work best for DNA segments in the 5-10 kb range and 
require some prior knowledge of the restriction sites within the target DNA. Nested 
deletion with exonuclease III requires a unique blunt-end or 5'overhang restriction 
site adjacent'to the region to be deleted, and a unique 3'overhang site distal to the 
deleted region to protect the vector DNA. When these sites are exposed after 
cleavage, exonuclease III will enter the DNA at the 5'overhang site and begin to 
digest or strand in the 3'-->5' direction. The enzyme does not recognise the 
3'overhang and therefore cannot initiate digestion on the opposite strand. At timed 
intervals, aliquots of the reaction mix are removed, the DNA blunt-ended, and ligated 
to recircularize the molecules. To sequence the genomic region between the CRH- 
R2a and CRH-R2'y exons, we used this method (Erase-a Base System Kit, Promega), 
but we were unsuccessful. 
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(3) Shotgun sequencing. 
The target DNA is fragmented by enzymatic digestion or physical shearing to 
fragment sizes in the range of 0.5-5 kb. Subtractions with a narrower size range (e. g. 
0.8-1.5 kb) are subcloned into either a plasmid or M13 vector. The subclones can then 
be sequenced from standard primer binding sites in the flanking vector DNA. Shotgun 
sequencing requires no prior knowledge of the insert sequence, and puts no 
limitations on the size of the starting DNA to be sequenced. Recently, projects 
encompassing entire bacterial genomes have been completed using a whole genome 
shotgun sequencing approach (Fleischmann et al., 1995). 
(4) Transposon-based strategies. 
An alternative approach that avoids subcloning uses mobile segments of DNA to 
introduce priming sites into a large segment of DNA (Kasai et al., 1992). A clone 
containing the target DNA is grown in a bacterial host strain carrying the appropriate 
element and a gene encoding an enzyme (transposase) that catalyses transposition of 
the element into the target DNA. In addition to sequences required for transposition, 
the transposable element carries an antibiotic resistance gene or suppressor tRNA 
gene that can be used as a selectable marker. Clones containing transposable elements 
are selected by transforming plasmid DNA isolated from the transposase-containing 
strain into a non-transposase-containing strain, with co-selection for markers carried 
by the plasmid vector and the inserted transposable element. An ordered array of 
insertions can be obtained by using PCR or restriction sites within the element to 
identify insertions at regular intervals in the target DNA. Priming sites at the ends of 
each element are then used for sequencing runs extending away from the element into 
the target DNA. 
The genomic clone JP 1 was digested with Sst I and Sph I, fractionated on I% agarose 
gel and transferred to Hybond-N filter membrane for Southern blot analysis. The filter 
was probed with a 32P-labeled cDNA fragment (197 bp) corresponding to the region 
of human CRH-R2a cDNA as indicated in exon I-II. A JP1-SstI 4.0 kb fragment and 
a JP1-Sph I 3.5 kb fragment were observed. In addition, the JP1-Sst I 4.0 kb fragment 
was digested again with Nco I and Kpn I. A JP1-Kpn 11.7 kb and Nco I 2.5 kb were 
also observed when a Southern blot of genomic DNA was hybridised with the cDNA 
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(197 bp) probe from exons I-II. The fragments were subcloned and sequenced. 
Isolated clones were sequenced using internal primers (Primer walking method) for 
the gene. Nucleotide sequences were determined by the dideoxy chain termination 
method with Sequenase version 2.0 77 DNA polymerase kit (Amersham) and with an 
automated DNA Sequencer. The nucleic acid sequence of the fragment revealed that, 
both JP1-Kpn 11.7 kb and Nco I 2.5 kb, contained CRH-R2a exon I of 103 bp, CRH- 
R2a intron I of 137 bp and exon II of 126 bp. The location of CRH-R2a intron I was 
identified by comparing the genomic DNA with cDNA sequence (Liaw et al., 1996). 
In order to sequence the genomic region between the CRH-R2oc and CRH-R2y exons, 
primer walking was employed. The JP1-Nco I 2.5 kb fragment contained CRH-R2y 
intron I of 608 bp length (ATG translation initiation codon in exon I, which is denoted 
as nt +1). The JP 1-Kpn I 1.7 kb fragment contained CRH-R2y intron I of 1333 bp 
length (ATG translation initiation codon in exon I, which is denoted as nt +1), as 
shown in Figure 7.1. 
In order to extend the upstream region of the CRH-R2a gene, we sequenced the JPI- 
Sst I 4.0 kb fragment. The nucleic acid sequence of the fragment revealed that, Jpl-Sst 
I 4.0 kb contained CRH-R2cx exon I of 103 bp, CRH-R2a intron I of 137 bp, the first 
common exon II of 126 bp and the CRH-R2y intron I of 2281 bp length (ATG 
translation initiation codon in exon I, which is denoted as nt +1). 
To confirm that clone JP I included the exon I of the CRH-R2y gene, the synthetic 
oligonucleotide (S 1), 5'-CTGTGCTCAAGCAATCTGCCTAC-3' was used that 
corresponds to a sequence in exon I. The Southern blot was hybridised with a [y- 
32P]dATP end-labeled oligonucleotide and a unique JP-1 Sph I 3.2 kb fragment signal 
was found. This fragment was subcloned and sequenced. The nucleic acid sequence of 
the fragment revealed that, Jpl-Sph I 3.2 kb contained CRH-R2y exon I of 227 bp, 
CRH-R20 intron Ib of 205 bp, and CRH-R2y intron I of 2831 bp length (Figure 7.1). 
The distance between the CRH-R2y exon I and the CRH-R2a exon I is 4068 bp. The 
genomic DNA sequence corresponded exactly to the cDNA of CRH-R2a sequence. 
I Sph I 
ATCTATGATCAATTCAATTGTATGCCCCTGAAAAAGGCAACGCATGCAAAATCACAGAGC 
AATTATGACTTCAGGCAGGGTTTAAATAGATTATTTCTA=ATTCATCACAGAGGCAGC 
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TACATATATTTGAAAAATATTAGGGCATATATTATGAGGCATATTAMATCCTATCCATA 
GATGATATAAAAATCCAAATGGACTATTTATTTATCI'IZTATTATTTITTGTAGGCTGGTC 
TTGAATTCCTGTGCTCAAGCAATCTGCCTACCTTGGCTTCCCCAAGTGCTGAGATTA 
TGGGTGTGAGCCACTGCACCTGGCCAAGAATCCGAATGGATTCAAAGATACCTTGAA 
ATAATTCCTCAATGCAACACACACACATATGCCAGGGTTGGTCAAATGGGAAGAGAG 
CCTTGGCCTGAAGACAGGGACCTGGGCTTTCCTCAGCTCTTCTGCCAAGGTATCTGT 
CCTTTCTTAGTGACTCACTGGGCTGAAGTCTAGAGCATTCCAATGGGTGCTGGGGATGGG 
TTAGTGAACCAGGACCAGCCCTGCCCTTGGGGAGGCATGGGCTGGTAGATGAGACAATGA 
ATAAAAAGCAACCTGGATGTGACATAGGCCAGCACCCAGCAGATGGGGTCACCAAGGAG 
CTGCATGTCTGAAGGATGAGTGTGGAGCTGTAAGGCCATTTCCAGTGCAGAAATACAAAC 
AAGGAACAGAGATAGCGAATGGTTTCTGGTAGTGA CA CATTGTTCTGGAGGGCCTTTCAAA 
TGAAGCAGGAGGGTGAGGATGGGGGACGATGATCATGAAGAACCTTCTTTGCAATACCA 
AAGATGGTTCCCAGGAATGACATGTTGTTCTGGAGGGGCCTTTCAAATGGAGCAGAAGGG 
TGAGGATGAGGGATAGATGATTACGAAGGACCTTCTTTGCAATACCAAAGAGGTGGTCTC 
CATCTCAAGGGCAATGGGTTGGCGGCACTCCTATGAGGAAGAGTGACAGGATCGTAAT 
TATAAAACATCG=ATCTGCCATGAGGAGACAGGGAGCCCATTTGGGCTGCTGCAGAG 
ATGAGGATGGCCTGGGAGAAGTAAGGGAGGGAAACCTCTITTGCTTGTCTGGGAATCCTA 
TTGTCCATCTGTAAAACAAGAATGTGGGATTGGATGTCACTGAGAGTCCTTTCTGTCCCCA 
CAGCTTAGTCCCATGGTTTGACATGAAGACACCAGGCCAATTCCTCTGTCCTGCAGTGGA 
GTAGGATAGGGTGAGGAGGGGGTGCCTGGCCTGGGACCCCTGTCTCCAGTGCTACAGGGC 
AAAAGTGCAGCACCTTCAGGCCCCTCTGGAACCTCTGTGCCCTCAGCAACCCCGTCGTAA 
TTCCCAGGAAACACCACGACTA7TCCAGCTGTGCCTGAATAGACTCCCTCTCTATGTAGTCT 
AACCAAGGACAGTCCCTTAGAGAAGCAAAGATGCATCCTGTCCCTTTAAATCCTG =C 
CAGCTGACATTTGAGTGGTAGGGGATGAATTAGAGAGAGAATGTGTGTGCATGGTGAAG 
ATGCATAACTGTGGCTCTGTGTGTGATTCTGTTGTGCCTACATGCCTGTTTGATGCCATGT 
ATTAGGCTTTGCAAGTGTGTCTGAGCTGGCCTGGAACTGTCCACTGCTGCTGCAGCTGAC 
ATCAGAGGTGGGCCATGGGATGGGATGCAGGGCACCAGAGGCACCTGCCTTACTCTGCTG 
CTCATGGTACACAGGGGTCTTCCAAAGTACCTGTCACACTTCCCTGAACCTATITGCCA 
ACCTGTCCCCAACAGCTTGGGGACACACAAACTGTTCCAAATACTTATCCCCTAATTCCTG 
GCCTCCAGCTGGGATGGGGCTGGCCTGCAGCGCTGGGAACCCATCACTATCCCAAAGCCT 
CTAATCTACCTCTGCITCTTTAGTTAGCAAAAATGCCCCTGTCTTTGMGTTTGTACTTGGA 
TTTAGTAAAATTGAGGGAA=GGGGCTCTTCCCAATTTCTTCCTCATTTGCCTGTTTGC 
AGACACTAAAGTGAGCTGTAAAATCAATTTGTTCCCAAACTGCTACCTTITCTAGTTTTCC 
CTCTGTCACATCTCGAATGACAACTGTGCCTATAATAATAAGATCCATGAAGAAATGGCC 
CCACATCCAGGGGACCTCGGGTCTGTGGGTCTGTGGGTATGTGCTCAGACCCCAACTGCT 
CATTCAGGATGCAGAACAGCCTTTGACTCTGCCACTGAAATGGTCACTTCCCAGAAGAAT 
I Sst I 
CTTTGGTATGTGAGCTCTCCCAGTTAAGAGCAATCCAGTTCACCCAGGCCAACCCTCTGT 
TTCTGCAGAAATCTGCATGAGATGAGAAGTCCCTGGCCTCTGGTCATTGGGAGCACACCA 
CCTCTTGACATAGCTGCATCTATAGGTGCTITAGGCACCACCTAGGTGGTGGCTGCAGTA 
ATGAACAAGGATAATAACTTAA GCTrGGCITA GGA TTTGTCCCTTCCTCTGTGCTGCACCGT 
GCTGTGTGAAGGGCTATCCCTTGTATATGAGGGACACTATTGCCCTGTGAATACATGGGC 
TGACCTGGCCAGCCACCCTCTGGCCTGTGTGGGACCCTGGGTAACAGGGCTCAGTCTAGG 
AGCGGAGGGTAGGACTCTGCCTAGGTCCTCCCCTGCTCCTGGCACTGGATAATATGAAGA 
CCAAGGAACCTCTACCTCTGCAGCTGCCCAGAGCTGAGCCTGGGCTCTCACTGTCCATTCA 
GGAGGCAGAGGGTAGACCTGGCTGG CTGCTCA GCA TCTTGTTCCTGCCAGTCAGCAGGCCC 
TGGAGAGATTCCAGGGCTCAGCCCTGGTCTTAGTGTGGTCTCACTCGCTCTGCCTGGGC 
AGTGACAGCACCATTAATATGGAGGCTGGTGAGAGCGGAGCACACAAAAGCAGCCTGCC 
TGCTGCTTTGCCTCTCTCTGCCCAGGGCATGGTGCTAGTTCATGGTGGTTTCAGCCTTTCCT 
AGCAGCTTAGGTTTATGTGGAG GATGGCAG GGGAACAGGACTGGTTTCTGA GA CTA GGTTC 
CACTCTCCTTGCCCTCTAAAGATAGAAACAAACAACACACAACACACATGTATGTCTTCC 
CAGACTCTCCGTCTCATAACTCAGAACCAGAGAGTCTCAGAGCTGAGAGGGGCCTCGGGG 
Kpn II 
AGATTTCACTGATGGAGAAAGCTCCAGAAGAGAGGGCAAGCATCCTGCCTGGGGTACCA 
SphIJ. 
TGGCAGGGAGAGCAGAGTCAGAGGCTGGACCAAAATGCAGCCTGAGTGGAAGCATGCC 
TTACCCCAGGCCCTGCTTCCCGAGCCCAATGCCCCACTCAGCTGGCAGACACAGCAGGCC 
CGCCCTGGGCACTCTGAGGGTGCAGCCACAGCAGATCACCAAGGAGGCATTCTGGGCCA 
GGGTGGGGTGGGGGGCCTGGGCAAGTTCTCTGGGGAGGTTTCCAGCTCCTCCACACCTGC 
TGTGGGGCCTGATTCTCCCCGCCCCTGCCCCGCTACTGGTGTGGAAACCAGGGTCAGGTGA 
135 
AGCCCTGCCCAAGCCTTGAGGAAGAGAGACACATTCTCACTTCTTCCTTTATTCTTTCTGG 
TGCCCAAGGCACTAACAACTGGGTGTATAAAGCCTTCCAGATAATTTCAGCCAATTTCTC 
CCCTAGACTTACTCCATCTGATTAAATGGCCACCCAGTCACTCAAGCAGGAGACCTGATGT 
TATCCCTGCCTCTGGGCTCCTACTTAAAACCAGCCACCCACTCCAGTTCCTCCTCACCAGG 
TCTGGCTGCCCCTCCGAAATCTCTCTCCATTCCAGCTTCCACGGTCTGATCCAAGGACTTC 
AACCCACTCAGGCCACTTGATCTCATTAGACTCATGGGTGTCTCCCTGCTTCCCTCCAGG 
NcoI.. 
CCTCCTCGATACATTTCCTTCCCAGAGGCTATGGAGGCITITGGAGGATGCAGATCTGCCC 
ATGGGCTCTCCGTCTCTGCCTCCCTCCAGTGTCCTCGCTCAGGGAGGGGAAGCTCAGGCGG 
AAAGCTGCCGAACTTTGGGTTGCGGCTGTCCCTCGATTAGCAGAGCTGCGGTGTTCTCCTC 
GGGCAGGCGGGCAGGTGGGCGCGCTTTGCTGCCCCCTGCAGCTCGGGGGCCTGCGATCCC 
CGCACAGAGCATTCCGTCACCCCAGGCCCACGCTCTCCAGCCCACCGCCCTCCTCTGGAC 
GCCGCGAGTGGAAGAGAGCTGCGAACTGAGAAGCCGTACTTTGGGCAGGGTGGAGGGCC 
CGGGGGCTGGAGACTGAGCCCCTCCGAGAGGAGCCGCCCGGCCCCGCCCCCCGGCGCAG 
CCATTGGCCGCGGCGGAGCGGCTGTACCCGCAGCTCCGTGCACTCGGCGGCTCCTCTCCG 
GGAAGGTCCCCACTTGACAGCTCTGGGCGACCGGAGGTGGCGCCCAAAGGCTGCCCGG 
GAGATCGGGGCTGGGCTGGCGGGGGCCAGGACCCCGCGCCCTCTCGGCCGCTCACTCTCG 
CGTCCACTCCCTCGCAGTCACGCCGGGCGCGCACTCCCACTCCCTCTCCGCACGCGGC 
TGCGGGACGCGATGGACGCGGCACTGCTCCACAGCCTGCTGGAGGCCAACTGCAGC 
CTGGCGCTGGCTGAAGAGCTGCTCTTGGACGGCTGGGGCCACCCCTGGACCCCGAG 
GGTAGCGGAAGCGAGCGGTCGAAGCTGCGCGGGCTCCTTCTCTCGCGCGCTGGGTGCGCC 
CCTGACCCCGCGCTCCGAGAGCCCCGCGTCCCTGCGGGCCCCTCTGAGCCCTACTGCGCTC 
TCTCCCGCCGCCAGGTCCCTACTCCTACTGCAACACGACCTTGGACCAGATCGGAACG 
TGCTGGCCCCGCAGCGCTGCCGGAGCCCTCGTGGAGAGGCCGTGCCCCGAGTACTT 
CAACGGCGTCAAGTACAACACGACCCGTGAGTGCCCCCGGCCCTCGCTGCCTGCTCT 
Figure 7.1 Nucleotide sequence of the genomic region between the CRH-R2a 
and CRH-R2y exons. 
Antisense and Sense internal primers for the sequences are shown in bold and 
italic letters (underlined), respectively. CRR-R2a exon I, CRH-R2y exon I and 
first common exon II sequences are in bold type, intron sequences are in normal 
type. 
Comparison of the genomic sequence with cDNA obtained by RT-PCR and 5'RACE 
established the organisation of the 5'end of the CRH-R2a gene. 5'RACE analysis 
extended the previously known exon I sequence of the human CRH-R2a and 
established that 5'untranslated region of CRH-R2a mRNA is 52 nt (for details, see 
Chapter 8). Exon I contains 52 bp of 5'untranslated and 103 bp of translated DNA 
sequence. Two nucleotides at both ends of the intron completely fulfil the GT-AG 
rule. This rule claims that dinucleotides GT and AG are invariably present at the 5' 
and 3' end of introns, respectively. The results suggested that the promoter of the 
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CRH-R2 is located upstream of the region. The distance between the CRH-R2y exon I 
and the CRH-R2a exon I was 4068 bp length. 
Between CRH-R2y I and CRH-R2a I intron (named CRH-R2y I), sequence data was 
analysed using ORF (open reading frame) Finder database searches from the National 
Centre for Biotechnology Information (NCBI). There are numerous ATG codons in 
the CRH-R2y I intron sequence leading to seventeen short open reading frames 
(ORFs). ORF frames range from 105 bp to 546bp. However, using 5'RACE and RT- 
PCR from cDNA made from some tissues (myometrium, hippocampus) was found no 
evidence for the presence of additional exons in this region for the human 5'end of 
CRH-R2 gene. 
7.3 Sequence analysis of the genomic region between the CRH. R2(3 Ib and CRH- 
R2y exons 
We sequenced the clone (JP1) which includes the exon I of the CRH-R2y and CRH- 
R2a genes. The nucleotide sequence of the genomic DNA revealed that JP1-SphI 3.2 
kb contained the CRH-R2y exon I of 227 bp and 205 bp of the CRH-R2ß intron Ib, 
but did not contain the CRH-R2ß exon I. In order to obtain the genomic sequence 
between the CRH-R2(3 and CRH-R2y exons, we used PCR with Elongase system 
(Gibco BRL) and human genomic DNA from peripheral blood leucocytes. First, we 
used a primer to the CRH-R2 f exon 5'end (B2: 5'- 
CTGGCATGAGGGGTCCCTCAG-3') and a primer to the 5'-end of the CRH-R2y 
specific exon (G3: 5'-GTAGGCAGATTGCTTGAGAC-3'), but genomic PCR was 
unsuccessful. Second, we used a primer to the CRH-R2ß exon 3'end (B4: 5'- 
CATGACCCTCACCAACCTCTC-3') and a primer to the 5'end of the CRH-R2y 
specific exon (G3: 5'-GTAGGCAGATTGCTTGAGAC-3') and generated a 2.6 kb 
fragment (Figure 7.2). The product was subcloned into the pGEM-T vector and 
sequenced with SP6 and T7 primers. Sequence analysis of this fragment confirmed 
the presence of the CRH-R2ß and CRH-R2y exon sequence at the 3'and 5'ends, 
respectively. The CRH-R2ß and CRH-R2y exons possess good consensus splice 
junctions flanking an apparent 2575 bp intron. 
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3054 bp 
1636 bp 
1018 bp 
506 bp 
Figure 7.2 PCR was used to amplify the genomic region between the CRH-R213 
lb and CRH-R2y exons. 
Lane 1 shows (human genomic DNA) PCR amplification of a 2.6 kb fragment, 
which contained CRH-R2ß and 2y exon sequence at the 3' and 5'ends. M is a 
lkb DNA size marker. Lane 2 PCR amplification of a 2.6 kb fragment from the 
clone JP 1. 
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Comparison of the genomic sequence with cDNA obtained by RT-PCR and 5'RACE 
established the organisation of the 5'end of the CRH-R2y gene. The CRH-R2y cDNA 
sequence identified was identical to the corresponding genomic DNA sequence. 
The resultant products of 5'RACE obtained using CRH-R2y exon I gene specific 
primers were cloned into the pGEM-T cloning vector and the clones were sequenced. 
The nucleic acid sequence of two fragments (A and B) revealed that 488 bp fragment 
corresponded to the CRH-R2(3 (280 bp) and CRH-R2y (208 bp) specific exons, the 
690 bp fragment contained CRH-R2ß (280 bp) and CRH-R2y (208 bp) specific exons 
and an extra 195 bp of intronic sequence (see Chapter 8). This product potentially 
encodes a truncated protein as a result of an in-frame termination codon in intron I. 
The extra 195 bp sequence is located at the region between CRH-R2(3 lb and CRH- 
R2y exon I (Figure 7.3A). The distance between the CRH-R20 lb and an extra 195 bp 
sequence is 182 bp. The distance between the CRH-R2y-exon I and the extra 195 bp 
sequence is 2016 bp. The extra 195 bp cDNA sequence corresponded exactly to the 
genomic DNA sequence (Figure 7.3B). 
The sequence data between CRH-R2(3 Ib and CRH-R2y I intron (named CRH-R2(3 Ib) 
was analysed using ORF (open reading frame) Finder database searches from the 
National Centre for Biotechnology Information (NCBI). There are numerous ATG 
codons in the CRH-R2(3 Ib intron sequence leading to seven short open reading 
frames (ORFs). ORF frames have a range from 102 bp to 366 bp. Using gene specific 
primers for RT-PCR and 5'RACE, one cDNA fragment of 195 bp was amplified from 
hippocampus cDNA (see Chapter 8) but not myometrial cDNA in the CRH-R2ß Ib 
intron. The CRH-R2(3 Ib intron was located in this region for the 5'end of CRH-R2 
gene, leading to the possibility of other exons within this region. 
I/ 
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A 
2ß la 2ß lb 
1821 
10 kb 
exor 
2y 
016 
. 57 kb' 4 kb first common 
exon 
2aI 
Insertion(195 bp) 
B 
I 
GenomicAGGGCTCAGGCTTGCCACTGATAATGAAGGGCTTGGCTGGGAG 
cDNA GGCTCAGGCTTGCCACTGATAATGAAGGGCTTGGCTGGGAG 
GenomicGCCACTCCCCATTCCCAGCTCCCACGATGGAAGTCAGCTGGGCT 
cDNA GCCACTCCCCATFCCCAGCTCCCACGATGGAAGTCAGCTGGGCT 
GenomicGGCATTCAGGAGTCCAAGAAGGGGATGACCCCTCAGC'mCCAA 
cDNA GGCATTCAGGAGTCCAAGAAGGGGATGACCCCTCAGCTTTCCAA 
GenomicCTCCAGGGAAACTGGCAGAAGGTGGTAAACATTCTCTGGTTGCC 
cDNA CTCCAGGGAAACTGGCAGAAGGTGGTAAACATTCTCTGGTTGCC 
Genomic GTGGCTACAGGTGTGACTTCCTGT 
T 
cDNA GTGGCTACAGGTGTGACTTCCT 
Figure 7.3. (A) The arrangement of the 5'-end of the CRH-R2 cDNA with extra 
195 bp. The CRH-R2a, 2ß (Ia + Ib), 2y and extra 195 bp alternative exons are 
represented as solid boxes. 
(B) Nucleötide sequence of human CRH-R2y 5'RACE-derived cDNA (extra 
195bp) and comparison to the corresponding genomic DNA sequence. The 
positions at which the fragment is inserted are indicated by (1). 
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7.4 Analysis of the genomic region between the CRH-R20 5' and 3'ends exon 
Analysis of human genomic DNA by PCR and by sequencing indicates that the CRH- 
R20 exon lies upstream of the CRH-R2y and CRH-R2a exons. Our results indicate 
the genomic order of the alternative exons to be CRH-R20-2y-2a. PCR with CRH- 
R20 exon-5'end and CRH-R2y exon-3'end primers was used to obtain the genomic 
DNA fragments, but the PCR was unsuccessful. PCR with CRH-R2(3 exon-3'end and 
CRH-R27 exon-5'end primers was used to amplify the region and generate a 2.6 kb 
fragment (see Section 7.2). The results of the genomic PCR are most likely due to the 
large intervening distance between the CRH-R2ß at the 5'- and 3'end. The result 
suggests that the CRH-R2(3 exon I is interrupted by a large intron in the 5'end of 
CRH-R2 gene. 
The complete sequence of human 7p14-15, including the entire CRH-R2(3,2y, and 2a 
gene, was made available recently (GenBank accession number A0004976). 
Comparison of the genomic sequence with cDNA obtained by RT-PCR and 5'RACE 
established the organisation of the 5'end of the CRH-R2 gene. The CRH-R213 exon I 
is divided into exon Ia and exon Ib by a large intron, intron Ia, of 1065bp. The 
5'(CAATAC) and 3'(GCAGCC) splice site sequences of CRH-R213 intron la include 
the invariant 5'-GT... AG-3' nt and are in general accord with splice rules. The CRH- 
R2(3 cDNA sequence is identical to the corresponding genomic sequence. 
The sequence data between CRH-R2ß Ia and Ib intron (named: CRH-R2(3 Ia) was 
analysed using ORF (open reading frame) Finder database searches from the National 
Centre for Biotechnology Information (NCBI). There are numerous ATG codons in 
the CRH-R2(3 Ia and Ib intron sequence leading to thirty-two short open reading 
frames (ORFs) ranging from 102 bp to 533bp. However, amplification of this region 
from cDNA made from some tissues (myometrium, hippocampus) has not indicated 
the presence of other exons in this region for the 5'end of CRH-R2 gene. 
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7.5 Alternative exon region of CRH-R2 genomic structure 
Alignment of the genomic sequence with the 5'-end cDNA sequence of the CRH-R2 
revealed that the 5'end of the gene is composed of 4 exons and 3 introns distributed 
over 18 kb (Figure 7.3). The entire human CRH-R2(3 gene consists of at least 13 
exons and spans approximately 48 kb. The human CRH-R2y consists of at least 12 
exons and spans approximately 34.5 kb. The human CRH-R2a gene spans 
approximately 30 kb, with the protein-coding sequence interrupted by 11 introns. 
2ß Ia 2ß Ib 2yI 2a I 
' 2.57 kb 
10 kb 4 kb First commom axon axon axon axon axon H 
Figure 7.4. The 5'end of the CRH-R2 gene structure. 
The 20 exon I is interrupted by a large intron (10659 bp) in the 5'end of CRH-R2 
gene. The CRH-R2ß Ib and CRH-R2y exons possess good consensus splice junctions 
flanking an apparent 2575 bp intron. The distance between the CRH-R2y exon I and 
the CRH-R2a exon I is 4068 bp. Accurate estimates of the distance between each 
exon and the composition of each exon was based on a combination of Southern 
analysis, DNA sequencing and PCR amplification. The cDNA sequence corresponded 
exactly to the genomic DNA sequence. 
Exon-intron junctions conform to the consensus sequences, with exons flanked by AG 
and GT at 5' and 3' ends, respectively. 
142 
7.6 DNA-binding protein motifs upstream of translation start 
We have cloned the 5'-flanking region of the CRH-R2 gene by the PCR based 
genomic walking method. The nucleotide sequence of 1.3 kb of the 5'flanking region 
was determined (see Section 6.3.2). A search of the 5'-flanking region sequence 
against the TRANSFAC (http: //transfac. gbf. de/TRANSFAC/index. html. ) revealed 
several potential consensus sequences of putative transcription factor binding sites. 
The binding site consensus sequences are in shown Figure 7.5. 
-1393 AGACCTGTGAGATTTCACAGGAGAGGGAGGTGGGACCTGGAAC 
-1350AGCCAGGAAGGCTGCCTGGAGGAAGGGGCTGAGGGTGGGGAGGAAGCACT 
GATA-3 
-1300 CAAGGACAGAAAAGTGTCCCATGTCTTAGATAGGGAGACCGGAAGGAGCA 
CRE-BP SF-1 
-1250 CAGAGTGTCTGAGTTACTTAAATCGGGACTGAGTTTTCCAAGGTCTCTCT 
-1200 CCACCATGCCTGCATCTCCAGGAGAAAGTTTGGTGCCCCACTAATCACAT 
USF 
-1150 TCCTCACATGCTTTCCCCTCAGATCCTAACAACAAGCAAGGTGCAACTGT 
MYoD 
-1100 GGCTTAAGCTTITAAACCCCCTGCACCAGGCCCACCTGTCAGGAACAGCT 
-105000TAAGGAGGCTTCTGAGGCTCTGGAAGAACAGACCTCACCTCATGAGCC 
SP1 
-1000CTGACCCAGCCCCAGGTTGAACCTGTCCCCGCCAAGAACAGCACTGCTCA 
CRE 
-950 GCCACCTGATATCAGGATCCCTAACCATTTCCTGAAATGGAACCTGGGCC 
-900 CCATACAGACAGACACCTGGGCCCCATCCCAAGCTACTTCATTGGAATCT 
c-MYb 
-850 CTGGGTGAGCCCTGCCATGGCTGTATTTGCTGTCGGTTGGGTT11TI'l IT 
Oct-1 
-800 TT ITI'I'ITTGAAAGCATTTTATTTTGATAGAATTTCAAACGTACAGAAAA 
HSF2 
-750 GTTGGAAGAATGATCCAAAGCATATCCATATACCCCTTTTCCAGATTTAC 
C/EBP 1/2GRE 
-700 CAACAATTTACATMGCCCCATCTGCTCTCTTGTTCTATCTATGTATCT 
GATA-1 
-650 ATCTGAGTTTATTTCTGAACCATTTGAAAGTATGTTGGAAACATGGTGCC 
-600 CCmAATCCTAAATGTGTATTTTCCAAGAATGAGAACATTCTCTTACCT 
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AP-4 
-550A000ACAGTACAGTATCAGAATCAGCAGATGTAGCATTGATACAGTACTA 
P300 AP-1 
-500 TCTAACCCAGCATCCACACTCCCATCTCAGTCATCCCAGTAGGCATTAGC 
GATA-2 AP-4 
-450 ACCTGTTAAAAGCTCCTCAGATAGGTGTTAGGCAGTGCTGGTTCAGCTGA 
CP2 
-400 GACCCAGGGCAGCCCAACCCTGTGCTGAAGCAGGGACCACAGCCTAGGCC 
delta EF1 
-350 CCTCCTGCCTGTCTCAATTCCTCTCTCCCACCTGGGGAGCTACAGCCCCG 
-300 GGCAATGCTGGCAGCCGATAGAAGGCATTAACCCCTTCTCTGCAGGCTGG 
AP-4 
-250 ATGGAGAGCATAGCCCCTTGGCTGGCTGGGTAGCAGCAGCTGTCTGGGAC T (2ß) 1 SP1 (2ß)2T 
-200 CAGCTATAAATAACCTGGAGGCTGTGGGCTGTGGGGCGGGGTCACCACTG 
AP-2 
-150 CCCTGTGGAAGAAGTGGGTGGAGAATACCTCCTCATGCCCAAGGCCTTAC 
-100 CTTGGCCTCCCCTCCAGGGCCGGGTGGGGTGGGGCTGGCCAGGGTGTGAC T(2y) 
-50 CACCGTGCTGGGCAGCAGGCTCCAGTCCCTAACCCCCAGCCACTACTGGC T(2(x) 
+1 ATGAGGGGTCCCTCAGGGCCCCCAGGCCTCCTCTACGTCCCACACCTCCTC 
Figure 7.5 Nucleotide sequence of human CRH-R type 2 promoter region with 
putative binding sites for transcription factors. 
The arrows represent the transcription start sites identified by 5'RACE. Putative 
binding sites for transcription factors are underlined. 
SP1 (GC box) = GGGCGG, Oct-1=ATTTGCAT, SF-1=CCAAGGTCA, 
C/EBP=ATTGCGCAAT, 1/2GRE=TGTTCT, AP-1=TGAGTCA, AP- 
2=GCCN3GGC, CRE-BP=TGACGTCA, HSF=CTNGAATNTTCTAGA. 
N indicates that any base (A, T, C and G) can be present at that position. 
Two Spl binding GC-rich motifs are found at -164 and -997. Spl sites have been 
frequently linked to transcriptional control of genes that lack a functional TATA box. 
There were several DNA motifs characteristic of genes involved in steroidogenesis 
and reproductive function, including an androgen response element/glucocorticoid 
response element half site at -665 bp as well as a single steroidogenic factor site at - 
1204 bp. These include one putative binding site for the enchancer factor AP1 
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(activator protein-1) at bp -473 and a cAMP-response element CP2 at bp -378 and a 
binding site for the upstream stimulatory factor USF at bp - 1139. In addition, three 
putative binding sites for the zinc finger transcription factor GATA are found at -425, - 
643, and -1285 and a octamer site for the homeobox domain factor Oct-1 at -824bp. 
The CRH-R2 promoter region up to -1410 bp contains sites for HSF2, deltaEF1, AP-2, 
and three AP-4. The promoter contains consensus sequences for putative DNA- 
binding proteins involved in tissue specificity (c/EBP and MyoD) or hormonal 
regulation (GRE and SF-1). In addition, the promoter region contains consensus motifs 
corresponding to inducible promoter elements that are known to bind transcription 
factors induced by exogenous stimuli. These include binding sites for the transcription 
factors CRE-BP [cAMP-response element (CRE)-binding protein] at bp -1238, CRE at 
-936. 
7.7 Discussion 
We have determined the structure of the 5'end of the CRH-R2 gene which is 
organised with the 5'alternative exons arranged as CRH-R20-2'y-2a. The human 
CRH-R2a gene spans approximately 30 kb, with the protein-coding sequence 
interrupted by 11 introns. Genes encoding receptors belonging to the glucagon 
receptor subfamily are interrupted by several introns. The location of introns in the 
hCRH-R2(3 gene was compared with those in reported genes of this subfamily 
including the human VIP! (Sreedharan et al., 1995), glucagon (Lok et al., 194), PTH- 
PTHrP (Kong et al., 1994) and calcitonin (Albrandt et al., 1995) receptors. The N- 
terminal extracellular domains are separated by four introns in all genes except for 
that of human PTH-PTHrP-R, which is separated, by five introns. The N-terminal 
extracellular domains of human CRH-R2a and CRH-R2y are separated by three 
introns and CRH-R2ß by four introns. Furthermore the arrangement of introns in each 
domain are quite similar in all these genes. This similarity supports a hypothesis that 
this subfamily probably emerged early during evolution. 
Among CRH-Rs of several species, human CRH-R1's, rat CRH-RI's and human 
CRH-R2a's gene structures have already been determined (Sakai et al., 1998, Tsai- 
Morris et al., 1996, Liaw et al., 1996). Rat CRH-R1 and human CRH-R2a genes 
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contain 13 and 12 exons, respectively. The locations of introns in the coding 
sequences are identical in human and rat CRH-R1. Human CRH-R2(3 and CRH-R2'y 
genes contain 13 and 12 exons, respectively. The N-terminal extracellular domains of 
human CRH-Rl, rat CRH-R1 and human CRH-R2(3 are divided with four introns, 
whereas the N-terminal extracellular domain of human CRH-R2oc and CRH-R2y are 
separated by three introns. However, in the domains toward the C-terminus, the 
locations of introns are quite similar among the three genes. The similarity of the 
hCRH-R2 gene to the hCRH-Rlgene is illustrated in Figure 7.6. 
J. 1 
hCRH-RI a MGGHPQLRLVKALLLLGLNPVSASLQDQHCESLSLASNISGLQC(44) 
I 
hCRH-R2a MDAALLHSLLEANCSLALAEELLLDGWGPPLDPEGPYSYC(40) 
11 
hCRH-R2a MRGPSGPPGLLYVPHLLLCLLCLLPPPLQYAAGQSQMPKDQPLWALLEQYCHTIMTLTNLSGPYSYC(67) 
1 
hCRH-R2? MGREPWPEDRDLGFPQLFCQGPYSYC(26) 
4. 
hCRH-R1 aNASVDLIGTCWPRSPAGQLVVRPCPAFFYGVRYNTTNNGYRECLANGSWAARVNYSECQEILN(107) 
hCRH-R2a NTTLDQIGTCWPRSAAGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDD(104) 
hCRH-R2(3 NTTLDQIGTCWPRSAAGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDD(131) 
4, 
hCRH-R2y N'ITL. DQIGTCWPRSAAGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDD(91) 
1112 
hCRH-RI aEEKKSKVHYHVAVII-NYLGHCISLVALLVA-FVLFLRLRSIRCLRNIIHWNLISAFILRNATWFVVQL(174) 
11L2 
hCRH-R2a KQRKYDLHYRIALVVNYLGHCVSVAALVAAFLLFLALRSIRCLRNVIHWNLITTFILRNVMWFLL(169) 
11J. 2 
hCRH-R20 KQRKYDLHYRIALVVNYLGHCVSVAALVAAFLLFLALRSIRCLRNVIHWNLITTFILRNVMWFLL(196) 
112 
hCRH-R2y KQRKYDLHYRIALV VNYLGHCVSVAALVAAFLLFLALRSIRCLRNVIHWNLITTF-ILL RNVMWFLL(15 5) 
134J. 
hCRH-R I aTMSPEVHQSNVGWCRLVTAAYNYFHVTNFFWMFGEGCYLHTAIVLTYSTDRLRKWMFICIGWGVP(239) 
1314 
hCRH-R2aOLVDHEVHESNEV WCHCTIT FVEGCYL HTAIVMTYSTERLRKCLFLFIGWCIP(234) 
l314 
hCRH-R2IOLVDHEVHESNEVWCHCITT FVEGCYLHTAIVMTYSTERLRKCLFLFIGWCIP(262) 
. i. 3 14 
hCRH-R2y OLVDHEVHESNEV WCHCITTIFNYFVVTNFFWMFVEGCYL. HTAIVMTYSTERLRKCLFLFIGWCIP(221) 
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115 
hCRH-RlaFPI VAWAIGKLYYDNEKCWFGKRPGVYTDYIYOGPMILVLLINFIFLFNIVRILMTKLRASTTSET(306) 
J. J. 5 
hCRH-R2a FPIIVAWAIGKLYYENEQCWFGKEPGDLVDYIYOGPIILVLLINFVFLFNIVRILMTKLRASTTSET(302) 
J. 15 
hCRH-R2ß FPINAWAIGKL YYENEQCWFGKEPGDLVDYIYOGPIILVLLINFVFLFNIVRILMTKLRASTTSET(339) 
d. J. 5 
hCRH-R21FPI VAWAIGKLYYENEQCWFGKEPGDLVDYIYOGPIILVLLINFVFLFNIVRLLMTKLRASTTSET(288) 
16J. 7 
hCRH-Rla IQYRKAVKATLVL LGITYMLFFVNPGEDEVSRVVFIYFNSFLESFOGFFVSVFYCFLNSEVRSAIRKR(377) 
J. 6 J. 7 
hCRH-R2aIQYRKAVKATLVLLPLGITYMLFFVNPGEDDLSQIMFIYFNSFLOSFOGFFVS VFYCFFNGEVRSAVR(371) 
16J. 
hCRH-R2ßIQYRKAV KATLVLLPLGITYMLFFVNPGEDDLSQIMFIYFNSFLOSFOGFFVS VFYCFFNGEVRSAVR((398) 
J. 6 J. 
hCRH-R2y IQYRKAVKATLVLLPLGITYMLFFVNPGEDDISQIMFIYFNSFLOSFOGFFVS VFYCFFNGEVRSAVR(357) 
hCRH-Rla WHRWQDKHSI RARVARAMSIPTSPTRVSFHSIKQSTAV(415) 
hCRH-R2a KRWHRWQDHHSLRVPM ARAMSIPTSPTRISFHSIKQTAAV(41 1) 
hCRH-R2ß KRWHRWQDHHSLRVPM ARAMSIPTSPTRISFHSIKQTAAV( 438) 
hCRH-R2yKRWHRWQDHHSLRVPM ARAMSIPTSPTRISFHSIKQTAAV(397) 
Figure 7.6 Alignment of amino acid sequences of human CRH-R2a (hCRH- 
R2cc) (Accession No. U34587), human CRH-R2ß (hCRH-R20) (Accession No. 
Y10151), human CRH-R2y (hCRH-R2y) (Accession No. AF019381), and 
human CRH-Rla (hCRH-Rlcc) (Accession No. L23333) proteins and the 
location of intron-exon boundaries. Arrows indicate the positions of introns. 
The putative transmembrane domains are underlined. The numbers in the right- 
hand column refer to the amino acid number. 
Comparison of the genomic sequence with cDNA obtained by 5'RACE and RT-PCR 
established the organisation of the 5'end of the CRH-R2 gene. The alternative exon 
region of CRH-R2 gene is composed of 4 exons and 3 introns distributed over 18 kb. 
The CRH-R2 exon-I is interrupted by a large intron (10659 bp) in the 5'end of the 
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CRH-R2 gene. Accurate estimates of the distance between each exon and the 
composition of each exon was based on a combination of Southern analysis, DNA 
sequencing and PCR amplification. Exon-intron junctions conform with the consensus 
sequences, with exons flanked by AG and GT at 5' and 3' ends, respectively. Table 
7.1 below shows the sequences around the exon-intron junctions. 
Table 7.1 Intron-Exon junction Sequences of the Human CRH-R2 5'-end Gene 
Exon Exon Intron Intron 
no length 5'Splice donor no length 3' Acceptor 
201a 312bp CAATAC gtaagtg 
2ßIb 93 bp CTCTCAG gtaggt 
2yI 227bp GCCAAG gtatct 
2aI 155bp CCGAGG gtaggc 
II 126bp CGACCC gtgagt 
20Ia * 10659bp ccctag GCAGCC 
2ßlb 2575bp ttgtag GCTGGT 
2yI 4068bp tcgcag TCACGC 
2a1 137bp cgccag GTCCCT 
Exon and intron sequences are shown in upper and lowercase letters, respectively. 
Lengths of the introns and exon were determined by PCR and sequencing, except for 
one marked with as asterisk, which was described by Andrews, et al 1998. 
The 5'-end cDNA sequence of the CRH-R2 (2(3,2y, and 2a) corresponded exactly to 
the genomic DNA sequence. Comparison of the genomic sequence with cDNA 
obtained by 5'RACE (with CRH-R2(x, 2(3, and 2y primers) established the 
organisation of the 5'end of the CRH-R2 gene. An extra 195 bp sequence can be 
generated by alternative splicing in the N-terminus of the CRH-R2 gene. The extra 
195 bp sequence located in the region between CRH-R2ß lb and CRH-R2y exon-I. 
The extra 195 bp cDNA sequence corresponded exactly to the genomic DNA 
sequence. 
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The typical eukaryotic gene consists of up to four distinct transcriptional control 
elements. They are: first, the promoter itself; second, upstream promoter elements 
located close to it which are required for efficient transcription in any cell type; third, 
other elements adjacent to the promoter which are interdigitated with the upstream 
promoter elements (UPEs) and which activate the gene in particular tissues or in 
response to particular stimuli; and finally, more distant enhancer elements which 
increase gene activity either in all tissues or in a regulated manner. 
The promoter region of most genes contains several elements. The first is a sequence 
called the TATA box, which located at about 25 to 30 bases upstream from the initial 
site of transcription (designated as -25 to -30). Some promoters have a second short 
conserved sequence, instead of or together with a TATA box, which surrounds the 
start site and is called the Initiator (Inr) element (O'Shea-Greenfield and Smale, 
1992). There are two key genetic elements within a core promoter: the TATA box 
and/or an initiator (Inr) element (Novina and Roy 1996). Core promoter structures can 
contain both elements (composite: TATA+ Inr), either one element (distinct: 
containing either TATA+ Inr or TATA7 Inr+) or no element (null: TATA7 Inf) (see 
Chapter 1.7.1). Neither TATA nor other initiator motifs were evident in the 1.3 kb 5'- 
flanking region (CRH-R2) upstream of the translation starts site. 
The absence of TATA and CCAAT motifs is not unique to the CRH-R2: other G 
protein-coupled receptor genes such as the Rat CRH-R1, the human vasoactive 
intestinal peptide receptor, the human growth hormone-releasing hormone receptor, 
and the human secretin receptor (Tsai-Morris, et al., 1996, Sreedharan et al., 1995, 
Petersenn et al., 1998, Ho et al., 1999) also lack these sequence motifs in their 
promoters. Promoter regions which are GC-rich and contain Spl-binding sites but not 
a TATA box have been shown to be activated by Spl recruiting specific co-activators 
to bind transcription factor II D (TFIID) (Pugh et al., 1990). Pei et al., 1995 have 
shown that Spl binds to the promoter and activates the rat vasoactive intestinal 
peptide receptor type 1 (VIPR1) gene (Pei et al., 1995). It is possible that a similar 
transcription mechanism, involving Spl rather than TATA binding proteins, operates 
for the CRH-R2 gene. 
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The first 1.3 kb of the 5'-flanking sequence contained Spl binding sites and lacked a 
consensus TATA box. All characteristics of gene promoters lacking tissue-specific 
expression. Moreover, the 5'-flanking region contains consensus-binding sites for 
several transcription factors that may be functionally important including AP-1, CRE- 
BP, Ap-2, CP2, GRE and SF-1. From the results of the present study, therefore, we 
speculate that the strong and housekeeping gene-like activity of the CRH-R2 gene 
promoter might contribute to the ubiquitous expression of the CRH-R2 gene. 
Furthermore, protein-binding studies such as footprinting or gel shift analysis will 
help to verify the involvement of the designated putative sites in the transcriptional 
control of the CRH-R2 gene. 
Some members of the secretin receptor family have multiple untranslated exons in the 
5'-untranslated region. The parathyroid hormone (PTH)/PTH-related peptide (PTHrP) 
receptor gene has three untranslated exons (Manen et al., 1998). The pituitary 
adenylate cyclase-activating polypeptide (PACAP) receptor gene has four 
untranslated exons in the 5'-untranslated region (Chatterjee et al., 1997). However, 
this does not appear to be the case for the CRH-R2. Multiple promoter regions have 
been described for PTH and glucagon receptor genes. The PTH receptor gene has 
been shown to be controlled by two promoters, one of which is not GC-rich and is 
only active in kidney (McCuaig et al., 1995). There is no evidence that the CRH-R2 is 
controlled by more than one promoter. 
Nucleotide sequence analysis of the 5'-flanking region of the CRH-R2 gene indicated 
the presence of several transcription factors binding sites. There were several DNA 
motifs characteristic of genes involved in steroidogenesis and reproductive function, 
including a single steroidogenic factor and an androgen response 
element/glucocorticoid response element. The 5'-flanking region of the CRH-R2 gene 
showed a putative binding site for the steroidogenic factor 1 (SF-1) located at from - 
1213 to 1204 bp (CCAAGGTCT) that corresponded to the reported SF-1 binding 
elements (PyCAAGGPyCPu) (Lynch et al., 1993). SF-1 is an orphan nuclear 
receptor, which regulates many genes directly involved in steroidogenesis or other 
target genes from the hypothalamo-pituitary-gonadal axis (Zhang and Mellon 1996, 
Sugawara et al., 1997). SF-1 is also implicated in the development of the adrenal 
gland and gonads (Sadovsky et al., 1995). These reports suggest an important role for 
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SF-1 in the regulation of steroidogenesis at a number of levels. Further analysis will 
be conducted to identify the steroidogenic factor 1 within the CRH-R2 gene. 
Glucocorticoids are the final effectors of the hypothalamo-pituitary-adrenal (HPA) 
axis and participate in the control of whole body homeostasis and the organism's 
adaptive response to stress. These hormones exert their effects through their nuclear 
receptors. Nuclear receptor molecules bind to short stretches of DNA and consensus 
sites for the receptor binding are based on certain arrangements of these half-sites. 
There is an androgen response element/glucocorticoid response element (GRE) half 
site located at -665 bp in the 5'-flanking region of the CRH-R2 gene. Glucocorticoids 
play a key regulatory role in the biosynthesis and release of CRH (Otth 1992). Further 
studies are required to substantiate the functionality of the half-GRE present in the 5'- 
flanking region of the CRH-2 gene. 
A number of putative binding sites for tissue specific factors (see Section 1.7.3.1) are 
located within the genomic 5'-flanking sequence, for instance, a site for the 
transcription factor GATA-1 (NF-E1), which is expressed at very high levels in 
erythroid cells. GATA-1 was originally identified on the basis of its binding to the 
promoter or enhancer regions of chicken and mammalian globin gene, and was shown 
to be essential for their erythroid-specific pattern of gene expression, deletion or 
mutation of GATA-1 binding sites resulting in the abolition of such expression. This 
factor plays a critical role in the regulation of a number of different erythroid-specific 
genes and thereby in erythroid cell differentiation. One binding site for tissue specific 
factor MyoD activates muscle-specific genes. MyoD was not identified on the basis of 
studying genes of this type. It was isolated on the basis of the finding that its artificial 
expression within undifferentiated fibroblast-like cells was sufficient to transform 
them into muscle precursor cells. Hence this factor is not only capable of switching on 
muscle-specific genes but also, by doing so, actually plays a central role in the 
production of the differentiated cell type itself. 
The CRH-R2 belongs to the family II of Gs -protein-coupled cell surface receptors 
that activate adenylate cyclase, resulting in a creased cAMP levels and activation of 
protein kinase A. Nucleotide sequence analysis of the 5'-flanking region of the CRH- 
R2 gene indicates the presence of several cAMP response element. These include 
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binding site for the CREB [cAMP-response element (CRE)-binding protein] at bp - 
1238. A 5'-GCCCAAGGC-3' sequence was found at position -106, corresponding to 
consensus sequence that binds the transcription factor AP-2 (Imagawa et al., 1987). 
The metallothionein IIA gene binds a transcription factor referred to as activator 
protein 2 (AP-2). AP-2 acts as a basal level enhancer (Mitchell et al., 1987), but it also 
stimulates transcription in response to both protein kinase C and cAMP (Imagawa et 
a!., 1987). AP-2 sites have been identified in a number of genes, allowing derivation 
of the relatively variable GC-rich consensus 5'-GCCN3GGC-3' (Williams and Tjian, 
1991). The action of AP-2 is regulated developmentally in a cell-specific fashion 
(Williams et al., 1988). An important step in 'the study of transcription factors has 
been the discovery that many constitute the terminal targets of specific signal 
transduction pathways. The two major signal transduction systems utilise cAMP and 
diacylglycerol (DAG) as secondary messengers. Each of these pathways is also 
characterised by the mobilisation of a specific protein kinase (protein kinase A and 
protein kinase C, respectively) and an ultimate DNA control element [cAMP- 
responsive element (CRE) and TPA-responsive element (TRE) respectively]. 
Although these two pathways were initially characterised as distinct systems, 
accumulating evidence points to extensive `cross-talk' between them (see Chapter 
1.7.4). Intracellular levels of cAMP are primarily regulated by adenylate cyclase. This 
enzyme is in turn modulated by various extracellular stimuli mediated by receptors 
and their interaction with G proteins (McKnight et al., 1988). The binding of a 
specific ligand to a receptor results in the activation of the cAMP pathway. CREB 
belongs to a family of nuclear proteins CREB-ATF that binds to an 8-bp consensus 
sequence, TGACGTCA (Deutsch et al., 1988). Activation of signalling pathways 
through protein kinase A modifies the phosphorylation state of CREB and increases 
its ability to activate transcription. 
A related but distinct DNA-binding protein family known as AP-1 or THE [12-0- 
tetradecanoyl phorbol-13-acetate (TPA)-response element] also binds to a unique cis- 
acting DNA element. At position -471, the sequence 5'-TCAGTCA-3' was present, 
which differs by only a single base (underlined) from the reported AP-1 site (5'- 
TGAGTCA-3'). Activation of the intracellular protein kinase C pathway is thought to 
alter the phosphorylation state and ability of AP-1 to activate transcription. There is 
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recent evidence that both CREB and AP-1 may interact on similar types of DNA 
sequences, allowing for `cross-talk' between these two factor (Hai et al., 1991). 
Examination of the CRH-R2 promoter revealed the presence of several cAMP 
response elements and TPA response elements (CREB, AP-1 and AP-2). Further 
experiments would be necessary to demonstrate the involvement of one or several of 
these elements or other ones in the cAMP and DAG regulation. 
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Chapter 8 Determination of transcriptional start sites using 5'RACE 
8.1 Introduction 
5'Rapid amplification of cDNA ends (5'RACE) is a procedure for amplification of 
nucleic acid sequences from a messenger RNA template between a defined internal 
site and unknown sequence of the 5'-end of the mRNA. Other researcher have also 
described the methodology of amplification with single-sided specificity as "one- 
sided" PCR (Ohara et al., 1989) or "anchored" PCR (Loh et al., 1989). In general, 
PCR amplification of relatively few target molecules in a complex mixture requires 
two sequence-specific primers that flank the region of sequence to be amplified. 
However, to amplify and characterise regions of unknown sequence, this requirement 
imposes a severe limitation. 5'RACE methodology offers a possible solution to this 
problem. 
5'RACE, or "anchored" PCR, is a technique that facilitates the isolation and 
characterisation of 5'region from low-copy messages (Frohman 1988 and Dumas 
1991). Although the precise protocol varies among different users, the general 
strategy remains consistent. The first strand cDNA synthesis reaction is primed using 
an oligonucleotide complementary to sequences in the gene. Tailing-mediated anchor 
PCR is a technique in which the terminal deoxynucleotidyl transferase is used to add 
homopolymeric tails to the 3'-ends of the cDNA. A typical PCR reaction follows, 
using an anchor primer complementary to the newly added tail and another primer to 
a known sequence within the gene. 
Ligation-mediated anchor PCR is another technique that uses single-stranded ligation 
of cDNA (SLIC) with T4 RNA ligase to covalently join an oligonucleotide anchor 
site adjacent to the 3'-end of the cDNA. The single-stranded -cDNA (ss-cDNA) can 
then be amplified by PCR. 
5'RACE requires a very small amount of primary material, and provides a rapid 
feedback on the generation of the desired product. Information regarding alternative 
promoters and splicing sequences can be obtained and a judicious choice of primers 
(e. g., within an alternately spliced exon) can be used to amplify a Subpopulation of 
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cDNAs from a gene for which the transcription pattern is complex. Furthermore, 
differentially spliced or initiated transcripts can be separated by electrophoresis and 
cloned separately, and essentially unlimited numbers of independent clones can be 
generated to examine rare events (Loh et al., 1989). For 5'end amplification, the 
ability of reverse transcriptase to extend cDNAs all the way to the 5'end of a message 
is greatly increased, because a primer extension library is created instead of one for a 
general purpose. In addition, random hexamer-primed cDNA has been adapted to 
5'RACE for amplification and cloning of multiple genes from a single first strand 
synthesis reaction (Harvey et al., 1991). Products of 5'RACE reactions can be used 
for the preparation of probes. The RACE procedures may be utilised in conjunction 
with exon trapping methods (Buckler et al., 1991) to enable amplification and 
subsequent characterisation of unknown coding sequences. 
In this chapter, the 5'RACE method was employed using specific PCR primers for 
each CRH-R2 subtype, to identify the transcriptional start sites of the CRH-R2 gene. 
A schematic representation of the 5'RACE strategy is shown in Figure 8.1. 
2ß la 2ß1b 2y 1 2a 1 
(1) 2A -2A (2) 1A (1)1A "*-1A -2A 
2 2A 
10 kb 2,57 k4 kb first 
common 
exon 
Figure 8.1 A schematic representation of 5'RACE strategy 
The CRH-R2cc, 20, and 2y alternative exons are represented by solid boxes. 
The figure illustrates diagrammatically the approximate locations of 
oligonucleotides used as primers for 5'RACE. CRH-R2a: IA is first round PCR 
specific primer. 2A is second round PCR specific primer. The primers are 
located in CRH-R2a exon-I. CRH-R2T. 1A is first round PCR specific primer. 
2A is second round PCR specific primer. The primers are located in CRH-R2y 
155 
exon-I. CRH-R2(3 lb: (1)1A is first round PCR specific primer. (1)2A is second 
round PCR specific primer. CRH-R2ß la: (2)1A is first round PCR specific 
primer. (2)2A is second round PCR specific primer. The primers are located in 
CRH-R213 exon-Ib. Approximate locations of oligonucleotides are shown by 
arrows. 
8.2 Identification of the transcriptional start sites 
8.2.15'RACE with CRH-R2cc exon-I gene specific primers 
The 5'end of the human CRH-R2 cDNA was obtained by 5'RACE using the 
commercially prepared Marathon Ready cDNA system (Clontech) according to the 
manufacturer's recommendations. An uncloned library of the adoptor-ligated cDNA 
prepared from human hippocampus was used to amplify the 5'-end of the CRH-R 
cDNA. First round PCR was performed with a CRH-R2a cDNA specific primer 
(located in exon-I, + 55/80) and the anchor primer API supplied by clontech. A 
nested PCR was then performed with the clontech primer AP2 and a second cDNA 
specific primer (located in exon-I, + 35/61). The products of the second PCR reaction 
were purified from a 1.0% agarose gel using "QIAquick Gel Extraction kit (Qiagen)" 
ligated using T4 DNA ligase kit into the plasmid pGEM-T and the clones sequenced. 
Next we performed nested PCR of the cDNA using a second nested primer 
complementary to nucleotide + 36 to + 61 of the CRH-R2a cDNA sequence and an 
anchor primer. The amplification resulted in two DNA fragments of apparently 309 
bp and 536 bp (Figure 8.2). 
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Figure 8.2 Determination of transcriptional start sites using 5'RACE with CRH- 
R2a exon I primer 
5'RACE was used to identify the transcriptional start sites of the CRH-R2 gene. 
Two cDNA fragments were generated, which have the following sizes: 309 (A) 
and 536 (B) bp. Human hippocampus cDNA (Lane 1). Lane 2 are DNA size 
markers. 
The nucleotide sequence has been submitted to GenBank under accesion numer 
AF 361106. 
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The nucleic acid sequence of one fragment revealed that the 309 bp fragment (A) 
corresponded to the CRH-R2ß (196 bp) and CRH-R2a (113 bp) exon-I (Figure 8.3a). 
GCCACTACT 
GGCATGAGGGGTCCCTCAGGGCCCCCAGGCCTCCTCTACGTCCCACACCT 
CCTCCTCTGCCTGCTCTGCCTCCTCCCACCGCCGCTCCAATACGCAGCCG 
GGCAGAGCCAGATGCCCAAAGACCAGCCCCTGTGGGCACTTCTGGAGCAG 
TACTGCCACACCATCATGACCCTCACCAACCTCTCAGTCACGCCGGGCGC 
GCACTCCCACTCCCTCTCCGCACGCGGCTGCGGGACGCGATGGACGCGGC 
ACTGCTCCACAGCCTGCTGGAGGCCAACTGCAGCCTGGCGCTGGCTGAAG 
Second round PCR 2A primer 
Figure 8.3a. 5'RACE with CRH-R2a exon-I primers, the nucleotide sequence 
of the PCR fragment (A) contains CRH-R2ß and 2a exon-I. The ATG 
translation initiation codon (CRH-R2(3) is shown in bold. The primer used for 
5'RACE (second round PCR 2A primer) is underlined. 
The sequence of another fragment (B) contained CRH-R2ß (196 bp), CRH-R2y (227 
bp) and CRH-R2a (113 bp) exon-I (Figure 8.3b). DNA sequencing of both fragments 
revealed that the 5'end of the CRH-R2 transcript is located at 12 bp upstream of the 
CRH-R2(3 of the ATG translation start site. 
GCCACTACTGGCATGAGGGGTCCCTCAGGGCCCCCA 
GGCCTCCTCTACGTCCCACACCTCCTCCTCTGCCTGCTCTGCCTCCTCCC 
ACCGCCGCTCCAATACGCAGCCGGGCAGAGCCAGATGCCCAAAGACCAG 
CCCCTGTGGGCACTTCTGGAGCAGTACTGCCACACCATCATGACCCTCAC 
CAACCTCTCAGGCTGGTCTTGAATTCCTGTGCTCAAGCAATCTGCCTACCT 
TGGCTTCCCCAAGTGCTGAGATTATGGGTGTGAGCCACTGCACCTGGCCA 
AGAATCCGAATGGATTCAAAGATACCTTGAAATAATTCCTCAATGCAACA 
CACACACATATGCCAGGGTTGGTCAAATGGGAAGAGAGCCTTGGCCTGAA 
GACAGGGACCTGGGCTTTCCTCAGCTCTTCTGCCAAGTCACGCCGGGCGC 
158 
GCACTCCCACTCCCTCTCCGCACGCGGCTGCGGGACGCGATGGACGCGGC 
ACTGCTCCACAGCCTGCTGGAGGCCAACTGCAGCCTGGCGCTGGCTGAAG 
Second round PCR 2A primer 
Figure 8.3b 5'RACE with CRH-R2a exon-I primers, the nucleotide sequence of 
the PCR fragment (B) containing CRH-R2(3,2y, and 2a exon-I. The ATG 
translation initiation codon (CRH-R2(3) is shown in bold. The primer used for 
5'-RACE (second round PCR 2A primer) is underlined. 
The nucleotide sequence has been submitted to GenBank with accession AF 
361107. 
These results confirmed the genomic order of the alternative exons to be CRH-R2ß- 
2y-2a. The mature receptor subtype mRNA appears to be generated via 5' exon 
differential splicing. 
8.2.2 5'RACE with CRH-R2y exon-I gene specific primers 
5'RACE was performed using the Marathon cDNA amplification Kit (Clontech) with 
human hippocampus cDNA. The cDNA was initially amplified using the kit supplied 
anchor primer and the CRH-R2y specific primer. The reaction products were then 
further amplified using a supplied nested anchor primer and a nested CRH-R2y 
specific primer. Specific primers for the CRH-R2y 5'RACE have been described in 
Section 2.18. Two bands of 495 and 690 bp in length were demonstrated by gel 
electrophoretic analysis as shown in Figure. 8.4. The bands were eluted from the gel 
and subcloned into the pGEM-T vector. For each cDNA fragment, the nucleotide 
sequence of six independent clones was determined, which was the same for all 
clones. 
The nucleic acid sequence of two fragments (A and B) revealed that 488 bp fragment 
corresponded to the CRH-R2ß (280 bp) and CRH-R2y (208 bp) specific exon-I 
(Figure 8.4), another fragment corresponded to the CRH-R2(3 (280 bp), CRH-R2y 
(208 bp) specific exons and an extra 195 bp intronic sequence. 
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Figure 8.4 The arrangement of the 5'-end of the CRH-R2 cDNA (5'RACE with 
CRH-R2y primers). 5'RACE was used to identify the transcriptional start sites 
of the CRH-R2 gene. The CRH-R2a, 20, and 2y alternative exons are 
represented by solid boxes. (A)RT-PCR product containing CRH-R20,2y and 
2a exon-I. (B) RT-PCR product containing CRH-R2ß, 2y, 2a exon-I and 
insertion (195bp). (C) Lane 2,3, and 4 are different concentrations of human 
hippocampus cDNA. Lane 1 and 5 are DNA size markers. 
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The nucleic acid sequence of one short fragment revealed that 488 bp fragment 
corresponded to the CRH-R2ß (280 bp) and CRH-R2y (208 bp) specific exon-I, which 
is shown in Figure 8.5. 
GCCTCCCCTCCAGGGCCGGTGGGGTGGGGCTGGCCAGGG 
TGTGACCACCGTGCTGGGCAGCAGGCTCCAGTCCCTAACCCCCAGCCACT 
ACTGGCATGAGGGGTCCCTCAGGGCCCCCAGGCCTCCTCTACGTCCCACA 
CCTCCTCCTCTGCCTGCTCTGCCTCCTCCCACCGCCGCTCCAATACGCAG 
CCGGGCAGAGCCAGATGCCCAAAGACCAGCCCCTGTGGGCACTTCTGGAG 
CAGTACTGCCACACCATCATGACCCTCACCAACCTCTCAGGCTGGTCTTG 
AATTCCTGTGCTCAAGCAATCTGCCTACCTTGGCTTCCCCAAGTGCTGAG 
ATTATGGGTGTGAGCCACTGCACCTGGCCAAGAATCCGAATGGATTCAAA 
GATACCTTGAAATAATTCCTCAATGCAACACACACACATATGCCAGGGTT 
GGTCAAATGGGAAGAGAGCCTTGGCCTGAAGACAGGGACCTGGGCTTT 
Second round PCR 2A primer 
Figure 8.5 5'RACE with CRH-R2y exon-I gene specific primers 
The nucleotide sequence of the PCR fragment contains CRH-R20, and CRH- 
R2y exon-I. The ATG translation initiation codon (CRH-R2(3) is shown in bold. 
The primers used for 5'-RACE (second round PCR 2A primer) is underlined. 
The sequence of another long fragment contained CRH-R2ß (280 bp), CRH-R2y (208 
bp) specific exons and an extra 195 bp (55 amino acids) of intronic sequence. The 
cDNA inserted between the CRH-R213 and CRH-R2y exons, potentially, encodes a 
truncated protein as a result of an in-frame termination codon in intron I as illustrated 
in Figure 8.6. 
GCCTCCCCTCCAGGGCCGGGTGGGGTGGGGCTGGC 
CAGGGTGTGACCACCGTGCTGGGCAGCAGGCTCCAGTCCCTAACCCCCAG 
CCACTACTGGCATGAGGGGTCCCTCAGGGCCCCCAGGCCTCCTCTACGTC 
161 
CCACACCTCCTCCTCTGCCTGCTCTGCCTCCTCCCACCGCCGCTCCAATA 
CGCAGCCGGGCAGAGCCAGATGCCCAAAGACCAGCCCCTGTGGGCACTTC 
I 
TGGAGCAGTACTGCCACACCATCATGACCCTCACCAACCTCTCAGGCTCA 
GGCTTGCCACTGATAATGAAGGGCTTGGCTGGGAGGCCACTCCCCATTCC 
CAGCTCCCACGATGGAAGTCAGCTGGGCTGGCATTCAGGAGTCCAAGAAG 
GGGATGACCCCTCAGCTTTCCAACTCCAGGGAAACTGGCAGAAGGTGGTA 
I 
AACATTCTCTGGTTGCCGTGGCTACAGGTGTGACTTCCTGGCTGGTCTTG 
AATTCCTGTGCTCAAGCAATCTGCCTACCTTGGCTTCCCCAAGTGCTGAG 
ATTATGGGTGTGAGCCACTGCACCTGGCCAAGAATCCGAATGGATTCAAA 
GATACCTTGAAATAATTCCTCAATGCAACACACACACATATGCCAGGGTT 
GGTCAAATGGGAAGAGAGCCTTGGCCTGAAGACAGGGACCTGGGCTTT 
Second round PCR 2A primer 
Figure 8.6 5'RACE with CRH-R2y exon-I primers, the nucleotide sequence of 
the PCR fragment contains CRH-R20,2y exon-I and an extra 195 bp intronic 
sequence. The ATG translation initiation codon (CRH-R2ß) is shown in bold. 
The primers used for 5'-RACE (2A) is underlined. The positions at which the 
fragment is inserted are indicated by (1). 
The nucleotide sequence data have been deposited in GenBank under No AF 
361108. 
DNA sequence of both fragments revealed that the S'end of the CRH-R2 transcript is 
located at 97 bp upstream of the CRH-R2ß of the ATG translation initiation site. 
8.2.3 5'RACE with CRH-R2ß exon-I gene specific primers 
To study the intact untranslated cDNA 5'end of the human CRH-R2 receptor, a 
Primer 1A (located in CRH-R20 exon-I) and a nested primer 2A (located in CRH- 
R2(3 exon-I) were used for the first and second amplifications, respectively, plus an 
anchor primer APi supplied by Clontech. For approximate primer locations, see 
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Figure. 8.1. The resultant products were cloned into the pGEM-T cloning vector and 
the clones were sequenced. DNA sequencing of PCR products revealed that the 5'- 
end of the CRH-R2 transcript is a cytosine residue located at 201 bp upstream of the 
ATG translation start site. 
In order to confirm the 5'end cDNA region, we designed a new primer (located at 
121-146 bp upstream of the ATG translation initiation site) based on the sequences of 
the above clones. Of those fragments amplified with the new primer, the products 
were characterised by cloning, sequencing, and analysis, which are shown in Figure 
8.7. 
GCTGGGTAGC 
AGCAGCTGTCTGGGACCAGCTATAAATAACCTGGAGGCTGTGGGCTGTGG 
T 
GGCGGGGTCACCACTGCCCTGTGGAAGAAGTGGGTGGAGAATACCTCCTC 
(2) 2nd: 2A primer 
ATGCCCAAGGCCTTACCTTGGCCTCCCCTCCAGGGCCGGGTGGGGTGGGG 
CTGGCCAGGGTGTGACCACCGTGCTGGGCAGCAGGCTCCAGTCCCTAACC 
CCCAGCCACTACTGGCATGAGGGGTCCCTCAGGGCCCCCAGGCCTCCTCT 
ACGTCCCACACCTCCTCCTCTGCCTGCTCTGCCTCCTCCCACCGCCGCTC 
(2) 1 st: 1A. ( 1)2nd: 2A, prime 
CAATACGCAGCCGGGCAGAGCCAGATGCCCAAAGACCAGCCCCTGTGGG 
CACTTCTGGAGCAGTACTGCCACACCATCATGACCCTCACCAACCTCTCA 
(1) 1st: 1A primer 
Figure 8.7 5'RACE with CRH-R213 exon-I gene specific primers 
The nucleotide sequence of the PCR fragment contains CRH-R20 exon-I. The 
ATG translation initiation codon (CRH-R20) is shown in bold. The primers used 
for 5'-RACE (1A and 2A) are underlined. The arrow represents the transcription 
start site. 
Apart from a faint band supporting the finding that transcription initiation occurs at C 
(- 201), an additional strong band was visible, which corresponds to G (- 226). 
Analysis of the 5'RACE products is shown in an ethidium bromide-stained gel in 
Figure 8.8. 
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Figure 8.8 Determination of transcriptional start sites using 5'RACE with CRH- 
R2(3 exon I primer 
5'RACE was used to identify the transcriptional start sites of the CRH-R2 gene. 
Two cDNA fragments were generated, which have the following sizes: 103 and 
128 bp. cDNA prepared from human hippocampus cDNA (Lane 1). Lane 2 are 
DNA size markers. 
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The nucleotide sequence of the fragments revealed that the 5'end of the CRH-R2 
transcript are located at 201 and 226 bp upstream of the CRH-R2ß of the ATG 
translation start site. 
8.3 Alignment 5'RACE-derived cDNA and genomic DNA sequences 
Comparison of the genomic sequence (Homo Sapiens PAC clone DJ1143H19 from 
7p14-pl5, GeneBank No: A0004976) with cDNA obtained by RT-PCR and 5'RACE 
established the organisation of the 5'end of the CRH-R2 gene. The 5'end of the CRH- 
R2 gene is composed of 4 exons and 3 introns distributed over 18 kb. The 2ß exon-I is 
interrupted by a large intron (10659 bp) in the 5'end of the gene. The CRH-R20 lb 
and CRH-R2y exons possess good consensus splice junctions flanking an apparent 
2575 bp intron. The distance between the CRH-R2'y exon I and the CRH-R2a exon I 
is 4068 bp (see Chapter 7). Accurate estimates of the distance between each exon and 
the composition of each exon was based on a combination of Southern analysis, DNA 
sequencing and PCR amplification. Exon-intron junctions conform to the consensus 
sequences, with exons flanked by AG and GT at 5' and 3' ends, respectively. The 
5'end of the CRH-R2 cDNA sequence corresponded exactly to the genomic DNA 
sequence (Figure 8.9). 
Genomic GCAGGCTGGATGGAGAGCATAGCCCCTTGGCTGGCTGGGTAGCAGCAGCT T 
5'-RACE GCTGGGTAGCAGCAGCT 
Genomic GTCTGGGACCAGCTATAAATAACCTGGAGGCTGTGGGCTGTGGGGCGGGG 
5'-RACE GTCTGGGACCAGCTATAAATAACCTGGAGGCTGTGGGCTGTGGGGCGGGG 
Genomic TCACCACTGCCCTGTGGAAGAAGTGGGTGGAGAATACCTCCTCATGCCCA 
5'-RACE TCACCACTGCCCTGTGGAAGAAGTGGGTGGAGAATACCTCCTCATGCCCA 
Genomic AGGCCTTACCTTGGCCTCCCCTCCAGGGCCGGGTGGGGTGGGGCTGGCCA 20 
5'-RACE AGGCCTTACCTTGGCCTCCCCTCCAGGGCCGGGTGGGGTGGGGCTGGCCA 
Genomic GGGTGTGACCACCGTGCTGGGCAGCAGGCTCCAGTCCCTAACCCCCAGCC 
5'-RACE GGGTGTGACCACCGTGCTGGGCAGCAGGCTCCAGTCCCTAACCCCCAGCC 
+1 
Genomic ACTACTGGCATGAGGGGTCCCTCAGGGCCCCCAGGCCTCCTCTACGTCCC 
5'-RACE ACTACTGGCATGAGGGGTCCCTCAGGGCCCCCAGGCCTCCTCTACGTCCC 
u 
Genomic ACACCTCCTCCTCTGCCTGCTCTGCCTCCTCCCACCGCCGCTCCAATACG 
5'-RACE ACACCTCCTCCTCTGCCTGCTCTGCCTCCTCCCACCGCCGCTCCAATACG 
Genomic CAGCCGGGCAGAGCCAGATGCCCAAAGACCAGCCCCTGTGGGCACTTCTG 
5'-RACE CAGCCGGGCAGAGCCAGATGCCCAAAGACCAGCCCCTGTGGGCACTTCTG 
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Genomic GAGCAGTACTGCCACACCATCATGACCCTCACCAACCTCTCAGGCTGGTCT I 
5'-RACE GAGCAGTACTGCCACACCATCATGACCCTCACCAACCTCTCAGGCTGGTC 
Genomic TTGAATTCCTGTGCTCAAGCAATCTGCCTACCTTGGCTTCCCCAAGTGCT 
5'-RACE TTGAATTCCTGTGCTCAAGCAATCTGCCTACCTTGGCTTCCCCAAGTGCT 2y 
Genomic GAGATTATGGGTGTGAGCCACTGCACCTGGCCAAGAATCCGAATGGATTC 
5'-RACE GAGATTATGGGTGTGAGCCACTGCACCTGGCCAAGAATCCGAATGGATTC 
Genomic AAAGATACCTTGAAATAATTCCTCAATGCAACACACACACATATGCCAGG 
5'-RACE AAAGATACCTTGAAATAATTCCTCAATGCAACACACACACATATGCCAGG 
Genomic GTTGGTCAAATGGGAAGAGAGCCTTGGCCTGAAGACAGGGACCTGGGCTT 
5'-RACE GTTGGTCAAATGGGAAGAGAGCCTTGGCCTGAAGACAGGGACCTGGGCTT 
u 
Genomic TCCTCAGCTCTTCTGCCAAGTCACGCCGGGCGCGCACTCCCACTCCCTCTL T 
5'-RACE TCCTCAGCTCTTCTGCCAAGTCACGCCGGGCGCGCACTCCCACTCCCTCT 
Genomic CCGCACGCGGCTGCGGGACGCGATGGACGCGGCACTGCTCCACAGCCTGC 
5'-RACE CCGCACGCGGCTGCGGGACGCGATGGACGCGGCACTGCTCCACAGCCTGC 2a 
Genomic TGGAGGCCAACTGCAGCCTGGCGCTGGCTGAAGAGCTGCTCTTGGACGGC 
5'-RACE TGGAGGCCAACTGCAGCCTGGCGCTGGCTGAAGAGCTGCTCTTGGACGGC 
Genomic TGGGGGCCACCCCTGGACCCGAGG 
5'-RACE TGGGGGCCACCCCTGGACCCGAGG y 
Figure 8.9 Nucleotide sequence of human CRH-R2 5'RACE-derived cDNA and 
comparison to the corresponding genomic DNA sequence. The 5'UTR of the 
5'RACE begins with nt denoted as -226, -201, -97, and -12, upstream from the 
A of the ATG translation initiation codon in the CRH-R20 exon I, which is 
denoted as nt +1. The bold letters represent the transcription start site. The 
underlined sequence corresponds to the previously determined sequence of the 
CRH-R20,2y and 2a cDNA (Valdenaire et al., 1997, Kostich et al., 1998, Liaw 
et al., 1996). (u) indicates intron positions. 
8.4 Discussion 
5'RACE with a CRH-R2a exon I primer was used to amplify the 5'-end cDNA for 
sequencing. The nucleic acid sequence of one fragment revealed that 309 bp fragment 
corresponded to the CRH-R20 (196 bp) and CRH-R2a (113 bp) exon-I. The PCR 
product was obtained with a splicing pattern of 20 to 2a (skipping 27). The sequence 
of another fragment contains CRH-R2ß (196 bp), CRH-R2y (227 bp) and CRH-R2a 
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(113 bp) exon-I. The fragment contains another splicing pattern: 20 to 2y to 2a. DNA 
sequencing of both fragments revealed that the 5'end of the CRH-R2 transcript is 
located at 12 bp upstream of the CRH-R2(3 of the ATG translation initiation site. On 
the other hand, 5'RACE analysis extended the previously known exon I sequence of 
the human CRH-R2a, and established that the 5'-untranslated region of CRH-R2a 
mRNA in human hippocampus is 52 nt. The 5'RACE cDNA of CRH-R2a sequence 
corresponded exactly to the genomic DNA sequence. 
5'RACE was performed using the CRH-R2y cDNA specific primer with human 
hippocampus cDNA. For each cDNA fragment, the nucleotide sequence of six 
independent clones was determined, which was the same for all clones. DNA 
sequencing of both fragments revealed that the 5'end of the CRH-R2 transcript is 
located at 97 bp upstream of the CRH-R2 f of the ATG translation initiation site. The 
nucleic acid sequence of one fragment revealed that 488 bp fragment corresponded to 
the CRH-R2(3 (280 bp) and CRH-R2y (208 bp) specific exon-I. The sequence of 
another fragment contains CRH-R2(3 (280 bp), CRH-R2y (208 bp) specific exons and 
an extra 195 bp intronic sequence. Alternative splicing in the N-terminus of the CRH- 
R2 can generate an extra 195 bp. The cDNA inserted at between the CRH-R20 lb and 
CRH-R2y exons, potentially encodes a truncated protein as a result of an in-frame 
termination condon in intron I. The potential physiological significance of such a 
truncated receptor is not currently clear. The corresponding mRNA cannot be translated 
into functional receptor, since this sequence contains in-frame termination codon. Moore 
et al., 1995 have identified a third isoform of the human calcitonin receptor, which 
can be generated by alternative splicing in the first intracellular loop. The presence of 
this alternatively spliced exon would result in the addition of six amino acids at the 
end of the first transmembrane domain, followed by the premature termination of 
translation (Moore et al.,. 1995). Recently, Miyata et al., have identified a novel 
isoform of the CRH receptor from the rat amygdala cDNA library. One of them 
contains intron 6, and the other contains both intron 6 and 7 of CRH-R2a genomic 
DNA. These two clones encode an identical truncated protein, which is composed of 
236 amino acids, because an in-frame stop codon is located in intron 6 (Miyata et al., 
1999). The above described method has also been used for myometrial tissues, but the 
extra 195 bp intronic sequence has not been detected in human myometrium. 
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The sequence of the complete 5'-UTR of the human CRH-R2ß mRNA is not known. 
The nucleotide sequence previously determined for the human CRH-R2ß cDNA 
included a sequence of 30 nt flanking the ATG translation start site (Valdenaire et al., 
1997). We have extended this 5'-UTR using 5'RACE. The long 5'RACE derived 
cDNA clones included the previously reported 30 nt 5'-UTR sequence upstream of 
the CRH-R2ß open reading frame as well as an additional 196 nt of 5'-UTR 
sequence. The short 5'RACE derived cDNA clones included the previously reported 
30 nt 5'-UTR sequence upstream of the CRH-R2ß open reading frame as well as an 
additional 171 nt of 5'-UTR sequence. Therefore, the 5'-UTR of the human CRH- 
R2 f cDNA are 226 and 201 nt. 
Individual genes can give rise to multiple size of transcripts and hence to multiple 
5'RACE fragments via at least two mechanisms: (1) Alternative splicing can cause 
multiple products in 5'RACE. (2) Use of different transcription start sites causes 
multiple 5'RACE products. The CRH-R2 gene is most likely due to both reasons. We 
have determined the structure of the 5'end of the CRH-R2 gene that is organised with 
the 5' alternative exons. When 5'RACE with CRH-R2(3 and CRH-R2ct primers were 
used to identify the transcriptional start sites of the CRH-R2 gene, each two different 
cDNA fragments were generated. 
In summary, the 5'RACE analysis identified four transcriptional start sites located at 
226,201,97, and 12 bp upstream of the translation initiation site of the CRH-R2J3. In 
TATA-less genes, the mechanism of transcriptional initiation and its regulation are 
not uniformly established. In general, GC-rich domains and initiator elements have 
been proposed to act co-operatively to direct gene transcription (Smale and Baltimore, 
1989). GC-rich promoters, found primarily in housekeeping genes, usually contain 
several transcription start sites spread over a fairly large region and several potential 
binding sites for the transcription factor Spl. The CRH-R2 prompter most likely 
belongs to this class. Other TATA-less promoters are not GC-rich and initiate 
transcription at only one or a few tightly clustered start sites (Sehgal et al., 1988). 
Many of these latter types of promoters, including the promoter for the terminal 
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deoxynucleotidyl transferase gene, are regulated during differentiation or 
development. 
On the other hand, it is probable that there is a single start site at 226 bp. It is more 
likely that the 12,97, and 201 bp are incomplete transcripts. There are several 
possible sources of incomplete fragments, which are generated from correctly primed 
sites. Premature termination of first strand cDNA synthesis caused by pausing of 
reverse transcription generally causes multiple 5'RACE products. This is a common 
problem with larger RNAs, and it is a difficult problem to overcome, since it is due to 
an intrinsic limitation of reverse transcription. Difficulty on amplifying certain 
"difficult" genes can cause multiple products in 5'RACE, often a result of high GC 
contents. The promoter of the human CRH-R2 gene is a GC-rich (61%) domain. 
Further studies will be required to confirm the transcriptional start sites of the CRH- 
R2 gene. The 5'RACE method can be employed using other tissues, as well as using 
S1 nuclease mapping, primer extension, and RNase protection assays methods. 
The CRH-R2a, 2y of 5'RACE derived cDNA clones included the 5'-Untranslated 
region (UTR) upstream of the CRH-R2ß open reading frame. The results suggest that 
there may be a single promoter regulating the expression of all (2a, 20, and 2y) 
subtypes. The promoter of CRH-R2 lies upstream of 5'-end of the CRH-R20. 
Alternative splicing is a widespread mechanism for producing variant forms of 
proteins from a single gene. We have determined the structure of the 5'end of the 
CRH-R2 gene which is organised with the 5' alternative exons arranged as CRH-R2(i- 
2y-2a. Structural comparison of these CRH-R2 subtypes showed that they differ only 
in their N terminus; the 34 amino acids N terminal to CRH-R2a are replaced by a 
61 amino acid sequence to form the CRH-R2(3 or a 20 amino acid sequence to form 
the CRH-R2y. The mature CRH-R2 subtypes mRNA appears to be generated via 5' 
exon differential splicing. The results conform that CRH-R2 exists in the three splice 
variant forms. 
Comparison of the genomic sequence with cDNA obtained by RT-PCR and 5'RACE 
established the organisation of the 5'end of the CRH-R2 gene. The 5'end of the CRH- 
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R2 (20,2y, and 2a exon-1) gene is composed of 4 exons and 3 introns distributed 
over 18 kb. The 20 exon-1 is interrupted by a large intron (10659 bp) in the 5'end of 
CRH-R2 gene. The CRH-R2(3 and CRH-R2y exons possess good consensus splice 
junctions flanking an apparent 2575 bp intron. The distance between the CRH-R2y- 
exon and the CRH-R2a-exon is 4068 bp (see Chapter 7). Accurate estimates of the 
distance between each exon and the composition of each exon was based on a 
combination of Southern analysis, DNA sequencing and PCR amplification. The 
5'end of the CRH-R2 (2(3,2y, and 2a exon-I) cDNA sequence corresponded exactly 
to the genomic DNA sequence. 
The CRH-R gene exhibits substantial similarity to the calcitonin/PTH receptor family 
that is characterised by the presence of introns within its transmembrane/cytoplasmic 
module, highly conserved cysteines in its extracellular domain, and a highly 
conserved first intracellular loop (Kong et al., 1994). Intron-exon junctions conform 
to the consensus sequences, with exons flanked by AG and GT at 5' and 3' ends, 
respectively. Elucidation of the gene structure of the porcine calcitonin receptor in 
1994 (Zolnierowicz et al., 1994) first revealed the unique intron-exon organisation of 
a receptor in the group of G protein-coupled receptors. The intron-exon organisation 
of the 5'end of the CRH-R1 (see Chapter 5) and CRH-R2 gene is strikingly similar to 
that of genes encoding other members of the group II family of G protein-coupled 
receptors (i. e. the secretin/calcitonin/PTH receptor family). 
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Chapter 9 Construction of expression vector for transient 
transfection of eukaryotic cells 
9.1 Introduction 
A variety of reporter gene assay systems are available to investigate transcriptional 
gene control. Regions of the distal and proximal promoter that are important for basal 
or regulated expression can be deduced by deleting or mutating putative control 
regions and observing the effect of such deletions on reporter gene activity. To 
determine whether a DNA sequence is both necessary and sufficient for either cell- 
specific or regulated expression, it can be fused in single or multiple copies upstream 
of a heterologous promoter; and the activity of this promoter can be measured using a 
reporter gene assay system. The reporter gene constructs can also be used to 
investigate protein/DNA interactions which regulate gene expression. 
A standard first approach is to perform a series of deletion mutants, generally making 
progressive truncations from the 5' end of the promoter. Such mutations can be made 
easily using convenient restriction sites, by digesting with a progressive nuclease such 
as ExoIII nuclease, or by using PCR to amplify different fragments of the promoter. 
Although this technique can reveal promoter regions which are important for 
activation or repression, it should be recognised that removal of elements may 
preclude subsequent studies of interactions between different regions of the promoter. 
A second and often subsequent strategy is to perform block mutations or point 
mutations in specific regions of the promoter. Frequently, these regions are identified 
based upon the earlier deletion studies or based upon candidate sites identified by 
computer or by inspection. Block type mutants can be inserted using "linker-scanning 
mutagenesis" or by PCR. Point mutations are generally introduced using various site- 
directed mutagenesis protocols. 
Reporter gene systems are designed for functional testing of eukaryotic transcriptional 
regulatory sequences. These systems are mammalian plasmid expression vectors 
containing several components. They include prokaryotic sequences that permit 
propagation and growth in E. coli, antibiotic resistance to facilitate recombinant 
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plasmid selection and a number of unique restriction endonuclease sites for insertion 
of the DNA sequences of interest. The reporter gene transcriptional unit comprises the 
reporter gene sequences, which are responsible for driving its expression, intron 
sequences and mRNA polyadenylation signals. The most commonly used reporter 
genes are those encoding enzymes such as firefly luciferase and chloramphenicol 
acetyl transferase (CAT). The latter has low background activity in mammalian cells. 
Eukaryotic cells never express this enzyme, but the CAT gene can be expressed from 
eukaryotic promoters (Gorman et al., 1982). 
The ß-galactosidase enzyme is another bacterial product that can be easily measured. 
Although less sensitive than luciferase or CAT, it has the additional advantage that it 
can be detected easily in histologic samples. Thus, (3-galactosidase is used frequently 
in transgenic studies. Recently, the green fluorescent protein, derived from jellyfish, 
has provided anther useful tool for examining expression in transfected cells or in 
various tissues. It has the advantage of spontaneous fluorescence, even allowing 
studies in living cells and animals. 
The characterisation of transcriptional regulatory sequences at the 5'flanking region 
of the CRH-R2 gene included functional studies using CAT reporter gene systems. 
The general scheme for such studies involved modification of native CRH-R2 
promoter sequences by deletion mutations. Reporter gene constructs were transiently 
transfected into HEK 293 cells for functional studies. 
9.2 pCAT3-Basic constructs 
9.2.1 Preparation of the CRH-R2 promoter cloning fragments 
The pCAT 3-Basic plasmid (Promega) was used as the cloning vector. This vector 
lacks eukaryotic promoter and enhancer sequences. Expression of CAT activity in 
cells transfected with this plasmid depends upon the insertion of a functional promoter 
upstream of the CAT gene. Circular map showing the multiple cloning sites is 
provided in Figure 9.1. 
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Figure 9.1 pCAT3-Basic vector circle map and sequence reference points. 
Sequence reference points: 
a. SV40 late poly (A) region 1001-1222 
b. CAT gene 31 1-967 
c. upstream poly (A) region 3887-4040 
d. Multiple cloning site (Kpnl - Bgl II) 1-58 
e. RV primer 3 binding site 3989-4008 
f. RV primer 4 binding site 1309-1290 
g. f3-lactamase gene (Amp') 3169-2312 
h. fl origin 3302-3756 
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A CAT reporter system (Promega) was used with the enzyme-linked immunosorbert 
assay (ELISA) method for monitoring CAT enzyme activity in transiently transfected 
cells (see Chapter 10). 
The polymerase chain reaction was employed to generate a 1457 bp fragment (named 
PF) of the DNA corresponding to the 5'proximal region, the exon I of the CRH-R2 
gene. The fragment was subcloned and sequenced. Sequencing analysis confirmed the 
identity of the amplified DNA. 
The PCR fragments spanning different regions of promoter were cloned upstream of 
the CAT reporter gene in the promega pCAT3-Basic vector. These inserts were 
generated from genomic DNA using PF as a template and PCR reaction with a high 
fidelity Advantage 2 Polymerase (Clontech). The oligonucleotides used for this PCR 
have a restriction site 5' to facilitate cloning into the pCAT3- Basic vector polylinker. 
For constructs derived from the putative promoter region of CRH-R2, a common 3' 
reverse oligonucleotide was used in combination with different 5' oligonucletides (see 
Table 9.1). 
Table 9.1 
Primers for generating deletion constructs 
Nucleotide number 
(5' to 3') 
Sequence Construt name 
-1393 to -1371 CCGGTACCGACCTGTGAGATTTCACAGGAG P1 
-1035 to 1014 CCGGTACCGAGGCTCTGGAAGAACAGACC P2 
-553 to --532 CCGGTACCACCTACCCACAGTACAGTATC P3 
Kpnl 
(5' to 3') CGGCTCGAGAGGTGTGGGACGTAGAGGAGG 
47 to 26 Xhol 
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The PCR amplifications were carried out in a total volume of 50µl of 40 mM Tricine- 
KoH pH 9.2,15 mm KOAc, 3.5 Mg (OAC)2,0.2 mM each dNTPs, 0.5 µ. M of each 
upstream and downstream primer and Advantage 2 Polymerase (Clontech). After an 
initial denaturation at 95° C for 2 minutes, 5 cycles of PCR were carried out, followed 
by denaturation at 95°C for 30 second and annealing/extension at 72°C for 1.5 
minutes. This was followed by 5 cycles of PCR involving denaturation at 95°C for 30 
second and annealing/extension at 70°C for 1.5minutes. A further 30 cycles of PCR 
was carried out with denaturation at 95°C for 30 second, annealing/extension at 68°C 
for 1.5 minutes. The final extension was at 72°C for 3 minutes. 
The PCR products were electrophoresed on a 1.0% agarose gel as shown in Figure 9.2 
and purified from the gel with a gel extraction kit (Qiagen). The PCR products were 
sequenced to confirm their identity by the dideoxy chain termination method using an 
Applied Biosystems 373A automated DNA sequencer. The PCR fragments were 
digested with Kpn I and Xho I and ligated into the equivalent site of the pCAT3-Basic 
vector. 
9.2.2 Preparation of the cloning vector pCAT3-Basic 
The original vector pCAT3-Basic was subjected to a double digest with the restriction 
endonucleases Kpn I and Xho I and electrophoresed on a 1.0% agarose gel and 
purified from the gel with a gel extraction kit (Qiagen). The fragment pCAT3-basic 
(Kpn I/Xho I) was used to prepare the expression vectors P1, P2, and P3. 
9.3 Ligated into equivalent site of the pCAT3-Basic 
Each double digest of PCR fragment was incubated with 0.1µg pCAT3-Basic plasmid 
(Kpn I and Xho I) at approximately equimolar quantity and ligated under the catalysis 
of T4 DNA ligase. Ligation mixtures were transformed into competent DH5a cells 
and recombinants were selected overnight on agar plates containing ampicillin. 
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Figure 9.2 Amplified different fragments of the promoter region using P('R 
Lane I is a DNA marker. Lane 2 shows PCR amplification of a 6(X) hp fragment 
(P3), which contained 553 bp upstream of the translation initiation site of the 
CRH-R2(3 and an 47 bp downstream sequence. Lane 3 shows PCR amplification 
of a 1082 bp fragment (P2), which contained 1035 bp upstream of the translation 
initiation site of the CRH-R2ß and an 47 bp downstream sequence. Lane 4 shows 
PCR amplification of a 1440 bp fragment (PI), which contained 1393 hp 
upstream of the translation initiation site of the CRH-R2ß and an 47 hp 
downstream sequence. 
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Figure 9.3 Analysis result of plsmid DNA for the insert by restriction enzyme 
digestion using Kpn I and Xho I. 
Two bands were visualised on an ethidium bromide stained agarosc gel that 
corresponds to the pCAT3-Basic plasmid (4047 bp) and the insert. Lane I and 2 
show P3 fragment. Lane 3 and 4 show P2 fragment. Lane 5 and 6 show PI 
fragment. Lane 7 are DNA markers. 
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Plasmid DNA was isolated from overnight culture derived from the single colonies on 
the agar plates. Plasmid DNA was digested using Kpn I and Xho I enzymes. Two 
bands were visualised on an ethidium bromide stained agarose gel corresponding to 
the plasmid and the insert (Figure 9.3). The inserts were sequenced using an 
automated DNA sequencer. 
All DNA plasmid used in transfections was purified using QIAGEN plasmid Maxi kit 
and analysed by agarose gel electrophoresis to verify plasmid integrity. Plasmid DNA 
was determined using an UV spectrophotometer (260 and 280 nM). 
9.4 Discussion 
For the purposes of the functional study of the 5'-flanking region of the CRH-R2 
gene, CAT expression vector containing parts of the CRH-R2 proximal promoter was 
constructed. A set of deletion constructs was generated. The deletion constructs were 
cloned just from 5' to the CAT cDNA and the length (upstream of the translation 
initiation site) of the CRH-R2 5' sequence inserted are 1393 bp (P1), 1035 bp (P2), 
and 553 bp (P3). 
One functional type of cloning vector, pCAT3-Basic, was employed to perform 
cloning and to demonstrate the presence of CRH-R2 regulatory sequences which are 
capable of initiating constitutive transcription. At the same time, we also studied the 
transcriptional effects due to additional regulatory sequences present in the inserted 
DNA fragment. The above described CAT expression vector have been constructed 
and can be used to study how the putative regulatory elements are responsible for the 
transcriptional induction of the CRH-R2 gene which are particularly stimulated using 
the treatments like adding CRH, forskolin, phorbol-myristate-acetate, glucocorticoids 
or estrogen. 
The functional investigation of CRH-R2 gene regulatory sequences has been carried 
out and reported in this chapter. The CAT reporter gene vector is also constructed for 
the purpose of determining the transcriptional activity of this promoter, which will be 
reported in Chapter 10. 
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Chapter 10 CAT reporter gene analysis of regulation of the CRH-R2 
gene 
10.1 Introduction 
The study of eukaryotic gene regulation and expression has been advanced by 
technology which allows the introduction of nucleic acids into eukaryotic cells. 
Physical and chemical methods are used to introduce nucleic acids in a process 
referred to as transfection. The most widely used procedure is the calcium phosphate- 
DNA precipitation technique. This procedure is inexpensive, efficiently transfects 
most transformed monolayer cell lines, and is relatively reproducible. The major 
technical problem is the exquisite sensitivity to pH. Another widely used protocol 
involves the use of DEAE-dextran which is particularly useful for cells that tend to 
grow in suspension. Recently, lipid-mediated or liposome-mediated transfection 
protocols have gained popularity. These techniques are highly efficient for most 
cultured mammalian cells. Although commercial sources for these reagents can be 
expensive, it is possible to prepare effective lipid mixtures from relatively inexpensive 
reagents (Rgse et al., 1991). Electroporation can be used to introduce DNA into most 
cell types, including primary cell cultures. This procedure uses an electric current to 
transiently open cell membranes and allows transfering of DNA into the cell. It 
requires an electroporation device and the cuvettes are relatively expensive. The 
electroporation conditions (voltage, capacitance) and other parameters for buffer and 
DNA concentration need to be optimised for each cell type. A number of viral vectors 
have also been developed for introducing genes into cells. The replication-deficient 
adenovirus can be used efficiently in a wide variety of cell types. Retroviruses are 
particularly useful for integrating DNA into cell lines in a stable manner. Finally, 
DNA can also be microinjected into cells. Although it is useful for certain special 
applications, in practical terms, only a limited number of cells can be microinjected at 
any one time. We therefore chose to use a liposome-mediated transfection method. 
Several key issues should be considered in the selection of a cell line for transfection 
experiments. For many genes, expression is limited to a restricted number of tissues 
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and cell types. Thus, it is critical to choose cell types that normally express the gene if 
one is to correctly identify critical regulatory elements and their cognate transcription 
factors. For this reason, cell lines should be screened to ascertain whether they 
normally express the gene of interest. Another issue concerns how easily the cells can 
be transfected and how stable the cells are in culture. 
To test the promoter activity of the 5'-flanking region of the CRH-R2 gene, two cell 
types (Myometrial primary cell cultures and HEK-293 cells) were employed. 
10.2 Transfection of HEK-293 and Myometrial cell with Lipofectamine reagent 
HEK 293 and Myometrial cells were maintained in Dulbecco's modified Eagle 
medium (DMEM) supplemented with 10% fetal bovine serum (Gibco-BRL), 
penicillin (200Units/ml), streptomycin (200mg/ml) and incubated in 5% CO2 at 37°C. 
Confluent cell flasks were trypsinized, the number of cells were counted and in six- 
well plates (Nunclon) were seeded with 3x 105 cell per well. Cells were grown in 2 
ml of Dulbecos modified Eagle medium, 10% fatal bovine serum, penicillin 
(200Units/ml), streptomycin (200mg/ml) and incubated in 5% CO2 at 37°C for 24-48 
hours before the tranfection. All DNA plasmid used in transfection were purified 
using QIAGEN plasmid Maxi Kit and were analysed by agarose gel electrophoresis to 
verify plasmid integrity. The pCAT3-Basic-less plasmid was routinely in all 
transfection experiments as negative controls. 
Liposome-mediated transfection was performed using Lipofectamine Reagent (Life 
Technologies) according to the method of Feigner et al. For each deletion construct, 
1.0-1.5 tg test DNA was diluted into 100µl of OPTI-MEM serum-free medium 
(solution A). PLUS Reagent was added to the DNA in solution A and incubated at 
room temperature for 15 minutes. This solution A was then mixed with lipofectamine 
(6µµ1 of lipofectamine in l00µ1 OPTI-MEM serum-free medium solution B). The 
solutions were combined and incubated for 30 minutes at room temperature. Then 
800µl of serum-free medium were added on, and the solution was then carefully 
dripped onto the cells, which had been washed once with serum-free medium. The 
180 
cells were incubated for 3 hours before the transfection solution was removed and 
replaced by serum-containing medium. After an incubation period of 48 hours, the 
cells were harvested. 
10.3 Determination of CAT activity 
10.3.1 Preparation of cell extracts 
The wells containing monolayers of transiently transfected cells were washed three 
times with 3m1 of ice cold PBS and the cells were removed with a fine-tipped Pasteur 
pipette. 340µ1 of lysis buffer (Boehringer mannheim) was then added and the cells 
were allowed to stand for 30 minutes at room temperature. The cells were transferred 
into microcentrifuge tubes and centrifuged at 13,000 rpm for 10 minutes at 4°C. The 
supernatants were transferred into microcentrifuge tubes. Cell lysis was ensured by 
three cycles of freeze thawing (2 minutes in ethanol/dry ice then 1 minute in 37°C 
water bath). The cell debris was subsequently removed by centrifugation at 13,000 
rpm for 10 minutes. The cell extracts were transferred into clean tubes and stored at - 
70°C until use. 
10.3.2 CAT enzyme-linked immunosorbent assay 
The CAT activity of cytoplasmic extracts from cells transiently transfected with CAT 
expression vectors was measured by the enzyme-linked immunosorbent assay 
(ELISA) method. 
The CAT activity was measured using a CAT ELISA kit (Boehringer, Mannheim) 
according to the manufacturer's instruction. The only modification was that lOµ1 of 
the cell extract was added into the well instead of the recommended (2001i1/well). 
Background CAT expression from the vector was determined by transfection of the 
empty pCAT3-Basic plasmid. 
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10.4 Transient expression analysis of the 5'-flanking region 
To further analyse the 5'-flanking region of the CRH-R2 gene for constitutive 
promoter activity in HEK 293 cells, various lengths of 5'-flanking regions created by 
PCR were placed onto upstream of the CAT reporter gene (Figure. 10.1). Only 
background activity was obtained with the promoterless pCAT3-basic CAT vector. 
To determine whether the CRH-R2 5'-flanking region can direct cell expression, the 
proximal 553 bp, 1035 bp and 1393 bp upstream of the translation initiation site of the 
CRH-R2(3 were inserted into a transient expression vector, pCAT3-Basic. The pCAT- 
Basic vector contains CAT as the reporter gene, and the resulting plasmids (-553 
CRH-R2/CAT, -1035 CRH-R2/CAT and -1393 CRH-R2/CAT) were transiently 
transfected into HEK 293 and myometrial primary cell culture. Gene transfer studies 
were carried out by liposome-mediated transfection and CAT activity was measured 
by the enzyme-linked immunosorbent assay (ELISA) method. 
Our studies showed that 1393bp (P1), 1035bp (P2), and 553bp (P3) of the CRH-R2 
promoter directed high levels of CAT expression in HEK 293 cells as compared with 
the promoterless pCAT3-basic CAT vector. In contrast, we observed no significant 
activity of any of these constructs in the myometrial cell cultures. 
A 72-fold increase in activity was observed with the construct containing 553 bp (p3) 
of 5'-flanking region (Figure. 10.2). The construct containing 1035 bp (p2) produced 
a 74-fold increase in activity compared with the promoterless control. Another 67-fold 
increase in activity was observed with the construct containing 1393 bp (P1) of 5'- 
flanking region. These results suggest that the regions between + 47 and -553, -553 
and -1035 contain important positive regulators of CRH-R expression in HEK 293 
cells. The negative control, pCAT3-Basic without any 5'-flanking region, caused very 
low CAT activity. 
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Figure 10.1 The deletion constructs of the CRH-R2 5'-flanking region 
The schematic diagrams represent a series of CRH-R2 promoter-CAT gene 
plasmids with variable 5'-end (from -1393 to-553) and the same 3'-end (+47). 
Each construct was transiently transfected into HEK 293 cells. The transcription 
factor binding elements are labelled above. Their relative nucleotide positions to 
ATG are indicated blow. ATG translation initiation codon in exon I, is denoted 
by nt +1. The arrow indicates the transcription initiation sites. 
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Figure 10.2 Deletion analysis of human CRH-R2 promoter activity. 
The average fold increase for each construct is indicated to the right of each bar. 
CAT activities of the test samples were referenced to those from promoterless 
pCAT3-Basic. Data are the means ± SEM of at least three independent 
experiments performed in triplicate. 
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10.5 Discussion 
The inspection of the 1.3 kb 5'-flanking promoter region revealed a broad selection of 
putative binding sites for transcription factors exhibiting a high degree of similarity to 
described consensus sequences. Such a computer-based search may be helpful as the 
first approach for detecting elements that are involved in transcriptional control. 
An examination of the CRH-R2 promoter and 5'-flanking sequences with a computer 
program to predict consensus DNA/ protein binding sites (Quandt, et al., 1995) 
revealed the presence of putative binding sites for transcription factors known to 
interact with the promoters of the regulated genes (Figure 10). These include one 
putative binding site for the enchancer factor AP-1 (activator protein-1) at -473 bp 
and one putative binding site for the enchancer factor AP-2 (activator protein-2) at - 
106 bp. Two GC boxes (Spl sites) characteristic for the promoters of housekeeping 
genes were found at -164 and -997 bp. One binding site for tissue specific factor 
MyoD was identified at -1079 bp, one putative binding site for Zinc finger 
transcription for GATA-1 was found at -653 bp and one CCAAT/enhancer binding 
protein (C/EBP) was found at -704 bp. The CRH-R2 promoter region up to -1393 bp 
contains sites for GATAs, HSF2, deltaEF1, Ap4, P300, Oct-1 and c-Myb. 
In addition, the promoter region contains consensus motifs corresponding to inducible 
promoter elements that are known to bind transcription factors induced by exogenous 
stimuli. These include binding sites for the transcription factors CRE-BP (cAMP- 
response element (CRE)-binding protein) at bp -1238, GRE at -665, SF-1 at -1204 
bp. 
The pCAT-basic promoter-less plasmid containing the chloramphenical 
acetyltransferase (CAT) gene was used for construction of reporter gene plasmid to 
analyse the CRH-R2 gene promoter function. An analysis of promoter and CAT 
constructs containing 5'-flanking fragments of different length up to -1393 bp by cell 
transfection revealed the first insight into the functionality and architecture of the 
promoter of the CRH-R2 gene. In HEK 293 cells, the constructs -553 bp (P3) and - 
1035 bp (P2) showed an approximately 70-fold increase in promoter activity 
compared to promoterless pCAT3-Basic. These results show that several potential 
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positive regulatory elements (possibly two Spl and one API) are located between - 
164 and -977 nt. This region contains two Sp-1 consensus binding sites, which may be 
critical for reporter gene expression. Sp-1 binding sites are known to be promoter- 
specific activation sequences of RNA polymerase II transcription. The construct - 
1393 bp (P1) showed approximately 10% diminished activity relative to P2 or P3, 
which possibly indicated that the sequence from -1035 to -1393 may contain the 
negative regulatory elements. In contrast, we observed no significant promoter 
activity of -553 CRH-R2/CAT, -1035 CRH-R2/CAT and -1393 CRH-R2/CAT in 
myometrial cells. The reason for that may be because of transfection problems. 
In addition, transfection of promoter deletion constructs led to the identification of 
stretches within the promoter necessary for maximal basal activity. Further studies are 
required to identify the basal level CRH-R2 promoter activity. 
Deletion analysis of the promoter region revealed that several putative Sp 1, AP-1, and 
AP-2 binding sites may be important for the basic promoter activity. Furthermore, it is 
of interest that there were consensus binding sites for MyoD (a transcriptionl regulator 
in myoblasts and skeletal muscle), GRE, and SF-1 in the strong positive regulatory 
region. Further studies are required to determine whether these binding sites are 
functional. 
The first 1.3 kb of the 5'-flanking sequence has many characteristics of the 
housekeeping gene promoter including the presence of Spi binding sites and the 
absence of a consensus TATA box. We demonstrated that this promoter initiates 
transcription from at least 4 start sites over a 214 bp region. Moreover, the 5'-flanking 
region contains consensus-binding sites for several transcription factors that may be 
functionally important, including AP1, CRE-BP, AP2, GRE and SF-1. From the 
results of the present study, therefore, we speculated that the strong and housekeeping 
gene-like activity of the CRH-R2 gene promoter might contribute to the ubiquitous 
expression of the CRH-R2 gene. Furthermore, protein-binding studies such as 
footprinting or gel shift analysis will help us to verify the involvement of the 
designated putative sites in the transcriptional control of the CRH-R2 gene. 
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In summary, our initial characterisation of the promoter region of the human CRH-R2 
gene demonstrates that this gene contains a TATA-less promoter region with activity 
in an HEK-293 cell line. A number of transcription factor-binding sites were 
identified by sequence homology. Furthermore, characterization of these and other 
regulatory sites using DNase I protection analysis, gel mobility shift assays, and site- 
directed mutagenesis will identify which of these putative sites are important for basal 
CRH-R2 gene expression and which sites play a role in CRH-R2 induction by various 
extracellular signals. 
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Chapter 11 Summary of the results and suggestions for future work 
11.1 Amplifying and cloning CRH-R subtypes from human myometrium 
Our results demonstrated the presence of multiple CRH-R mRNAs in the human 
myometrium. Six subtypes of the CRH receptor, la, 1(3, lc, 2a, 2ß, and 27, were found 
in the pregnant human myometrium at term before the onset of labor, whereas only three 
subtypes, 1a, lß, and 2(3 were found in the non-pregnant myometrium. This finding 
demonstrates, for the first time, that during pregnancy, there is an alteration in the pattern of 
CRH-R subtype expression. This original observation coupled with our laboratory previous 
studies (Hillhouse et al., 1993. Grammatopoulos et al., 1995,1996) argue for a functional 
role for CRH and/or related peptides in myometrial function. Of particular interest is the 
finding that the CRH-R2a and CRH-R2y subtypes are present in human pregnant 
myometrium. This is the first report of the expression of the CRH-R2? gene in a human 
peripheral tissue. The location of this subtype was previously thought to be limited to the 
brain only. Multiple CRH-R mRNAs have been identified in human myometrium with 
different expression pattern during pregnancy, which argues for multiple roles for CRH 
and/or related peptides in myometrial function and suggests distinct functional roles for 
each receptor during pregnancy. Although the physiological role of CRH in myometrial 
function is not fully understood, the pattern of expression of the CRH-R mRNA suggests 
that this receptor have a physiological role in the regulation of uterine function. Further 
studies are currently under way in order to identify the distribution of CRH receptor 
subtypes in uterine feto-maternal regions as well as to investigate the signals that regulate 
the pattern of expression of the CRH-R subtypes. 
A novel CRH-R20 spliced variant has been isolated from human myometrium by 
employing the RT-PCR technique in this project. This variant of the CRH-R2(3 contains a 
315 bp deletion in the exon 3-5. This mutant lacks the entire first and second putative 
transmembrane domain. This variant of the CRH-R2(3 took place just at the splicing site, 
suggesting that it may be due to aberrant splicing event. To date, nothing is known about the 
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function properties of the mutant receptor protein. It is possible that the CRH-R2(3 variant 
may modulate the function of the CRH-R2ß. Further studies will be required to determine 
whether the CRH-R2(3 variant activates the signalling pathway coupled to adenylate cyclase. 
Alternative splicing is a widespread mechanism for producing variant forms of proteins 
from a single gene. Alternative splicing is responsible for the generation of a number of 
G protein-coupled receptor isoforms. Since alternative splicing is generally believed that 
the transmembrane domains and the intracellular loops contribute to signal transduction 
(Probst et al., 1992), alternative splicing events in these regions might give rise to 
receptor isoforms with different signaling properties. The existence of alternative splicing 
events indicates that there may be other unknown, splice variants of CRH-R. 
11.2 Clone and characterize the promoter region of the human CRH-R2 gene 
The genomic organisation of human CRH-R2 alternative exons has been determined in 
the project. The genomic orders of the alternative exons to be CRH-R20-2y-2a. The 
5'end of the CRH-R2 (2(3,2y, and 2a exon I) gene is composed of four exons and three 
introns distributed over 18 kb. Accurate estimates of the distance between each exon and 
the composition of each exon was based on a combination of DNA sequencing, PCR 
amplification and Southern analysis. The CRH-R2(3 exon I is interrupted by a large intron 
(10659 bp) in the 5'end of CRH-R2 gene. The CRH-R213 ]b and CRH-R2y I exons 
possess good consensus splice junctions flanking an apparent 2575 bp intron. The 
distance between the CRH-R2y exon I and the CRH-R2a I exon is 4068 bp. Exon-intron 
junctions conform with the consensus sequences, with exons flanked by AG and GT at 5' 
and 3' ends, respectively. The CRH-R2ß, 2a, and 2y cDNA sequences corresponded 
exactly to the genomic DNA sequence. In addition, between CRH-R2(3 Ia and Ib intron 
sequence data (10659 bp) was analyzed using ORF (open reading frame) Finder database 
searches from the National Center for Biotechnology Information (NCBI). There are 
numerous ATG codons in between CRH-R2(3 Ia and Ib intron sequence leading to thirty- 
two short open reading frames (ORFs). ORF frames have the range from 102 bp to 
533bp. However, amplification of this region from cDNA obtained from some tissues 
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(myometrium, hippocampus) has not indicated the presence of other exons in this region. 
There are numerous ATG codons in the CRH-R20 Ib intron sequence (2575 bp) which 
led to seven short open reading frames (ORFs). ORF frames have the range from 102 bp 
to 366 bp. Using gene specific primers for RT-PCR and 5'RACE, one cDNA fragment of 
195 bp was amplified from hippocampus but not myometrial biopsies in the CRH-R2ß lb 
intron. An extra 195 bp can be generated by alternative splicing in the N-terminals of the 
CRH-R2. The corresponding mRNA cannot be translated into functional receptor, since this 
sequence contains in-frame termination codon. The CRH-R2ß lb intron was located in this 
region for the 5'end of CRH-R2 gene, leading to the possibility of other exons with this 
region. The potential physiological significance of such a truncated receptor is not 
currently clear. This finding remains to be further investigated, such as isolation of full- 
length receptor, examination of the expression of this truncated receptor in the different 
tissues and cAMP accumulation assay. 
A number of transcription start sites exist (typically for a TATA-less CG-rich promoter) 
and the promoter of the human CRH-R2 most likely belongs to this class. By the 5'- 
rapid amplification of cDNA end, the transcription start sites were mapped to -256, -201, 
-97, and -12 bases upstream of the ATG translation initiation codon of the CRH-R20. 
This is a hypothesis or prediction only and further experiments may be required for 
providing more solid evidence. On the other hand, it is probable that there is a single start 
site at 226 bp. It is more likely that the 12,97, and 201 bp are incomplete transcripts. 
Further studies will be required to confirm the transcriptional start sites of the CRH-R2 
gene. The 5'RACE method can be employed using other tissues, as well as using 
S lnuclease mapping, primer extension, and RNase protection assays methods. 
We have cloned the 5'-flanking region of the CRH-R2 gene by the PCR based genomic 
walking method. CRH-R2(3 specific primer was designed, based on the published CRH- 
R2(3 cDNA (Valdenaire et al., 1997) and the 5'RACE-derived cDNA sequence. We 
amplified, cloned and sequenced the longer 1393 base pair fragment, which included the 
previously reported 30 nt 5'-UTR sequence upstream of the CRH-R2ß open. Alignment 
of the 5'-flanking sequence with the 5'RACE derived cDNA sequence of the CRH-R2(3 
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revealed that the DNA fragment included the 226 nt 5'-UTR sequence upstream of the 
CRH-R2ß open reading frame. The promoter of CRH-R2 lies upstream of the 5'-end of 
the CRH-R2(3. The results suggest that there may be a single promoter regulating the 
expression of all (2(x, 2(3, and 2y) subtypes. Further studies will be required to examine 
whether the CRH-R2 transcripts are expressed in a tissue-specific fashion, as well as 
those found in the rodent system. 
For functional analysis, 5'-flanking sequence up to -1393 bp were used to the 
Chloramphenicol acetyltransferase (CAT) gene and tested using a HEK-293 cell line by 
transfection CAT assays. An analysis of promoter and CAT constructs containing 5'- 
flanking fragments of different lengths up to -1393 bp by cell transfection revealed the 
first insight into the functionality and architecture of the promoter of the CRH-R2 gene. 
In HKT 293 cells, the constructs -553 bp (P3) and -1035 bp (P2) showed an 
approximately 70-fold increase in promoter activity compared to promoterless pCAT3- 
Basic. These results showed that several potential positive regulatory elements (possibly 
Spl, AP-1 AP-2) are located at between -164 and -977 nt. This region contains two Sp-1 
consensus-binding sites, which may be critical for report gene expression. Sp-1 binding 
sites are known to be promoter-specific activation sequences of RNA polymerase II 
transcription. The results confirm that analyzed gene is the actively transcribed CRH-R2 
gene. Further studies are required to identify the basal level CRH-R2 promoter activity. 
The hormonal regulation of the CRH-R2 promoter must be identified by further analysis. 
It is also required to analyze the effect of various agents on -1393 bp of CRH-R2 
promoter in HEK 293 cells, such as forskolin, phorbol-myristate-acetate. 
The 5'-flanking region of the human CRH-R2 gene was determined. The promoter region 
lacks a typical TATA or CCAAT box. There are potential cis-acting elements (SP1, AP1, 
AP2, GATA, CRE-BP and MyoD) in the 5'-flanking sequence. The CRH-R2 5'-flanking 
sequence has many characteristics of a housekeeping gene promoter including its 
residence in a GC-rich region, contain several transcription start sites spread over a fairly 
large region, several potential binding sites for the transcription factor Spl and the 
absence of a consensus TATA box. The absence of TATA and CAAT box motifs is a 
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feature shared with other related family II GPCR genes. Therefore, we speculated that the 
strong and housekeeping gene-like activity of the CRH-R2 gene promoter might 
contribute to the ubiquitous expression of the CRH-R2 gene. 
The promoter region of eukaryotic genes are generally composed of multiple binding 
sites for transcriptional activators and repressors that act in combination to regulate 
expression of linked gene (Roesler and Park 1998). Our initial characterization of the 
promoter region of the human CRH-R2 gene demonstrates that this gene contains a 
TATA-less promoter region with activity in an HEK-293 cell line. Comparison of the 5'- 
flanking sequence of the CRH-R2 gene revealed the existence of several transcription 
factor-binding sites. Further, characterization of these and other regulatory sites using 
DNase I protection analysis, gel mobility shift assays, and site-directed mutagenesis will 
identify which of these putative sites are important for basal CRH-R2 gene expression 
and which sites play a role in CRH-R2 induction by various extracellular signals. In 
addition, clarifying the role of CRH-R2 gene regulation should facilitate further studies 
on delineating the mechanisms of hormone regulation of the promoter region. 
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Appendix DNA sequence of the 5'end of the CRH-R2 gene 
1 tccagtccct aacccccagc cactactggc atgaggggtc cctcagggcc cccaggcctc 
61 ctctacgtcc cacacctcct cctctgcctg ctctgcctcc tcccaccgcc gctccaatac 
121 gtaagtgcag ggagtgggag tccacgaggt ggggcgccag gagcacggag ctcccagctc 
181 tcatgactag gggcgggggt ctcagggcct ggtggctggg ctggatcggg gatccttgtg 
241 tctgatgatg aattggagat cccgtgcctg ggtgaggggg tctcagggcc tggtggctgg 
301 gctggatcgg ggatccttgt gtctgatgat gaattggaga tcccgtgcct gggtgagggg 
361 gcaggggaag ggaagatgaa actgtgaggc tggccaggat gagactggga gacccctgtg 
421 gataagcaga gggttctggg gtgacatcct agcatccaga acttgactac ctcagggtcc 
481 aagattccct gtctcctatc cattctctcc ccacccccat gacccccctc catctctcct 
541 gcaagatcct tgacttcttt ccccagccca cccctagttc tgacccttac ccccagggac 
601 ccgcagagag ccacctcctg cccctgctgc cttgtctcca tccttcctct cagtgcctgg 
661 aatcaggcag cccccagtac cagatgagcg atggggacag agtgggctct gggagaacca 
721 gcctctccaa gggtttctca agactcagag cttcatccag ccacaccccg tgcctttgtc 
781 cagagtcagg ggccaccgat ggaaggtggg gagaagggac acagagcgac catcaaaaga 
841 gagctgaaga agtaggggag aggctggtgg gagtggtcca cctccagcct tctccccatt 
901 ttacagatgg ggaaactgag gctcagagtg gtagggtgac ctgtcctagg cctcacaatc 
961 tggaaagtag tgcctgtgga agctaagagg cttgtcgctg tcctgactct gccacagacc 
1021 agctttgggg accattctct ggggcttagt gtccctatac gtataaggag gataatacat 
1081 tcaacagtaa ttcaacagat aattgcctac aaaaccaatc cagatccctg ctttgctgct 
1141 taatgtgtga ccttggacag gttactcaaa tcctcagttt cctcatcagt aaaatgagga 
1201 tcacaacggt gcttactgaa caagcttgtt gtgaggaaca ttgaggtaat acaagtaaag 
1261 caagcagcat catgcttggt gtggtgtgag cacgcagtga atgccagcta tgcttttgtg 
1321 ccagccgcca cagatacagc atgaggacat gagggtccct gccttcctgg gggcctggcc 
1381 aggtggagga gagaggtggg aggcaggtag tatgctgagc tgtggtcagt gtccgatagg 
1441 cagatggccc ccagacctgc tgagtccttt gagtgacttt gcagactgca attgggatgg 
1501 gtgaaggttg tacagggggc tcaccatcca cccctctgcc cccaagacat cttgggcttt 
1561 gagctctctt gccctctccc acttgttttc cagataggtg ccttccagga gatccaagtg 
1621 ttggggcaag ggttgcccct cagcccgtcc ctctggggtc catgctgcca gccgcccaag 
1681 ctggttagac ggaggaagct tctgctggct gctccagagg tgccctagga ttctcagggc 
1741 aacactgtgg tctcagcgtc ccttgaggtc atcccaggcc ctgcgcctag ctctcctgcg 
1801 gatcccggag tgggatagag accagttact tacccacagc cactcagcat gtaagcagct 
1861 ggagagcact taaacctcgg cctttctgac gccaaagccc agccttcctc tcacggggcc 
1921 ttcatggcaa tgggactttt tcccgggtcc tgagacgatg agacctggag caggcagtcg 
1981 ggagggaagg cagcccagga gagcccagcc ttggaggctt ctcagttatt catccagtgt 
2041 ttaaggagga ctgcccatgg ggaggatcca gggtctgaac gctcatctgg ttcctgttct 
2101 tgtggtgttt atagcccaga agcgggtgtg gcaggaaaga aaggagtctg tgtttacaag 
2161 ttccagtaaa tgggctcaga agaagcatgt gtaggtgtga gggcccttga caggatgggg 
2221 gagcctggtg ggaggtgggc agcatagcag agttggagat gggtagtcca agggaaggga 
2281 taggggagca ggttgggggt aaggccccag ggccccaacc ctgaaaagac attatgtggg 
2341 agactgcaga gctgtatggg tcctggtggg atctgaggac atggggagct ctctgagcag 
2401 gggaggtgcc tggtctgatc tgcaattgta agggttccag ctggtgcttt tgagtgaaga 
2461 ggatgccctg gcccagggca cactgagagc ctggaggaac ccacccagcc ttgaccctgg 
2521 tgctccctat tccccgtgga ggccttcggg aagctggtcc ggaggcaggt ggtaatctag 
2581 cagctgttaa gtggtgttag gcgccttact caaacaccgg gaaggtggga ccacttattt 
2641 acagacagga aacaagttta aagaggctca gcaatgccac ttgcctccca ctctgtgaag 
2701 atcacaggag cctctcagcc cctgctgact aagtccagct ccttggagct ttggacagcg 
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2761 agacaccccc cagggtctca ggatggtgcc tctgtgacct cttgccccag gtcctggctt 
2821 ctggtgggcc catctgcccc aagaaggctc aacaaagaga acagaacaca gagaagtccc 
2881 tggcagtccc tggaccctcc ctgacctgtc cggctcacac caaagaccga gtccacagtg 
2941 tcccctaaca tacacacact gagggtctgc agagccgggg ctccagggcc atttgccagc 
3001 agctaatgca ttgaatgact tttcccaaaa attcaactcc cttctgagcg ttttctagcc 
3061 tcactagcta atttagtctc tagttttgcc attttgttgg tgtttcagta tttttttttt 
3121 aaatctgtct gagggcaatg gctacttaat tctgtattcc tcctaaatct caaatttgca 
3181 gcactttaag aattatggga ctactcttta tcttcttagc tgtcatattc tacttcattt 
3241 aatttaaacc attttatcta cagctagttt atctacagtc acttcttcca aaattctaac 
3301 tttttaaatt ttaattttaa ttattttatt ttattttttt gagatggagt ctcactctgt 
3361 tgcccaggct ggagtgcagt ggcacaatct cggctcactg caacctctgc ctcctgggtt 
3421 caagcgattc tcctgcctca gcctcctgag tagccaggac tataggcgcc tgccaacata 
3481 cccagctaat ttttttttgt acttttagta gagattgggt ttcaccatgt tggccaggat 
3541 ggtctcgatc tcctgacctc atgatccacc cacctcggcc tcccaaagtg ctgggattac 
3601 aggtgtgaac caccgcgcct ggccttaatt tttattttta atttttgtgg gtacatagta 
3661 ggtatatata tttgtgggat acatgagata ttttgataca ggcatgcaat gtgtagaaaa 
3721 tcacatcatg taaaatgggg tatccatccc ctcaagaatt tatcctttgt gttacagaca 
3781 atctaattat acttttagtt atttttaaat gtacaattaa attattgact acagtcaccc 
3841 tgttgtacta tgaaatacta cgtcgtattc attctatttt tttttggtac ctgttagccc 
3901 atcccctact acccttccca gcctccggta accattcttc cactctctat ctccatgcga 
3961 ttgttttgaa ttttaaatcc cacaagtaag tgataacatg cgatgtttgt ctttctcaac 
4021 attctaattt ttagtcattg caaacccatg ggggacagat tattcaataa gcttatttta 
4081 ttttacttag cagccctaca gggcctatca tgggcactga tgcacctcac ctatttttac 
4141 cttcatacca acgccctgag ttaaaaccat cctctcccca ttttgcagat gaggaagtga 
4201 ggtgagctca cgtgcccagg gccgctcagc tggtatgtgg caggaccagg attccggccc 
4261 acagcctgac tccagattcc tttcctttaa caaaatttta attttaatgt tatttaattt 
4321 taatgtcaag ttatttttag gacattcgga cagactccaa aacaaatcag aagagatgtg 
4381 acttttatgc aaactggaca ttagatgtgt tgataattaa ggagatagct ttaggccaag 
4441 tggcctgcta cgggacctcc tgctggccag ttcctgcccc tatgttgggc caagtcacct 
4501 ctccctcccc tccccttccc cctcctactc cagtcagtgt tcagggccca gggctcggca 
4561 caggtgagac aagcaggact gaggggagag ggattcatgg gcgttcagag agaagagaga 
4621 acagcagaat gaggagaggc ctaaagcctc c cgggggagc tggaggggaa ctgggaagga 
4681 agagtggggc atcctaggaa gacgaacttg gccgagcaca gactcaggaa caagaaagcc 
4741 gctgggagct gcccaggagg ccaaggggat tctcactcaa catccaacac cctacaagtt 
4801 agaactgagt atctaaagtc tcctcttcca aggagcctgc ctgaacacac cagaaaacaa 
4861 tgacccactt ccctcatctg acaccccacc cctcgcccgc ccctcggcca gtctcagctc 
4921 ccatttctgc cccctatgtc tgtgcagggc ctgactgcct cgtcctcccc ctccttcctc 
4981 atgtccacct tcctcccctc ttccccctcc tccccgttcc tgtatccttc cttcctcccc 
5041 cacctcctcc cctttctctt cccagtctcc tccacctcct tcccccatac tcctcttcct 
5101 ccccttcctt ccttctctcc tccccattct ccccctctcc cttttctgac cccttcttct 
5161 ctcctcatca tcccctctcc tccctgctcc tccttcctcc tttcttccct tcccttttcc 
5221 tactcctctg cactcctcct cccctctttt ccagtcttct cctccaagcc ttctccttct 
5281 cttccctctc ctcttgctcc ttcctctaac tctgtgctcc ctaaggggca gggcctgagc 
5341 tcaggctcaa tgaaatccac tgaatgaaag caaacatggg gtggaatgct gcccctccca 
5401 gctgagtcct tctctgacct tgggaagcag agggagaaag cagggaggga gctcacccca 
5461 ttcccctccg gtccctggca gcctgggccc aggacacatg gtcctgtaaa tctccccagc 
5521 ttataccatg ggctaaattt agacagaagc tttgtcgcca ggccctggag ggaacactag 
5581 actgggccag acccccaggt tccagggagg cgataccttt gaggcctgtc ggggccccgg 
5641 gcacaggttc tgtttggata ggacccaagg tggaagaaga gcagctggag tcttggctct 
5701 cattcctgca tccttcccca gccagggcct ctcctttgcc tcttctaagg tgagggcctc 
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5761 ccatgccagg cactgagagg cgggaaccag gacctgggcc ctcacacagg ctaggctcag 
5821 agcaaagttc agagagaagg aaatataaca agcaggaaaa gcccacaacc tggtctcccg 
5881 ggattagggg tggggatgta gctctacctg gctgaggggg ccatggtttc attaatccat 
5941 ccaagcagtc agtcagttga caaacattta ttgagcacct gctgtgtgcc aggctctgaa 
6001 ctggggactg gggacacaga tgtggaccct gtgctcccac agcctacagt cagtctcatg 
6061 ggctggggtg tgcatggtgg agagctctct gccctagaac agccaagagc taatcagcac 
6121 aggtgtccaa gacgttcccc tcagaagaaa gaaaaatgga aacaggaaaa cattccattt 
6181 cttctctaca ctcttacaca cctctgacac caaaagtgtg gattttctgc cccaagcaat 
6241 tctccacttc tctggggacc ccaactgggt gtcctccaat tcaattcaat tctgatgcta 
6301 tcttcctgga gttggcatca gcctccacag gtaaagcctc agtcccacaa gactgccccc 
6361 aattcagatg ccagtcgcaa gacagggctt ctcattctcc caaccgacag gctatataaa 
6421 tcaagagttc ccatgaccct ctctttgggt tcaatagtgt gctataacat tttgcaaaac 
6481 tcaaggaaac atttctattt acaggtttat tttaaagtct atcacaaagg atatagctga 
6541 acagccagat ggagaggcac acaggccaag ctgtggggag ggcgcagagc accgtgccct 
6601 cactggatgc caccctcccc gcaccaccag gtggtcacca accagaagcc cccaatccca 
6661 cctttgaggg gtttcacgga ggctccatta cagaggcata ttaacccaat ctccagcccg 
6721 tctcccttcc ccaaggtgta ggaaggtgct gaaagctcca accttctaac ctgtagggca 
6781 tttagaggca ggtctagcac tagagtaagt gctgacttca cgtgaaagaa gcctcccctt 
6841 cctgcctgtc tcccctcttc ttctcttggc acctccatac cagatggtgc agtttcctgt 
6901 gtgggccctg ggctcgcctg cctctgaggg tttgctttct cagcttctac ctgggtcact 
6961 ttctcctctt cttactgctg ttcctatggc ccaagtcctt ccatcctttt agattccgct 
7021 ccaatgtcca gttcgccgaa cggccttcgg tttcctcaat gagcattcac tgagcaccgc 
7081 tgaggggcga gctcagtgag ggagatggag gctgcacctt caggggccca ttgtccgagg 
7141 gaaagctgct gagggcaaac ggagtcccac actgactgga gagctgggga aggggggcac 
7201 agggtttcca ggaagctttt ctgggcagga agagcttgag ctgggccttg ggagtcccga 
7261 tgaggggact cgacctccca tcactgagct ctctaactag ccccctccta aagtccttgc 
7321 caagagtcac cattcagcgt gcgcattcta cgtgccaggc tcttgaccta cagtaatttg 
7381 ttgaatgcac acaaaatcct gtgggatttg tattatcccc attttaaaga tgaggagatc 
7441 aaggctcaga gaacttaagt ggcttgccaa ggccacacag ctaagcccag catccccaga 
7501 actctgcaca ctgggatgtg tgcactctac ccactctgac agctcttctc aagtccttgg 
7561 aatgggatta tccaagatat gtctgtccct gactttcctg gaccatgtgt tttctgagga 
7621 cagcagcctc tctttcctcc tcctccctgc ccacccatca ccaccaccac taggggctct 
7681 gcccaaaatt gacacctgca tggtagatta cgacttcgga ctgagtcaaa tccacccaaa 
7741 caagcccctt gaagagaatg agtatctttg gctgtgtcag cttttggggc cagcagagaa 
7801 gttataggag atgaagccag gatctgggat tactccaaaa attacttctg atatgcctgt 
7861 accaaatttt gcccagaccc aaagagcaag catcagttgc agagtatggt aaccctgtgc 
7921 ccactcccca caaagtgctt gctcagccag aagatggcca cagcctgaga ccacagaatc 
7981 caaggcaagg accatcccac attgcctgag tcctggggga ggatgccctg accccatcat 
8041 gggttcaaag catgtgtcag aaaccccggt aaagtcaaac aggagatcac ctcagtgatg 
8101 gggctacaaa tgtcacagct caggggcttt gagagaaggc actaacatct gagatggaat 
8161 ggctgcatct gcctaagggc gcaccgtgga cactgcatgc ctctgggttg cccgtaccct 
8221 gacctccaga ggctgggatt cactgggaac cctcccacag agggcattac tagctgcttc 
8281 tcaaacaagg gcgatgggcg ccataaagag ggtgatgggt cagacctaga gccctcactg 
8341 tccccagacc cagccaaaag tatggcctga gaattcttcc tggaaggtct cagtgtctgg 
8401 agtgttccct cccctcccca gccccccaac ccctggcagt ggctcacggg gtcagcaagg 
8461 tcttcctgat gcccgagaag ctggagctga ggaactctca gcagctccct tgatatgtgg 
8521 acagcaagac catggccccc agtgtttgtc ctgcaggcca agaggccaga actcctggct 
8581 gacagctcag gaggccccca cagtgccgag acacacacac aacacacaca cctgctcccc 
8641 tgcatttccc tctctacctc acttcgtggg gtgggagttt ggcagaacac aggtgcagtg 
8701 agtgcctcca agtggtgtct gcctcaccct aggcttccgg gaggggtgca gggggcagca 
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8761 ctctcctgtc tgagcaggtg gggtcattca ttagaagctc caggctgacg tggtgagggc 
8821 tgagcatgca gcttccagtc ccagcacagg aaatggactg agcccaatgt ggagaacgtg 
8881 atgtttgagg gcttttgggc tctggcccct ggggacatcc gaattcttcc tggaaggtct 
8941 cagtgtctgg agtgttccct cccctcccca gccccccaac ccctggcagt ggctcacggg 
9001 gtcagcaagg tcttcctgat gcccgagaag ctggagctga ggaactctca gcagctccct 
9061 tgatatgtgg acagcaagac catggccccc agtgtttgtc ctgcaggcca agaggccaga 
9121 actcctggct gacagctcag gaggccccca cagtgccgag acacacacac aacacacaca 
9181 cctgctcccc tgcatttccc tctctacctc acttcgtggg gtgggagttt ggcagaacac 
9241 aggtgcagtg agtgcctcca agtggtgtct gcctcaccct aggcttccgg gaggggtgca 
9301 gggggcagca ctctcctgtc tgagcaggtg gggtcattca ttagaagctc caggctgacg 
9361 tggtgagggc tgagcatgca gcttccagtc ccagcacagg aaatggactg agcccaatgt 
9421 ggagaacgtg atgtttgagg gcttttgggc tctggcccct ggggacatcc tggggcaaac 
9481 attgacccag ctgccaggaa gagtacatct gacaggcagc aggaagagaa ggggctgcac 
9541 actgatggag cagtgtcttc tggaatccca gaatcaggaa tctcagggtt gggaggggca 
9601 caaaagtcac acacgtgtgt gcatgtactc acacacacac acgctgacca tagagcaaga 
9661 aaaggagtgg tcttgggagg aatggggcca agcgttagaa tttagagtga attgctctcg 
9721 ttcagtcata caccatgcat tttccagcct ctctgccttt gcacatgctg tgctctctaa 
9781 ctagaatgcc cttcctggcc tgatcagctt ggcaagctcc tactcaccct tcaaaaccca 
9841 cattagcatg acctcttctg tgatgctacc cctgccctcc tcagtaaatc gtacatgccg 
9901 taaaactgta catcctatcc atctttccca ccagaagatg gtcccttcac gggtgcacat 
9961 gcccacatct actttatccg tgcacatcca gcacccactc tgatgatttt ttaggagacg 
10021 ggatcctggg tgcttttcta tcttttggat ggaattgcca ttattgcaac aatcacatat 
10081 cttccctagt gagtgcctaa gctggcccta tggtcccttc ttttgtccct actcatcttt 
10141 ctgggtgccc caaaatgcta cctctcccaa taagccttcc ctgtcttcct gaatccaggt 
10201 taggcacttc tctcacgtat taacctaatg ctcttcgttg caagtgcctg cttacctgtg 
10261 tgacagggaa acaaagttaa atcatgcatt tgcctcctct tccttctgca ctttctaagt 
10321 ctagaggatc cctacctggc ctgggactac ctgaaggaca cccatcagtt cccccagcca 
10381 gggcctgaca cacagtaggt gttctgcaaa tatttgttgg ttgaatgaac aactaatgga 
10441 acccaccccc cacccagctt tgctgacaga aggacacaag ccccatgaca gtgacacatc 
10501 ccagcctgag gaggagacag ccttgggggc tgagggatgg acagagcaga cccctgccta 
10561 ggaggcaaca ctgcattggg ccacttctga ggcctttctt cggtccagcc caggccagac 
10621 tgctgctgct ccatgtggcc atgggcatct ccctccttgt tctccctctc tgtactaaga 
10681 ggagtaaggg atgagtgata ggataggatg ggggcagaca ggcactgtca atggctagcc 
10741 tgggcctgat ctttgaccct catccttgct gtcccctagg cagccgggca gagccagatg 
10801 cccaaagacc agcccctgtg ggcacttctg gagcagtact gccagaccat catgaccctc 
10861 accaacctct caggtaggta ccctctgcca ccaccctgca gcagcccctg gagatgtggg 
10921 tgggccctgc gggaggaaga ggctttcctg gggccagccc aggctcagca gggtggtggg 
10981 tggggtgctg gtttccagtc ctggtttgat ttctgccttg ctgagggccc ttacgcaggc 
11041 ccttccccat tctaggctca ggcttgccac tgataatgaa gggcttggct gggaggccac 
10101 tccccattcc cagctcccac gatggaagtc agctgggctg gcattcagga gtccaagaag 
11161 gggatgaccc ctcagctttc caactccagg gaaactggca gaaggtggta aacattctct 
11221 ggttgccgtg gctacaggtg tgacttcctg gtaaggactt gcaaagcagc agcccggccc 
11281 tgagttctgg cccctcagag gtttccagtg gctgattcac agggtcaggg ccagccactg 
11341 cagagctgca cagagccctg gattctgctg ggttccagag agatgtctcc agtgtcccac 
11401 cctgtatcct ggccttccca ggtctgcatc cacaggatgg gagtgggggt gacccttgct 
11461 cgggcctggg gccactgcca gggcacaagg agacaagggt gctggccagc acccagaccc 
11521 agcctacagg cactgcccaa gccaggcgtc aaagagaaag tcttgctgcc tgttctcctt 
11581 ccactggggc agtcaatagc tccggtgttg ggatcaggta gatccaagtc tggatcctag 
11641 ctcttccacc cagcggcctc gcccagcccc tggaaactca cctaacccat ctgtattagt 
11701 gtcctggggc cactggaaca aagcaccaca gactgggggc ttgagcagaa gctgatttca 
215 
11761 tcaccattct ggaggctggt aggccaagat caagctgtgg gcagggttgg ttcctcctga 
11821 ggcctcccta cttggcttgc agatggccat ctttctccct atgtcttcat atggtctctc 
11881 ctctgcatgt ctgtgtccca atctcttctt cttctaagaa caccagtcct attggattaa 
11941 agcccgctta ccttacttta ctttaatcac ctcatcgaag accctaaatc caaacaaggc 
12001 cacattctga ggtactggga gttaggactt caacatacaa attttggagc aacacagttc 
12061 agcctgtgac accatctgaa gctagtttcc tcatctgttt agcaatggat ctaagtccac 
12121 ctcggaggct cacagtgaag gctgaatga gagcccacggg gacacctagc acaggccatg 
12181 ccagcatcag acaggaaatg gaggcccctc ccttcaggaa agcccaacct tccctcaccc 
12241 tcagaggcag cgtgggtttg tcagcagacc catagccttc tccctgcctt cctctgccct 
12301 ccctccagca ggtggcacag acccttccct gtctcccttg gcggatggtc cccgctctga 
12361 gtgcagcgga tagggtccca gcttctccaa acatacagcc ttgcctgttc agcttctaac 
12421 agcattcatc catttgcaaa agggatccac atgatttcta taaaattggg cacaaaaaaa 
12481 tttaactcaa aggagaagat gataagtact cattctccca caacccagga atttttataa 
12541 tgcctcatat ccctcaagaa tttatgcatt catagagcct catgttcaat tgttttttta 
12601 ttttcttttt cttttctttt ttttttaatg ggataatagt gtgtccatag tttcgtcgcc 
12661 tgctttttcc tcttataact cagagtgaac atttccccat gtcattaaat attcaaccac 
12721 cgcatcgctt gtgacgctgc ctagcagcca ctctggggat gcatcacccc acatgaacca 
12781 tgaccggatg gtggatgtag aggctgctag ggagcccctc gagcttcagg aatcatttct 
12841 caagtcccca aattgataat gaccttcttt tcagtgtcca ctgcttgggg aaatgcatca 
12901 tgtcta acgc agagttcaaa accaagtaaa accaaacact atatctttta gatgtacata 
12961 cctgtgagaa aactgaaaaa aaatatgagc cagagaatga caaatgcaat agtcaaggga 
13021 atgttccctc tggggaagga gaatagaaat aaatagataa gtgactggta atgatgtagt 
13081 ttccaattgg gtggtaggctt attatattg tctactacat acaataaaaa gactaaataa 
13141 aataaagact aaaaaataaa gttaagccat gcatgggcta atgcacagac taataatgac 
13201 aaagggtcac gaatctatga tcaattcaat tgtatgcccc tgaaaaaggc aacgcatgca 
13261 aaatcacaga gcaattatga cttcaggcag ggtttaaata gattatttct attttattca 
13321 tcacagaggc agctacatat atttgaaaaa tattagggca tatattatga ggcatattat 
13381 ttatcctatc catagatgat ataaaaatcc aaatggacta tttatttatt ttttattatt 
13441 ttttgtaggc tggtcttgaa ttcctgtgct caagcaatct gcctaccttg gcttccccaa 
13501 gtgctgagat tatgggtgtg agccactgca cctggccaag aatccgaatg gattcaaaga 
13561 taccttgaaa taattcctca atgcaacaca cacacatatg ccagggttgg tcaaatggga 
13621 agagagcctt ggcctgaaga cagggacctg ggctttcctc agctcttctg ccaaggtatc 
13681 tgtcctttct tagtgactca ctgggctgaa gtctagagca ttccaatggg tgctggggat 
13741 gggttagtga accaggacca gccctgccct tggggaggca tgggctggta gatgagacaa 
13801 tgaataaaaa gcaacctgga tgtgacatag gccagcaccc agcagatggg gtcaccaagg 
13861 agctgcatgt ctgaaggatg agtgtggagc tgtaaggcca tttccagtgc agaaatacaa 
13921 acaaggaaca gagatagcga atggtttctg gtagtgacac attgttctgg agggcctttc 
13981 aaatgaagca ggagggtgag gatgggggac gatgatcatg aagaaccttc tttgcaatac 
14041 caaagatggt tcccaggaat gacatgttgt tctggagggc ctttcaaatg gagcagaagg 
14101 gtgaggatga gggatagatg attacgaagg accttctttg caataccaaa gaggtggtct 
14161 ccatctcaag ggcaatgggt tggcggcact cctatgagga agagtgacag gatcgtaatt 
14221 ataaaacatc gttttatctg ccatgaggag acagggagcc catttgggct gctgcagaga 
14281 tgaggatggc ctgggagaag taagggaggg aaacctcttt tgcttgtctg ggaatcctat 
14341 tgtccatctg taaaacaaga atgtgggatt ggatgtcact gagagtcctt tctgtcccca 
14401 cagcttagtc ccatggtttg acatgaagac accaggccaa ttcctctgtc ctgcagtgga 
14461 gtaggatagg gtgaggaggg ggtgcctggc ctgggacccc tgtctccagt gctacagggc 
14521 aaaagtgcag caccttcagg cccctctgga acctctgtgc cctcagcaac cccgtcgtaa 
14581 ttcccaggaa acaccacgac tattccagct gtgcctgaat agactccctc tctatgtagt 
14641 ctaaccaagg acagtccctt agagaagcaa agatgcatcc tgtcccttta aatcctgttt 
14701 tccagctgac atttgagtgg taggggatga attagagaga gaatgtgtgt gcatggtgaa 
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14761 gatgcataac tgtggctctg tgtgtgattc tgttgtgcct acatgcctgt ttgatgccat 
14821 gtattaggct ttgcaagtgt gtctgagctg gcctggaact gtccactgct gctgcagctg 
14881 acatcagagg tgggccatgg gatgggatgc agggcaccag aggcacctgc cttactctgc 
14941 tgctcatggt acacaggggt cttccaaagt acctgtcaca cttccctgaa cctatttgcc 
15001 aacctgtccc caacagcttg gggacacaca aactgttcca aatacttatc ccctaattcc 
15061 tggcctccag ctgggatggg gctggcctgc agcgctggga acccatcact atcccaaagc 
15121 ctctaatcta cctctgcttc tttagttagc aaaaatgccc ctgtctttgt ttgtttgtac 
15181 ttggatttag taaaattgag ggaattttgg ggctcttccc aatttcttcc tcatttgcct 
15241 gtttgcagac a taaagtga gctgtaaaat caatttgttc ccaaactgct accttttcta 
15301 gttttccctc tgtcacatct cgaatgacaa ctgtgcctat aataataaga tccatgaaga 
15361 aatggcccca catccagggg acctcgggtc tgtgggtctg tgggtatgtg ctcagacccc 
15421 aactgctcat tcaggatgca gaacagcctt tgactctgcc actgaaatgg tcacttccca 
15481 gaagaatctt tggtatgtga gctctcccag ttaagagcaa tccagttcac ccaggccaac 
15541 cctctgttct gcagaaatct gcatgagatg agaagtccct ggcctctggt cattgggagc 
15601 acaccacctc ttgacatagc tgcatctata ggtgctttag gcaccaccta ggtggtggct 
15681 gcagtaatga acaaggataa taacttaagc ttggcttagg atttctccct tcctctgtgc 
15741 tgcaccgtgc tgtgtgaagg gctatccctt gtatatgagg gacactattg ccctgtgaat 
15801 acatgggctg acctggccag ccaccctctg gcctgtgtgg gaccctgggt aacagggctc 
15861 agtctaggag cggagggtag gactctgcct aggtcctccc ctgctcctgg cactggataa 
15921 tatgaagacc aaggaacctc tacctctgca gctgcccaga gctgagcctg ggctctcact 
15981 gtccattcag gaggcagagg gtagacctgg ctggctgctc agcatcttgt tcctgccagt 
16041 cagcaggccc tggagagatt ccagggctca gccctggtct tagtgtggtc tcactcgctc 
16101 tgcctgggca gtgacagcac cattaatatg gaggctggtg agagcggagc acacaaaagc 
16161 agcctgcctg ctgctttgcc tctctctgcc cagggcatgg tgctagttca tggtggtttc 
16221 agcctttcct agcagcttag gtttatgtgg aggatggcag gggaacagga ctggtttctg 
16281 agactaggtt ccagctctcc ttgccctcta aagatagaaa caaacaacac acaacacaca 
16341 tgtatgtctt ccccagactc tccgtctcat aactcagaac cagagagtct cagagctgag 
16401 aggggcctcg gggaagattt cactgatgga gaaagctcca gaagagaggg caagcatcct 
16461 gcctggggta ccatggcagg gagagcagag tcagaggctg gaccaaaatg cagcctgagt 
16521 ggaagcatgc cttaccccag gccctgcttc ccgagcccaa tgccccactc agctggcaga 
16581 cacagcaggc ccgccctggg cactctgagg gtgcagccac agcagatcac caaggaggca 
16641 ttctgggcca gggtggggtg gggggcctgg gcaagttctc tggggaggtt tccagctcct 
16701 ccacacctgc tgtggggcct gattctcccc gcccctgccc cgctactggt gtggaaacca 
16761 gggtcaggtg aagccctgcc caagccttga ggaagagaga cacattctca cttcttcctt 
16821 tattctttct ggtgcccaag gcactaacaa ctgggtgtat aaagccttcc agataatttc 
16881 agccaatttc tcccctagac ttactccatc tgattaaatg gccacccagt cactcaagca 
16941 ggagacctga tgttatccct gcctctgggc tcctacttaa aaccagccac ccactccagt 
17001 tcctcctcac caggtctggc tgcccctccg aaatctctct ccattccagc ttccacggtc 
17061 tgatccaagg acttcaaccc actcaggcca cttgatctca ttagactcat gggtgtctcc 
17121 ctgcttccct ccaggcctcc tcgatacatt tccttcccag aggctatgga ggcttttgga 
17181 ggatgcagat ctgcccatgg gctctccgtc tctgcctccc tccagtgtcc tcgctcaggg 
17241 aggggaagct caggcggaaa gctgccgaac tttgggttgc ggctgtccct cgattagcag 
17301 agctgcggtg ttctcctcgg gcaggcgggc aggtgggcgc gctttgctgc cccctgcagc 
17361 tcgggggcct gcgatccccg cacagagcat tccgtcaccc caggcccacg ctctccagcc 
17421 caccgccctc ctctggacgc cgcgagtgga agagagctgc gaactgagaa gccgtacttt 
17481 gggcagggtg gagggcccgg gggctggaga ctgagcccct ccgagaggag ccgcccggcc 
17541 ccgccccccg gcgcagccat tggccgcggc ggagcggctg tacccgcagc tccgtgcact 
17601 cggcggctcc tctccgggaa ggtccccact tgacagctct gggcgaccgg aggtggcgcc 
17661 caaaggctgc ccgggagatc ggggctgggc tggcgggggc caggaccccg cgccctctcg 
17721 gccgctcact ctcgcgtcca ctccctcgca gtcacgccgg gcgcgcactc ccactccctc 
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17781 tccgcacgcg gctgcgggac gcgatggacg cggcactgct ccacagcctg ctggaggcca 
17841 actgcagcct ggcgctggct gaagagctgc tcttggacgg ctggggccac ccctggaccc 
17901 cgagggtagc ggtcgaagct gcgcgggctc cttctctcgc gcgctgggtg cgcccctgac 
17961 cccgcgctcc gagagccccg cgtccctgcg ggcccctctg agccctactg cgctctctcc 
18021 cgccgccagg tccctactcc tactgcaaca cgaccttgga ccagatcgga acgtgctggc 
18081 cccgcagcgc tgccggagcc ctcgtggaga ggccgtgccc cgagtacttc aacggcgtca 
18141 agtacaacac gaccc 
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